WO2016201096A1 - Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors - Google Patents

Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors Download PDF

Info

Publication number
WO2016201096A1
WO2016201096A1 PCT/US2016/036689 US2016036689W WO2016201096A1 WO 2016201096 A1 WO2016201096 A1 WO 2016201096A1 US 2016036689 W US2016036689 W US 2016036689W WO 2016201096 A1 WO2016201096 A1 WO 2016201096A1
Authority
WO
WIPO (PCT)
Prior art keywords
quinuclidin
benzo
amine
isoxazol
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/036689
Other languages
French (fr)
Inventor
Raksha Acharya
Duane A. Burnett
Matthew Gregory Bursavich
Andrew Simon Cook
Bryce Alden Harrison
Andrew J. Mcriner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forum Pharmaceuticals Inc
Original Assignee
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2017145964A priority Critical patent/RU2017145964A/en
Priority to HK18105734.0A priority patent/HK1246184A1/en
Priority to US15/736,235 priority patent/US10370370B2/en
Priority to CA2988968A priority patent/CA2988968A1/en
Priority to CN201680045409.2A priority patent/CN107847494A/en
Priority to EP16808279.0A priority patent/EP3307269A4/en
Priority to JP2017564556A priority patent/JP2018516973A/en
Priority to MX2017016231A priority patent/MX2017016231A/en
Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Priority to KR1020187000332A priority patent/KR20180044256A/en
Priority to AU2016274694A priority patent/AU2016274694A1/en
Publication of WO2016201096A1 publication Critical patent/WO2016201096A1/en
Priority to IL256226A priority patent/IL256226A/en
Anticipated expiration legal-status Critical
Priority to NO20180002A priority patent/NO20180002A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to novel aminobenzisoxazole compounds
  • compositions of the same that are suitable as agonists or partial agonists of the cc7- nicotinic acetylcholine receptor, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function.
  • methods of administering the compound or composition to a patient in need thereof for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
  • acetylcholine esterase inhibitors may ameliorate the cognitive deficits in patients with cognitive disease.
  • the most widely used acetylcholine esterase inhibitor is donepezil hydrochloride (Aricept ® ).
  • Nicotinic acetylcholine receptors form a large family of ion channels which are activated by the messenger acetylcholine which is produced in the body (Galzi and Changeux, Neuropharmacol. 1995, 34, 563-582).
  • a functional nAChR consists of five subunits which may be different (certain combinations of a 1-9 and ⁇ 1-4, ⁇ , ⁇ , ⁇ subunits) or identical (a7-9). This leads to the formation of a diversity of subtypes which differ in the distribution in the muscles, the nervous system and other organs (McGehee and Role, Annu. Rev. Physiol. 1995, 57, 521-546).
  • nAChR Activation of nAChR leads to influx of cations into the cell and to stimulation of nerve cells or muscle cells. Selective activation of individual nAChR subtypes restricts this stimulation to the cell types which have a corresponding subtype and is thus able to avoid unwanted side effects such as, for example, stimulation of nAChR in the muscles.
  • Clinical experiments with nicotine and experiments in various animal models indicate that central nicotinic acetylcholine receptors are involved in learning and memory processes (e.g. Rezvani and Levin, Biol. Psychiatry 2001, 49, 258-267).
  • Nicotinic acetylcholine receptors of the alpha7 subtype have a particularly high concentration in regions of the brain which are important for learning and memory, such as the hippocampus and the cerebral cortex (Seguela et al., J. Neurosci. 1993, 13, 596-604).
  • the al nAChR has a particularly high permeability for calcium ions, modulates neurotransmission, influences the growth of axons and, in this way, modulates neuronal plasticity (Broide and Leslie, Mol. Neurobiol. 1999, 20, 1-16).
  • WO 2003/055878 describes a variety of agonists of the a7 nAChR said to be useful for improving cognition.
  • WO 2003/055878 suggests that certain agonists of the a7 nAChR are useful for improving perception, concentration, learning or memory, especially after cognitive impairments like those occurring for example in situations/diseases/syndromes such as mild cognitive impairment, age- associated learning and memory impairments, age-associated memory loss, Alzheimer's disease, schizophrenia and certain other cognitive disorders.
  • An aspect of the invention provides an aminobenzisoxazole compound represented by Formula (I).
  • R 1 , R 2 , R 3 , and R 4 independently represent -H, -D, halogen radical, -CN, an unbranched Ci-C - alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 6 -cycloalkyl radical, an unbranched a branched or cyclic -OC 3 -C 4 -alkyl, -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -S0 2 C 1 -C 4 -alkyl, -S0 2 N(R 5 )(R 6 ), -(CH 2 ) m S0 2 C 1 -C 4 -alkyl, -(CH 2 ) m S0 2 N(R 5 )(R 6 ), -N(R 5 )S0 2 d-C 4 -alkyl, an
  • aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, -CN, -OR 5 , -(CH 2 ) m OR 5 , -N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -(CH 2 ) m N(R 5 )(
  • R 5 and R 6 independently represent -H; an unbranched Ci-C 6 -alkyl radical, a branched
  • n independently represents an integer from 1 to 6;
  • An aspect of the invention relates to the aminobenzisoxazole compound represented by Formula (la):
  • An aspect of the invention relates to the aminobenzisoxazole compound represented by
  • An aspect of the invention relates to a method comprising administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of maintaining, treating, curing and/or improving at least one cognitive function in a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of maintaining, treating, curing and/or improving at least one cognitive function in a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating a patient in need thereof, comprising: administering to the patient, for example, a patient diagnosed with having a cognitive impairment, Limited Cognitive Impairment, Mild Cognitive Impairment, Alzheimer's disease, and/or schizophrenia, an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; such that the patient may derive a benefit therefrom.
  • a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; such that the patient may derive a benefit therefrom.
  • Another aspect of the invention provides a method of treating one or more symptoms associated with a cognitive impairment, comprising administering to a patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the patient suffers from, or has been diagnosed as having, a cognitive impairment.
  • Another aspect of the invention provides a method of improving cognition of a patient in need thereof, comprising: administering to the patient an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of improving cognition in a patient suffering from a cognitive impairment, such as a cognitive impairment associated with either schizophrenia or Alzheimer's disease, for example mild Alzheimer's disease, moderate Alzheimer's disease, severe Alzheimer's disease, or mild-to-moderate Alzheimer's disease, comprising
  • an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating a patient suffering from, diagnosed with having, or suffers from one or more symptoms associated with, a cognitive impairment, for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • a cognitive impairment for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia
  • Another aspect of the invention provides a method of treating a patient previously treated, or currently being treated, with an AChEI, that is suffering from, or has been diagnosed with having, a cognitive impairment, for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents; wherein the method improves one or more symptoms associated with the cognitive impairment in the previously, or currently, AChEI treated patient.
  • a cognitive impairment for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia
  • Another aspect of the invention provides a method of treating a patient suffering from, or diagnosed with having a cognitive impairment, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the method provides a positive effect on cognition or a positive effect on clinical function in said cognitively impaired patient, and wherein said patient has been previously treated or is currently being treated with an AChEI.
  • Another aspect of the invention provides a method of improving or substantially improving one or more symptoms in a cognitve disease patient, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of slowing the rate of deterioration of at least one symptom in a cognitve disease patient, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient the pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating one or more symptoms associated with a cognitive disease in a patient suffering therefrom, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent
  • Another aspect provides a method of minimizing or substantially halting the rate of progression of one or more cognitive diseases in a patient suffering from a cognitive disease, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of substantially stopping or reversing progression of one or more cognitive diseases, in a patient suffering therefrom, comprising:
  • an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the effective amount of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein said effective amount is administered in an effective dose.
  • Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, wherein the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a
  • pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the pharmaceutical composition is in the form of a tablet.
  • Another aspect of the invention provides a method of treating a patient having a cognitive disease and being administered an acetylcholine esterase inhibitor, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the treatment comprises halting the administration of the acetylcholine esterase inhibitor prior to treating with the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
  • An embodiment of the present invention provides an aminobenzisoxazole compound represented by Formula (la) or Formula (lb):
  • R 1 R independently represent -H, -D, halogen radical, -CN, an unbranched Ci-C 4 - alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 6 -cycloalkyl radical, an unbranched -OCi-C 4 -alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -S0 2 C 1 -C 4 -alkyl, -S0 2 N(R 5 )(R 6 ), -(CH 2 ) m S0 2 C 1 -C 4 -alkyl, -(CH 2 ) m S0 2 N(R 5 )(R 6 ), -N(R 5 )S0 2 Ci-C 4 -alkyl
  • aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, -CN, -OR 5 , -(CH 2 ) m OR 5 , -N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -(CH 2 ) m N(R 5 )(
  • n independently represents an integer from 1 to 6;
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 , R 2 , R 3 , and R 4 independently representing -H, -D, halogen radical, -CN, an unbranched Ci-C 3 -alkyl radical, a branched C 3 -C -alkyl radical, a C 3 -C 5 -cycloalkyl radical, an unbranched -Od-C 4 -alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -S0 2 C !
  • R 5 and R 6 may independently represent -H, an unbranched Ci-C 6 -alkyl radical, such as -CH 3 or -CH 2 CH 3 , a branched C 3 -C 6 -alkyl radical, such as -CH(CH 3 ) 2 , or a C 3 -C 6 -cycloalkyl radical, such as a cyclopropyl radical, or the N(R 5 )(R 6 ) moiety forms a cycle, wherein R 5 and R 6 taken together represent a C 2 -
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 and R 2 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C 3 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 4 -cycloalkyl radical, -CHF 2 , -CH 2 F, -CF 3 , an unbranched -OCi-C 3 -alkyl, a branched or cyclic -OC 3 -alkyl, -OCF 3 , -S0 2 CH 3 , -S0 2 N(CH 3 ) 2 , or -N(R 5 )S0 2 CH 3 ; wherein the alkyl portion of the unbranched Ci-C 3 -alkyl radical, the branched C 3 -C 4 -alkyl radical,
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 and R 2 independently representing -H, -D, -F, -CI, -CH 3 , -CH 2 CH 3 , a cyclopropyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -OCF 3 , -S0 2 CH 3 , -S0 2 N(CH 3 ) 2 , or -N(H)S0 2 CH 3 .
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R 1 and R 2 independently representing -H, -D, or halogen radical, for example, -F, -CI, or -Br.
  • R 1 and R 2 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F.
  • R 1 and R 2 may independently represent -H or -D.
  • R 1 may independently represent -H or -D
  • R 2 may independently represent -F or -CI, such as -F.
  • R 1 may independently represent -F or -CI, such as -F
  • R 2 may independently represent -H or -D.
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 3 independently representing -F, -CI, -Br, -CN, an unbranched Ci- C 4 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 6 -cycloalkyl radical, an unbranched -OC 1 -C4- alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -S0 2 d-C 4 - alkyl, -S0 2 N(R 5 )(R 6 ), -(CH 2 ) m S0 2 C 1 -C 4 -alkyl, -(CH 2 ) m S0 2 N(R 3 ) -alkyl
  • aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR 5 , -(CH 2 ) m OR 5 , -N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -(CH 2 ) m N(
  • R 5 and R 6 may independently represent -H, an unbranched Ci-C 6 -alkyl radical , such as -CH 3 or -CH 2 CH 3 , a branched C 3 -C 6 -alkyl radical, such as -CH(CH 3 ) 2 , or a C 3
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 3 independently representing -F, -CI, -Br, -CN, an unbranched Ci- C 4 -alkyl radical, a branched C 3 -C -alkyl radical, a C 3 -C -cycloalkyl radical, an unbranched -OCi-C - alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -OCHF 2 , -OCH 2 F, -OCF 3 , -OCH 2 CF 3 , -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -S0 2 CH 3 , -S0 2 N(R 5 )(R 6 ), -CH.CH.SOzd-C.-alkyl, or
  • R 5 and R 6 may independently represent -H, an unbranched Ci-C 6 -alkyl radical, such as -CH 3 or -CH 2 CH 3 , a branched C 3 -C 6 -alkyl radical, such as -CH(CH 3 ) 2 , or a C 3 -C 6 -cycloalkyl radical, such as a cyclopropyl radical, or the N(R 5 )(R 6 ) moiety forms a cycle, wherein R 5 and R 6 taken together represent a C 2 -
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 3 independently representing -F, -CI, -Br, -CN, -CH 3 , -CH 2 CH 3 , cyclopropyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, -OCHF 2 , -OCH 2 F, -OCF 3 , -OCH 2 CF 3 , -S0 2 CH 3 , a phenyl radical or a heteroaryl radical, such as an N-pyrazole radical, a furan radical, a thiophene radical, an imidazole radical, an oxazole radical, a thiazole radical, a pyridyl radical, a pyrazine radical,
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 3 independently representing -F, -CI, -Br, -CN, -CH 3 , -CH 2 CH 3 , cyclopropyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, -OCF 3 , -S0 2 CH 3 , a phenyl radical or a heteroaryl radical, such as an N-pyrazole radical, a furan radical, a thiophene radical, an imidazole radical, an oxazole radical, a thiazole radical, a pyridyl radical, a pyrazine radical, a pyrimidine radical, or an oxadiazole radical; wherein the phenyl
  • R 3 may independently represent -F, -CI, -Br, -CN, -CH 3 , -CH 2 CH 3 , cyclopropyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, or -OCF 3 .
  • R 3 may independently represent -F, -CI, -Br, -CH 3 , or -OCH 3 , such as R 3 may independently represent -CI, -CH 3 , or -OCH 3 .
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 4 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C 4 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 6 -cycloalkyl radical, an unbranched -OC 1 -C 4 -alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -N(R 5 )(R 6 ), -(CO)N(R 5 )(R 6 ), -NR 5 (CO)(R 6 ), -SO.d-C.-alkyl, -S0 2 N(R 5 )(R 6 ), -(CH 2 ) m S0 2 C 1 -C 4 -alkyl, -(CH 2 ) m
  • aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR 5
  • R 5 , -(CO)N(R 5 )(R 6 ), -OCF 3 an unbranched Ci-C 6 -alkyl radical, a branched C 3 -C 6 -alkyl radical, a C 3 -C 6 -cycloalkyl radical, a Ci-C 6 -hydroxyalkyl radical, a Ci-C 2 -haloalkyl radical, or -OCi- C 2 -haloalkyl radical; and wherein R 5 and R 6 may independently represent -H, an unbranched Ci-C 6 - alkyl radical, such as -CH 3 or -CH 2 CH 3 , a branched C 3 -C 6 -alkyl radical, such as -CH(CH 3 ) 2 , or a C 3 - C 6 -cycloalkyl radical, such as a cyclopropyl radical, or the N(R 5 )(R 6 ) mo
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 4 independently representing -H, -D, -F, -CI, -CN, an unbranched Ci-C 3 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 4 -cycloalkyl radical, unbranched -OCi-C 3 - alkyl, a branched or cyclic -OC 3 -C 4 -alkyl, -OCHF 2 , -OCH 2 F, -OCF 3 , -OCH 2 CF 3 ; wherein the alkyl portion of the unbranched Ci-C 3 -alkyl radical, the branched C 3 -C -alkyl radical, the C 3 -C -cycloalkyl radical, the unbranched -OCi-C 3 -alkyl, or the branched or cycl
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 4 independently representing -H, -D, -F, -CI, -CN, -CH 3 , cyclopropyl radical, cyclobutyl radical, -CH 2 F, -CHF 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, -OCHF 2 , -OCH 2 F, -OCF 3 , or -OCH 2 CF 3 .
  • R 4 may independently represent -H, -D, -F, -CI, -CN, -CH 3 , cyclopropyl radical, cyclobutyl radical, -CH 2 F, -CHF 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, or -OCF 3 , such as R 4 may independently represent -H, -D, -F, -CI, -CH 3 , -OCH 3 , -OCH 2 CH 3 , or -CF 3 .
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise: R 1 and R 2 independently representing -H or -D, R 2 and R 4 independently representing -H or -D, R 1 and R 4 independently representing -H or -D, or R 1 , R 2 , and R 4 independently representing -H or -D; and R 3 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C 3 -alkyl radical, for example, -CH 3 or -CH 2 CH 3 , a branched C 3 -C -alkyl radical, a cyclopropyl radical, a cyclobutyl radical, -CHF 2 , -CH 2 F, -CF 3 , an unbranched -OC 1 -C3- alkyl, such as -OCH 3 or -OCH 2 CH 3 , a branched Ci-C 3 -al
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently
  • Ci-C 3 -alkyl radical for example, -CH 3 or -CH 2 CH 3 , -CH(CH 3 ) 2 , a cyclopropyl radical, a cyclobutyl radical, -CHF 2 , -CH 2 F, -CF 3 , an unbranched -OCi-C 3 -alkyl, such as -OCH 3 or -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, -OCHF 2 , -OCH 2 F, -OCF 3 , -OCH 2 CF 3 , -S0 2 CH 3 , a phenyl radical or a heteroaryl radical, such as an N- pyrazole radical or an oxadiazole radical; and R 4 independently representing -H, -D, -F,
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently
  • Ci-C 3 -alkyl radical for example, -CH 3 or -CH 2 CH 3 , -CH(CH 3 ) 2 , a cyclopropyl radical, a cyclobutyl radical, -CHF 2 , -CH 2 F, -CF 3 , an unbranched -OCi-C 3 -alkyl, such as -OCH 3 or -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O-cyclopropyl, -OCHF 2 , -OCH 2 F, -OCF 3 , -OCH 2 CF 3 , or -S0 2 CH 3 ; and R 4 independently representing -H, -D, -F, -CI, -CN, an unbranched Ci-C 3 -alkyl radical, for example, -CH 3 or -CH
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R 3 independently representing R 1 independently
  • R 4 independently representing -H, -D, -F, -CI, -CN, -CH 3 , -CH 2 CH 3 , a cyclopropyl radical, a cyclobutyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , or -O-cyclopropyl, or -OCF 3 ; and R 4 independently representing -H, -D, -F, -CI, -CN, -CH 3 , -CH 2 CH 3 , a cyclopropyl radical, a cyclobutyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , or
  • R 1 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F;
  • R 2 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F:
  • R 3 may independently represent -F, -CI, -Br, -CN, -CH 3 , -CH 2 CH 3 , a cyclopropyl radical, -CHF 2 , -CH 2 F, -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , or -O-cyclopropyl, or -OCF 3 , such as -F, -CI, -Br, -CH 3 , or -OCH 3 , or such as -CI, -CH 3 , or -OCH 3 ; and R 4 may independently represent
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), at least one of R 1 , R 2 , R 3 , and R 4 does not independently represent -H.
  • R 1 independently represents -H, and at least one of R 2 , R 3 , and R 4 does not independently represent -H
  • R 2 independently represents -H, and at least one ofR ⁇ R 3 , and R 4 does not independently represent -H
  • R 3 independently represents -H, and at least one ofR ⁇ R 2 , and R 4 does not independently represent -H
  • R 4 independently represents -H, and at least one of R 1 , R 2 , and R 3 does not independently represent -H.
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise R 5 , R 6 , or both R 5 and R 6 , independently representing -H; an unbranched Ci-C 6 -alkyl radical, such as -CH 3 or -CH 2 CH 3 , a branched C 3 -C 6 -alkyl radical, such as -CH(CH 3 ) 2 ; or a C 3 -C 6 -cycloalkyl radical, such as a cyclopropyl radical or a cyclobutyl radical.
  • an unbranched Ci-C 6 -alkyl radical such as -CH 3 or -CH 2 CH 3
  • a branched C 3 -C 6 -alkyl radical such as -CH(CH 3 ) 2
  • a C 3 -C 6 -cycloalkyl radical such as a cyclopropyl radical or a cyclobutyl radical.
  • R 5 and R 6 may independently represent -H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , a cyclopropyl radical, or a cyclobutyl radical, such as independently represent -H, -CH 3 , or -CH 2 CH 3 .
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise an N(R 5 )(R 6 ) moiety, wherein the N(R 5 )(R 6 ) moiety forms a cycle, wherein R 5 and R 6 taken together represent a C 2 -C 6 -alkyl di-radical or a (3-6 membered)-heteroalkyl di-radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci- C 4 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 4 -cycloalkyl radical, -(CO)-unbranched Ci- C 4 -alkyl
  • the N(R 5 )(R 6 ) moiety may form a cycle, wherein R 5 and R 6 taken together represent a C 2 -alkyl di-radical, a C 3 -alkyl di-radical, C 4 -alkyl di-radical, or C 5 - alkyl di-radical, such as a C 2 -alkyl di-radical.
  • the N(R 5 )(R 6 ) moiety may, for example, form a cycle wherein the R 5 and R 6 taken together represent a (3-6 membered)-heteroalkyl di-radical, such as (4-5 membered)-heteroalkyl di-radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H; an unbranched Ci-C 4 -alkyl radical, such as -CH 3 , -CH 2 CH 3 , or -CH 2 CH 2 CH 3 , a branched C 3 -C 4 - alkyl radical, such as -CH(CH 3 ) 2 ; a C 3 -C 4 -cycloalkyl radical; -(CO)-unbranched Ci-
  • the N(R 5 )(R 6 ) moiety may form a cycle, wherein R 5 and R 6 taken together represent a (4-5 membered)-heteroalkyl di-radical, wherein the (4-5 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen or nitrogen, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H; -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , a cyclopropyl radical. -(CO)CH 3 , -(CO)CH 2 CH 3 , -(S0 2 )CH 3 , or -(S0 2 )CH 2 CH 3 .
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise racemic mixture of enantiomers, a mixture of diastereomers, a single enantiomer, or a single diastereomer, of the compound, or a pharmaceutically acceptable salt thereof.
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may comprise a mixture of tautomers, substantially a single tautomer form, or a single tautomer form, such as a tautomer contained within the aminobenzisoxazole ring system or a tautomer resulting from one or more substitutents substituted on the aminobenzisoxazole ring system, for example, a tautomer may be contained within the aminobenzisoxazole ring system or one or more substitutents substituted on the aminobenzisoxazole ring system containing a heteroaryl ring nitrogen adjacent to a heteroaryl ring carbon substituted with a hydroxyl group.
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the compounds listed below, and single enantiomers and pharmaceutically acceptable salts thereof:
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the compounds listed below, and single enantiomers and pharmaceutically acceptable salts thereof:
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof: (i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
  • aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
  • the aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be more potent against al nAChR (according to the al nAChR Binding Assay (Ki)) than against a 5- HT 3 serotonin receptor (according to the [ H]BRL 43694 competition binding (Ki)).
  • the aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be at least 1.5 times more potent against al nAChR than against a 5-HT 3 serotonin receptor, as determined by the a7 nAChR Binding Assay and the [ H]BRL 43694 competition binding assay, respectively, such as at least 2 times more potent, at least 3 times more potent, at least 4 times more potent, at least 5 times more potent, at least 6 times more potent, at least 7 times more potent, at least 8 times more potent, at least 9 times more potent, at least 10 times more potent, at least 15 times more potent, at least 20 times more potent, or at least 25 times more potent against al nAChR than against a 5-HT 3 serotonin receptor, as determined by the a7 nAChR Binding Assay and the [ H]BRL 43694 competition binding assay, respectively.
  • treating includes the generally accepted meaning which encompasses improving, modifying, decreasing, prohibiting, preventing, restraining, minimizing, slowing, halting, stopping, curing, and/or reversing a symptom associated with a disease and/or a disease.
  • Treatment may include both therapeutic and prophylactic administration.
  • treatment of a cognitive impairment, in a patient diagnosed as having a cognitive impairment may include, but is not limited to, curing the cognitive impairment, preventing the deterioration of one or more symptoms associated with the cognitive impairment; improving cognition in a patient suffering from the cognitive impairment, slowing the progression of the cognitive impairment and/or modifying the cognitive impairment.
  • the term "effective dose” (or “dose”), unless otherwise specified, is understood to include a thereapeutically acceptable dose, a thereapeutically acceptable amount, a thereapeutically effective dose, a thereapeutically effective amount, a pharmaceutically acceptable dose, a pharmaceutically acceptable amount, a pharmaceutically effective dose, or a pharmaceutically effective amount.
  • the term "cognitive impairment,” unless otherwise specified, includes at least one of the following: Limited Cognitive Impairment (LCI), Mild Cognitive Impairment (MCI), Alzheimer's disease (or dementia of an Alzheimer' s-type) or a particular stage of Alzheimer's disease, inclusive of pre-Alzheimer's disease, early Alzheimer's disease, mild Alzheimer's disease, moderate Alzheimer's disease, severe Alzheimer's disease, pre-Alzheimer' s-to-mild Alzheimer's disease, mild-to-moderate Alzheimer's disease, moderate-to-severe Alzheimer's disease,
  • LCI Limited Cognitive Impairment
  • MCI Mild Cognitive Impairment
  • Alzheimer's disease or dementia of an Alzheimer' s-type
  • a particular stage of Alzheimer's disease inclusive of pre-Alzheimer's disease, early Alzheimer's disease, mild Alzheimer's disease, moderate Alzheimer's disease, severe Alzheimer's disease, pre-Alzheimer' s-to-mild Alzheimer's disease, mild-
  • schizophrenia for example, paranoid type schizophrenia, disorganized type schizophrenia, catatonic type schizophrenia, undifferentiated type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of
  • Alzheimer's disease may include, unless otherwise specified, any of the sub-diagnostic categories used to characterize the type or degree of cognitive impairment in a patient for treatment purposes.
  • a commonly referenced diagnostic scale for characterizing the degree of cognitive impairment for a patient with Alzheimer's disease includes the 3 -stage Alzheimer Disease Model.
  • the 3-stages consist of: mild stage (also referred to as “early Alzheimer's disease” or "mild
  • Alzheimer's disease or “early stage Alzheimer's disease” or “mild dementia of an Alzheimer's- type”
  • moderate stage also referred to as “middle Alzheimer's disease” or “moderate Alzheimer's disease” or “middle stage Alzheimer's disease” or “moderate dementia of an Alzheimer's-type”
  • severe stage also referred to as "late Alzheimer's disease” or “severe Alzheimer's disease” or “late stage Alzheimer's disease” or “severe dementia of an Alzheimer's-type”
  • stages it is also not uncommon for treatment purposes to characterize stages together, such as pre-Alzheimer's disease-to-mild stage Alzheimer's disease, mild- to-moderate Alzheimer's disease, or moderate-to-severe Alzheimer's disease.
  • Another useful diagnostic scale that is used in characterizing the degree of cognitive impairment for a patient having Alzheimer's disease is the Seven Stage Alzheimer's Disease Model (sometimes known as the "Seven Stage Global Deterioration Scale” or the "Reisberg Scale”).
  • This diagnostic scale divides the progression of the cognitive disorder associated with Alzheimer's disease as follows: Stage 1-no Alzheimer's disease (generally characterized by absence of impairment, no impairment, or normal function), Stage 2-pre-Alzheimer's disease (generally characterized by minimal impairment, normal forgetfulness, or very mild cognitive decline), Stage 3-early-stage Alzheimer's disease (generally characterized by a noticeable cognitive decline, early confusional/mild cognitive impairment, or mild cognitive decline), Stage 4-early-stage/mild Alzheimer's disease (also referred to as late
  • Stage 5- middle-stage/moderate Alzheimer's also referred to as early dementia/moderate Alzheimer's disease and generally characterized by moderately severe cognitive decline
  • Alzheimer's disease includes all of the above named diagnostic catagories or disease characterizations.
  • Alzheimer's disease it is also not uncommon for a physician to categorize any one or more of the above noted states of Alzheimer's disease as being probable, for example, probable mild-to-moderate Alzheimer's disease or probable severe Alzheimer's disease, when their diagnosis does not include, for example a physical biopsy or other definitive analysis.
  • Mild Cognitive Impairment is considered by some to be an intermediate stage between normal aging and the onset of Alzheimer's disease.
  • MCI may be characterized by persistent forgetfulness, but may lack some or many of the more debilitating symptoms of Alzheimer's disease.
  • Another set of criteria that may characterize a patient as having mild cognitive impairment suitable for treatment includes a patient that meets the following: 1) memory complaints corroborated by an informant, 2) objective memory impairment for age and education, 3) normal general cognitive function, 4) intact activities of daily living, and 5) the patient does not meet criteria for dementia.
  • a patient characterized as having mild cognitive impairment may not yet have a clinical cognitive deficit.
  • Mild cognitive impairment may also be distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. On the clinical diagnostic scale, mild cognitive impairment is followed, in increased severity, by Alzheimer's disease.
  • Limited Cognitive Impairment describes a cognitive impairment (i.e., symptoms or conditions), which precedes mild cognitive impairment on a clinical diagnostic scale, and includes any chronic or temporary impairment in cognition, learning or memory that prevents or reduces the ability of a patient from achieving their individual potential in these areas.
  • LCIs may include minor impairments to memory associated with focus and concentration (e.g., accuracy and speed of learning and recalling information), working memory (e.g., used in decision making and problem solving), cognition, focus, mental quickness, and mental clarity.
  • stereoisomer refers to a molecule capable of existing in more than one spatial atomic arrangement for a given atomic connectivity (e.g., enantiomers, meso compounds, and diastereomers). As used herein, the term “stereoisomer” means either or both enantiomers and diastereomers.
  • aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more stereogenic centers. Accordingly, compounds of this invention can exist as either individual stereoisomers or mixtures of two or more stereoisomers. A compound of the present invention will include both mixtures (e.g., racemic mixtures) and also individual respective stereoisomers that are substantially free from another possible stereoisomer.
  • substantially free of other stereoisomers means less than 25% of other stereoisomers, less than 10% of other stereoisomers, less than 5% of other stereoisomers, less than 2% of other stereoisomers, or less than "X"% of other stereoisomers (wherein X is a number between 0 and 100, inclusive) are present.
  • aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more tautomeric forms. Accordingly, compounds of this invention can exist as either individual tautomers or mixtures of tautomeric forms. A compound of the present invention will include both mixtures (e.g., mixtures of tautomeric forms) and also individual respective tautomers that are substantially free from another possible tautomer.
  • the aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more geometric isomers. Accordingly, compounds of this invention can exist as either geometric isomers or mixtures of geometric isomers. A compound of the present invention will include both mixtures (e.g., mixtures of geometric isomers) and also individual respective geometric isomers that are substantially free from another possible geometric isomer.
  • haloalkyl refers to an alky group having from 1 to 5 halogen substituents independently selected from -F, -CI, -Br, and -I.
  • a haloalkyl may represent a -CF 3 group, a -CCI3 group, a -CH 2 CF 3 group, or a -CF 2 CF 3 group.
  • heteroaryl refers to an aromatic ring system comprising at least one or more hetero- ring atoms, such as two, three, four, or five hetero- ring atoms, independently selected from N, O, and S.
  • Suitable heteroaryl groups may include a single ring, for example, thienyl, pyridyl, thiazolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, pydridazinyl, triazinyl, oxadiazolyl, and furazanyl.
  • Sutiable heteroaryl groups may include a fused ring system, for example, a six-six fused ring system, a six-five fused ring system, or a five-six fused ring system, such as benzothienyl, quinolyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, isoindolyl, purinyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl.
  • a fused ring system for example, a six-six fused ring system, a six
  • Suitable "heterocycloalkyl” groups include those having at least one or more hetero- ring atoms, such as two or three hetero- ring atoms, independently selected from at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci- C 4 -alkyl radical, a branched C 3 -C 4 -alkyl radical, a C 3 -C 4 -cycloalkyl radical, -(CO)-unbranched Ci- C 4 -alkyl, -(CO)-branched C 3 -C 4 -alkyl, -(S0 2 )-unbranched Ci-C 4 -alkyl, or -(S0 2 )-branched C 3 -C 4 - alkyl, and with the further proviso that when the at least one ring atom is sulfur, the
  • Suitable heterocycloalkyl groups may include, for example, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazino, azetidino, azetidinono, oxindolo, oxetano, dihydroimidazolo, and pyrrolidinono.
  • the pharmaceutically acceptable salt of the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), according to the present invention may be acid addition salts with inorganic or organic acids.
  • these salts include acid addition salts with, for instance, mineral acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid or phosphoric acid; organic acids, for example carboxylic acids or sulfonic acids, such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, isethionic acid, glucuronic acid, gluconic acid, methane sulfonic acid or ethane sulfonic
  • a pharmaceutical composition may comprise an
  • aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof are suitable for use as medicaments for the treatment and/or prophylaxis of diseases in humans and/or animals.
  • the invention relates to a method comprising administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof act as ligands, in particular as l- nAChR agonists.
  • a method of treating a patient in need thereof comprising administering an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
  • a method of treating a patient in need thereof comprising administering a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
  • a method of treating a patient in need thereof comprising administering a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
  • the patient may suffer from a cognitive impairment or suffers from one or more symptoms associated with a cognitive impairment, such as Limited Cognitive Impairment (LCI), Mild Cognitive Impairment (MCI), Alzheimer's disease, dementia of an cognitive impairment
  • Alzheimer' s-type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, or schizophrenia with dementia.
  • the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof can, because of their pharmacological properties, be employed alone or in combination with other active ingredients for the treatment and/or prevention of cognitive impairments, for example, Alzheimer's disease or schizophrenia.
  • the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof are particularly suitable for improving cognition, providing procognitive effects, improving perception, improving concentration, improving learning or memory, improving one or more aspects of cognition, e.g., one or more of: executive function, memory (e.g., working memory), social cognition, visual learning, verbal learning and speed of processing, especially after or associated with cognitive impairments like those occurring for example in situations/diseases/syndromes such as mild cognitive impairment, age- associated learning and memory impairments, age-associated memory loss, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post-stroke dementia), post-traumatic brain syndrome, general concentration impairments, concentration impairments in children with learning and memory problems, attention deficit hyperactivity disorder, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome,
  • Parkinson's disease dyskinesias associated with dopamine agonist therapy in Parkinson's Disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia (e.g., paranoid type, disorganized type, catatonic type, and
  • schizophreniform disorder schizoaffective disorder
  • delusional disorder positive symptoms of schizophrenia, negative symptoms of schizophrenia, schizophrenia with dementia, Korsakoff s psychosis, depression, anxiety, mood and affective disorders, traumatic brain injury, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, treatment (including amelioration, prevention or delay of progression) of sleep disorders (e.g., narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/or cataplexy), treatment (including amelioration, prevention or delay) of progression of fatigue, or use for facilitation of emergence from general anesthesia.
  • sleep disorders e.g., narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/or cataplexy
  • treatment including amelioration, prevention or delay
  • aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof can be employed alone or in combination with other active ingredients for the prophylaxis and treatment of acute and/or chronic pain (for a classification, see "Classification of Chronic Pain, Descriptions of Chronic Pain
  • cancer-induced pain and chronic neuropathic pain like, for example, that associated with diabetic neuropathy, postherpetic neuralgia, peripheral nerve damage, central pain (for example as a consequence of cerebral ischaemia) and trigeminal neuralgia, and other chronic pain such as, for example, lumbago, backache, or rheumatic pain.
  • active ingredients are also suitable for the therapy of primary acute pain of any origin and of secondary states of pain resulting therefrom, and for the therapy of states of pain which were formerly acute and have become chronic.
  • the invention relates to a method comprising administering to a patient in need thereof, such as a patient suffering from, or diagnosed as having, a cognitive impairment or having one or more symptoms associated with a cognitive impairment, an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the method may treat and/or improve the one or more symptoms associated with a cognitive impairment and/or the cognitive impairment.
  • a certain embodiment of the present invention provides a method of improving one or more cognitive symptoms, improving one or more behavioral symptoms, or both, associated with a cognitive impairment, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the method provides a pro-cognitive effect in a patient suffering from, or diagnosed as having, a cognitive disease or dementia, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the method provides at least one of the following: visual motor, learning, delayed memory, or executive function; for example provides a pro-cognitive effect, exclusive of attention, in said patient; for example provides a pro-cognitive effect in at least one of the following: visual motor, learning, delayed memory, or executive function.
  • a certain embodiment of the present invention provides a method of treating a patient with a cognitive disease, comprising: administering to the patient a daily dose of a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the method provides a pro-cognitive effect in a patient suffering from, or diagnosed as having, schizophrenia, for example, paranoid type schizophrenia, disorganized type schizophrenia, catatonic type schizophrenia, undifferentiated type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, or schizophrenia with dementia, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to a patient in need thereof, a pharmaceutical composition comprising an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents; wherein the method provides at least one of the following: visual motor, learning, delayed memory, or executive function; for example provides a pro-cognitive effect
  • any one of the above-noted embodiments includes wherein the daily dose is an initial daily dose.
  • a certain embodiment of the present invention provides a method of improving cognition of a patient in need thereof, comprising: administering to the patient an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents.
  • a method of treating or improving one or more symptoms associated with a cognitive disease and/or a cognitive impairment in a patient in need thereof comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
  • any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with a cognitive disease.
  • an ⁇ 7 one of the above-noted embodiments, wherein the method specifically includes preventing progression of a cognitive disease.
  • any one of the above-noted embodiments, wherein the patient has been diagnosed as having a cognitive disease wherein the patient has been diagnosed as having a cognitive disease.
  • any one of the above-noted embodiments, wherein the patient has been diagnosed as having Alzheimer's disease wherein the patient has been diagnosed as having Alzheimer's disease.
  • any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with Alzheimer's disease.
  • any one of the above-noted embodiments, wherein the patient has been diagnosed as having schizophrenia any one of the above-noted embodiments, wherein the patient has been diagnosed as having schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes treating a sy mptom associated with positive symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with positive symptoms of schizophrenia.
  • the method specifically includes preventing progression of positive symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having positive symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with negative symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes preventing progression of negative symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having negative symptoms of schizophrenia.
  • any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having schizophrenia with dementia.
  • any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having a disease associated with chronic inflammation, including atherosclerosis, rheumatoid arthritis and
  • any one of the above-noted embodiments, wherein the pharmaceutical composition is in the form of a tablet.
  • compositions also includes pharmaceutical preparations which, besides inert, nontoxic, pharmaceutically suitable excipients, adjuvants and carriers, contain one or more aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a
  • An aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be formulated for administration in solid or liquid form.
  • an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be formulated for administration in a capsule, a tablet, or a powder form.
  • an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be formulated alone or as part of a pharmaceutical composition, suitable for oral administration, such as in a capsule or tablet, intravenous administration, parenteral administration, topical administration, or transdermal administration, such as in a patch, to a patient in need thereof.
  • An aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be administered as a pharmaceutical composition, for example, in the presence of carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants, and the like, for example, administered as a pharmaceutical composition (e.g., formulation) comprising at least an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, together with one or more
  • pharmaceutically acceptable carriers include the generally accepted meaning which encompasses combinations, compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for consumption by humans without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Suitable pharmaceutically acceptable carriers, adjuvants, excipients, and diluents can include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
  • polyethylene glycol sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- poly oxypropylene -block polymers, polyethylene glycol and wool fat.
  • the formulations can additionally include, but are not limited to, pharmaceutically acceptable lubricating agents, glidants, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, and/or flavoring agents.
  • the pharmaceutical compositions of the present invention may be formulated so as to provide quick release, immediate release, sustained release, or delayed release of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, after administration to the patient by employing procedures well-known in the art.
  • Another embodiment of the invention further comprises methods of making
  • composition comprising admixing at least an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers, or other materials.
  • the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof are to be present in these preparations in a concentration of from 0.1 to 99.5% by weight, preferably from 0.5 to 95% by weight, of the complete mixture.
  • the pharmaceutical preparations may also contain other active pharmaceutical ingredients.
  • the novel active ingredients can be converted in a known manner into conventional formulations such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceutically suitable excipients or solvents.
  • the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the entire mixture, i.e., in amounts which are sufficient to reach the stated dose range.
  • the formulations are produced, for example, by extending the active ingredients with solvents and/or excipients, where appropriate with use of emulsifiers and/or dispersants, it being possible for example when water is used as diluent where appropriate to use organic solvents as auxiliary solvents.
  • administration may take place in a conventional way, for example, orally, transdermally or parenterally, especially perlingually or intravenously.
  • administration may also take place by inhalation through the mouth or nose, for example, with the aid of a spray, or topically via the skin.
  • the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof may be administered in amounts of about 0.01 to 10 mg/kg, on oral administration, for example, about 0.05 to 5 mg/kg, of body weight to achieve effective results.
  • LCMS (A) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5 mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 10- 80AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: Boston Green ODS 2.1x30 mm, 3 ⁇ ; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (B) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 1.5 ml TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 5-95AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (C) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 2 mL NH3H20; Mobile phase B: Acetonitrile; Method name: 5-95CD_4.5MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (D) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 1.5 mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 5- 95AB_R_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP- 18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (F) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 2 ml NH3H20, Mobile phase B: Acetonitrile; Method name: 5-95CD_2MIN_ 2W; Flow Rate: 1.2 mL/min.; Gradient: 5%-95%; Column: XBrige Shield RP-18 2.1x50 mm, 5 ⁇ ; Column temperature: 30 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (G) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 2 mL NH3H20, Mobile phase B: Acetonitrile; Method name: 10-80CD_4MIN _2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: XBridge C-18 2.1x50 mm, 5 ⁇ ; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (H) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 1.5 mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 10- 80AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: Xtimate C-18, 2.1x30 mm, 3 ⁇ ; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (I) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 2 mL NH3H20, Mobile phase B: Acetonitrile; Method name:0-60CD_4.5MIN_2W; Flow Rate: 0.8 ml/min.; Gradient: 0%-60%; Column: XBrige Shield RP-18 2.1x50 mm, 5 ⁇ ; Column temperature 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (J) Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 ⁇ 2mL NH3H20, Mobile phase B: Acetonitrile; Method name: 10-80CD_2MIN_POS_2W; Flow Rate: 1.2ml/min.; Gradient: 10%-80%; Column: Xbridge C-18 2.1x50 mm, 5 ⁇ ; Column
  • LCMS (K) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 0- 30AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-30%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (L) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA;Method name: 0-30AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (M) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 0- 60AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (O) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-30CD_2MIN_POS_2W; Flow Rate: 1.0 mL/min.; Gradient: 0%-30%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (P) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-60CD_2MIN_POS_2W; Flow Rate: 1.0 mL/min.; Gradient: 0%-60%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (Q) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-60CD_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-60%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (R) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 10- 80AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 10%-80%; Column: Xtimate C18, 2.1x30mm, 3um; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (S) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 2mL NH3H20, Mobile phase B: CAN; Method name: 30- 90CD_4MIN_POS_2W; Flow Rate: 0.8 mL/min.; Gradient: 30%-90%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (T) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 5- 95AB_15MIN_YMC; Flow Rate: 1.0 mL/min.; Gradient: 5%-95%; Column: YMC-Pack ODS-A 5 ⁇ 150x4.6mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (W) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 0- 60AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (X) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 0- 60AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (Y) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5 ml TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 5-95AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (Z) Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 ⁇ 1.5 mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: 5- 95AB_R_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP- 18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (AA) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 2mL NH 3 H 2 0, Mobile phase B: ACN; Method name: 10-80CD_2MIN_NEG; Flow Rate: 1.2 mL/min.; Gradient: 10%-80%; Column: Xbridge C18 2.1x50 mm, 5 ⁇ ; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (BB) LCMS (BB)
  • Instrument Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA;Method name: 0- 60AB R 2W; Flow Rate: 1.5 mL/min.; Gradient: 0%-60%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (CC) Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 ⁇ 1.5mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA;Method name: 0- 30AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (DD) LCMS (DD)
  • Instrument Agilent 1200 Series LCMS
  • Mobile phase A 4L H20 ⁇ 1.5mL TFA
  • Mobile phase B 4L ACN ⁇ 0.75 mL TFA
  • Methodhod name 10- 80AB R 2W
  • Flow Rate 1.5 mL/min.
  • Gradient 10%-80%
  • Column Chromolith@Flash RP-18E 25x2 mm
  • Column temperature 50 °C
  • Wavelength 220 nm & 254 nm.
  • LCMS (EE) Instrument: Agilent 1200 Series; Mobile phase A: 1L H20 ⁇ 0.375mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: WUXIAB00; Flow Rate: 0.6 -l.OmL/min; Gradient: 0%-80%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (FF) LCMS (FF)
  • Instrument Agilent 1200 Series; Mobile phase A: 1L H20 ⁇ 0.375mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: WUXIAB01; Flow Rate: 0.8 -l.OmL/min; Gradient: l%-90%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS (GG) Instrument: Agilent 1200 Series; Mobile phase A: 1L H20 ⁇ 0.375mL TFA, Mobile phase B: 4L ACN ⁇ 0.75 mL TFA; Method name: WUXIABIO; Flow Rate: 0.8 -l.OmL/min; Gradient: 10%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
  • LCMS Conditions 2 (“LCMS (2)"): Instrument Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315D, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800, ELSD Alltech 3300 gas flow 1.5 mL/min., Gas
  • cSFC Analytical Conditions Flow rate: 3mL/min; Wavelength: 220 nm; and Column temperature: 35°C, were used for each of the specified conditions below: [00177] cSFC Analytical Conditions A ("cSFC analytical (A)"): Column: Chiralpak OD-3
  • N- chlorosuccinimide (1 eq.). The reaction was stirred for 1 or more hours until TLC showed the reaction was complete. The solution was diluted with ethyl acetate and water and filtered through Celite to remove particles. The layers were separated, and the organic layer was washed with water and brine (2x), dried with sodium sulfate, filtered, and concentrated in vacuo to afford the N- hydroxybenzimidoyl chloride product, which was used as such in the next step.
  • Example 1A -chlorobenzo[d]isoxazol-3-amine
  • Example 4A 6-cyclopropylbenzo[d]isoxazol-3-amine (A-4)
  • cyclopropylboronic acid (0.81 g, 9.4 mmol) in a mixture of toluene (10 mL) and water (1.0 mL) under nitrogen at room temperature were added potassium phosphate (1.0 g, 9.4 mmol), palladium acetate (53 mg, 0.2 mmol) and tricyclohexylphosphine (0.11 g, 0.4 mmol).
  • the resulting mixture was stirred at 100 °C for 6 hours, then diluted with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vaccuo.
  • Example 5A 6-methoxybenzo[d]isoxazol-3-amine (A-5)
  • Example 6A 3 4-dichloro-2-fluorobenzaldehyde oxime (A-6)
  • Example 7A 3,4-dichloro-2-fluorobenzonitrile (A- 7)
  • compound A-10 was prepared from 2-chloro-6- fluorobenzaldehyde :
  • Example 11 A 4-cyano-2-fluoro-N-hydroxybenzimidoyl chloride (A-14)
  • Example 12A 2-fluoro-N-hydroxy-4-(methylsulfonyl)benzi 16)
  • compound A-16 was prepared from 2-fluoro-4- (methylsulfonyl) benzaldehyde:
  • Example 13A l-(tert-butyl)-3-fluorobenzene (A- 17)
  • Example 16A (4,5-dichloro-2-fluorophenyl)methanol (A-21)
  • Example 19A 2-fluoro-N-hydroxy-4-(trifluoromethoxy)benzimidoyl chloride (A-26)
  • compound A-26 was prepared from 2-fluoro-4- (trifluoromethoxy) benzaldehyde:
  • compound A-28 was prepared from 2,3- difluorobenzaldehyde :
  • Example 21A 2,5-difluoro-N-hydroxybenzimidoyl chloride (A-30)
  • compound A-34 was prepared from 2,3-difluoro-4- methylbenzaldehyde :
  • compound A-36 was prepared from 2, 3, 4- trifluorobenzaldehyde :
  • Example 28A 4-chloro-2-fluoro-3-methylbenzaldehyde (A-41)
  • Example 30A 4-chloro-2-fluoro-N-hydroxy-3-methoxybenzimidoyl chloride (A-45)
  • compound A-45 was prepared from 4-chloro-2-fluoro- 3 -methoxybenzaldehyde :
  • Example 31A 4-chloro-2-fluoro-3-(trifluoromethyl)benzaldehyde (A-46)
  • Example 32A 4-chloro-2-fluoro-N-hydroxy-3-(trifluoromethyl)benzimidoyl chloride (A-
  • Example 33A ( -bromo-4-chloro-2-fluorophenyl)methanediol (A-49)
  • Example 34A (3-bromo-4-chloro-2-fluorophenyl)methanol (A-50)
  • Example 35A (4-chloro-3-cyclopropyl-2-fluorophenyl)methanol (A-51)
  • Example 37A 4-chloro-3-cyclopropyl-2-fluoro-N-hydroxybenzimidoyl chloride (A-54)
  • Example 38A 4-chloro-2,6-difluoro-N-hydroxybenzimidoyl chloride (A-56)
  • compound A-56 was prepared from 4-chloro-2,6- difluorobenzaldehyde :
  • Example 40A 2,4-dichloro-6-fluoro-N-hydroxybenzimidoyl chloride (A-59)
  • compound A-61 was prepared from 2,3-difluoro-4- methoxybenzaldehyde :
  • Example 42A 3-chloro-2-fluoro- 4-methoxybenzaldehyde (A-62)
  • Example 43A 3-chloro-2-fluoro-N-hydroxy-4-methoxybenzimidoyl chloride (A-64)
  • Example 44A 3-chloro-2-fluoro-4-methylbenzaldehyde (A-65)
  • compound A-67 was prepared from compound A-65: [00324]
  • Example 49A 4-ethoxy-2-fluorobenzaldehyde (A-72)
  • Example 50A 4-ethoxy-2-fluoro-N-hydroxybenzimidoyl chloride (A- 74)
  • Example 51A 6-chloro-2-fluoro-3-formylbenzonitrile (A- 75)
  • Example 52A 4-chloro-3-cyano-2-fluoro-N-hydroxybenzimidoyl chloride (A-77)
  • Example 53A 3-chloro-2,4-difluoro-N-hydroxybenzimidoyl chloride (A- 79)
  • Example 54A 2-fluoro-4-(lH-pyrazol-l-yl)benz )
  • Example 57A 4-bromo-3-fluorobenzoh drazide (A-84)
  • Example 58A 2-(4-bromo-3-fluorophenyl)-5-methyl-l,3,4-oxadiazole (A-85)
  • Example 59A 2-(3-fluoro-4-vinylphenyl)-5-methyl-l,3,4-oxadiazole (A-86) PPh 3 ' PdCI 2 ' CS 2 C0 3 HF'H 2 0
  • Example 61A 2-fluoro-N-hydroxy-4-(5-methyl-l,3,4-oxadiazol-2-yl)benzimidoyl chloride (A-
  • Example 65A l-chloro-2-ethoxy-3-fluorobenzene (A-94)
  • Example 66A 4-chloro-3-ethoxy-2-fluoro-N-hydroxybenzimidoyl chloride (A-96)
  • tetrahydrofuran (20 mL) at -70°C under nitrogen was added tert-butyllithium (1.3 M in pentane solution, 14 mL, 18 mmol) dropwsie. The resulting yellow solution was stirred at -70°C for 0.5 hour. Then a solution of l-fluoro-2,3-dimethyl-benzene (2.0 g, 16 mmol) in anhydrous tetrahydrofuran (12 mL) was added dropwise. The mixture was stirred at -70 °C for 1 hour.
  • Example 69A 4-chloro-2,3-difluoro-N-hydroxybenzimidoyl chloride (compound-A-101)
  • Example 70A 4-chloro-2,5-difluoro-N-hydroxybenzimidoyl chloride (compound-A-103)
  • Compound A-105 (2.3 g, 82% yield) was prepared as a white solid from compound A- 104 (2.4 g, 11.0 mmol) using 20 mL of N,N-dimethylformamide and a reaction time of 3 days.
  • the reaction was stirred at 25 °C for 3 hours, then quenched with saturated aqueous potassium carbonate solution, resulting in the formation of a solid.
  • the mixture was filtered, and the filtrate was extracted with dichloromethane (5 ⁇ 50 mL).
  • the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
  • the filter cake from the original filtration was slurried with methanol, and the mixture was filtered.
  • the filtrate was directly evaporated to dryness.
  • the combined residue from both batches was dissolved in 4N hydrochloric acid (20 mL) and stirred at room temperature for 4 hours.
  • N-hydroxybenzimidoyl chloride intermediate (1 eq.) in methanol (7 mL/mmol imidoyl chloride intermediate) was added dropwise over 30 min. to a solution of amine A-NH 2 (1.2-2 eq.) and triethylamine (2 eq) in methanol (5-10 mL/mmol imidoyl chloride intermediate) at room temperature. The resulting mixture was stirred at room temperature for 30 min. On completion, the reaction mixture was concentrated in vacuo and purified by prep-HPLC to give the N-hydroxyimidamide intermediate.
  • Example 2 7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-2)
  • rac-2 was prepared from A-l (0.30 g, 1.8 mmol).
  • the product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 ⁇ ; Mobile phase: 40-70% acetonitrile in H 2 0 (add 0.5% NH 3 H 2 0, v/v)] to give rac-2 (170 mg, 34% yield) as an off-white solid.
  • rac-3 was prepared from A-2 (0.30 g, 1.8 mmol).
  • the product was purified by prep-HPLC [Instrument: PREP -A; Column: Phenomenex Gemini C18 150 21.2 mm, particle size: 5 ⁇ ; Mobile phase: 30-55% acetonitrile in H 2 0 (add 0.05% NH 3 H 2 0, v/v)] to give rac-3 (210 mg, 43% yield) as an off-white solid.
  • rac-4 was prepared from A-3 (0.20 g, 1.2 mmol).
  • the product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 ⁇ ; Mobile phase: 44-74% acetonitrile in H 2 0 (add 0.5% NH 3 H 2 0, v/v)] to give rac-4 (45 mg, 14% yield) as a white solid.
  • Example 5 6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3 -amine (rac-5)
  • rac-5 was prepared from 6-methylbenzo[d]isoxazol -3- amine (0.50 g, 3.4 mmol) using 4 equivalents sodium borohydride and a reaction time of 16 hours for the first step.
  • the product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 ⁇ ; Mobile phase: 44-74% acetonitrile in H 2 0 (add 0.5% NH 3 H 2 0, v/v)] to give rac-5 (0.70 g, 14% yield) as a white solid.
  • Example 6 6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-6)
  • rac-6 was prepared from A-4 (0.20 g, 1.1 mmol) using 10 eq. of titanium(IV) isopropoxide.
  • the product was purified by prep-HPLC [Instrument: GX-I; Column: Xtimate C18 150x25 mm, particle size: 5 ⁇ ; Mobile phase: 25-55% acetonitrile in H 2 0 (add 0.1% TFA, v/v)] to give rac-6 (150 mg, 40% yield) as a white solid.
  • rac-8 was prepared from 6-(trifluoromethyl)benzo[d] isoxazol-3 -amine (0.40 g, 2.0 mmol) using 4 equivalents of sodium borohydride and a reaction time of 16 hours for the first step.
  • the product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 ⁇ ; Mobile phase: 28-58% acetonitrile in H 2 0 (add 0.5% NH 3 H 2 0, v/v)] to give rac-8 (0.15 g, 24% yield) as a white solid.
  • Example 10 (i?)-4-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-10)
  • Example 11 (i?)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydochloride ((i?)-ll)
  • Example 14 (i?)-6-(tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydro
  • Example 16 (i?)-N-(quinuclidin-3-yl)-6-(trifluoromethoxy)benzo[£/]isoxazol-3-amine hydrochl
  • the product was purified by prep-HPLC [Instrument: GX-H; Column: Waters Xbridge C18 150x25 mm, particle size: 5 ⁇ ; Mobile phase: 26-56% acetonitrile in H 2 0 (add 0.5% NH 3 H 2 0, v/v)].
  • the product was purified twice by prep-HPLC [Instrument: GX-D; Column: Boston Green ODS 150x30 mm, particle size: 5 ⁇ ; Mobile phase: 6- 42% acetonitrile in H 2 0 (add 0.225% FA, v/v), and Instrument: GX-B; Column: Phenomenex Synergi CI 8 150x30 mm, particle size: 4 ⁇ ; Mobile phase: 23-53% acetonitrile in H 2 0 (add 0.1% TFA, v/v)], treated with 0.2 M hydrochloric acid and lyophilized to give:
  • Example 17 (i?)-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride
  • Example 18 (i?)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-18) and (5)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride (( )-18)
  • Example 20 (i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((K)-20)
  • Example 21 (i?)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochlo
  • Example 22 (i?)-5-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((R)-22)
  • Example 25 (i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3- amine
  • Example 26 (i?)-6-chloro-7-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
  • Example 27 (i?)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((K)-27)
  • Example 28 (i?)-4,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
  • Example 29 (i?)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((R)-29)
  • Example 30 (i?)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-30) and (5)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Description

AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF
C.7-NICOTINIC ACETYLCHOLINE RECEPTORS
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority from U.S. Provisional Application No. 62/173,717, filed June 10, 2015. The foregoing related application, in its entirety, is incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to novel aminobenzisoxazole compounds, and
pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of the cc7- nicotinic acetylcholine receptor, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
BACKGROUND OF THE INVENTION
[0003] The prevalence of cognitive disease, for example dementia in North America, is approximately 6 to 10% of the population, with Alzheimer's disease accounting for a substantial portion of these cases. Many forms of cognitive disease represent a steadily growing medical and social problem of our aging societies around the world. Some believe the main pathological features may relate to intraneuronal neurofibrillary tangles, formation of amyloid beta plaques and/or neurodegeneration of mainly cholinergic and, in later stages, also serotonergic, noradrenergic, and other neurons, resulting in deficiencies of acetylcholine and other neurotransmitters. Some theories suggest that the gradual development of an acetylcholine signaling deficiency may be responsible for the early clinical manifestations of cognitive disease. Consequently, some believe that compounds that improve cholinergic functioning, such as acetylcholine esterase inhibitors may ameliorate the cognitive deficits in patients with cognitive disease. The most widely used acetylcholine esterase inhibitor is donepezil hydrochloride (Aricept®).
[0004] Nicotinic acetylcholine receptors (nAChR) form a large family of ion channels which are activated by the messenger acetylcholine which is produced in the body (Galzi and Changeux, Neuropharmacol. 1995, 34, 563-582). A functional nAChR consists of five subunits which may be different (certain combinations of a 1-9 and β1-4,γ,δ,ε subunits) or identical (a7-9). This leads to the formation of a diversity of subtypes which differ in the distribution in the muscles, the nervous system and other organs (McGehee and Role, Annu. Rev. Physiol. 1995, 57, 521-546). Activation of nAChR leads to influx of cations into the cell and to stimulation of nerve cells or muscle cells. Selective activation of individual nAChR subtypes restricts this stimulation to the cell types which have a corresponding subtype and is thus able to avoid unwanted side effects such as, for example, stimulation of nAChR in the muscles. Clinical experiments with nicotine and experiments in various animal models indicate that central nicotinic acetylcholine receptors are involved in learning and memory processes (e.g. Rezvani and Levin, Biol. Psychiatry 2001, 49, 258-267). Nicotinic acetylcholine receptors of the alpha7 subtype (al nAChR) have a particularly high concentration in regions of the brain which are important for learning and memory, such as the hippocampus and the cerebral cortex (Seguela et al., J. Neurosci. 1993, 13, 596-604). The al nAChR has a particularly high permeability for calcium ions, modulates neurotransmission, influences the growth of axons and, in this way, modulates neuronal plasticity (Broide and Leslie, Mol. Neurobiol. 1999, 20, 1-16).
[0005] WO 2003/055878 describes a variety of agonists of the a7 nAChR said to be useful for improving cognition. WO 2003/055878 suggests that certain agonists of the a7 nAChR are useful for improving perception, concentration, learning or memory, especially after cognitive impairments like those occurring for example in situations/diseases/syndromes such as mild cognitive impairment, age- associated learning and memory impairments, age-associated memory loss, Alzheimer's disease, schizophrenia and certain other cognitive disorders.
BRIEF SUMMARY OF THE INVENTION
[0006] An aspect of the invention provides an aminobenzisoxazole compound represented by Formula (
Figure imgf000003_0001
wherein:
R1, R2, R3, and R4 independently represent -H, -D, halogen radical, -CN, an unbranched Ci-C - alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched
Figure imgf000003_0002
a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02d-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C -alkyl radical, the branched C3-C -alkyl radical, the C3-C6- cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C4-alkyl, the -S02Ci-C4-alkyl, the -(CH2)mS02Ci-C4-alkyl, or the -N(R5)S02Ci-C4-alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, -OR5, -(CH2)mOR5,
-N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C1-C4-alkyl,
-S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6),
-N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched d- C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6), -(CH^SO.d-C,- alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2- haloalkyl radical, or -OCi-C2-haloalkyl radical;
R5 and R6 independently represent -H; an unbranched Ci-C6-alkyl radical, a branched
C3-C6-alkyl radical; a C3-C6-cycloalkyl radical; or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di- radical or a (3-6 membered)-heteroalkyl di -radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci-C -alkyl radical, a branched C3-C - alkyl radical, a C3-C -cycloalkyl radical, -(CO)-unbranched Ci-C -alkyl, -(CO)-branched C3-C4-alkyl, -(S02)-unbranched Ci-C4-alkyl, or
-(S02)-branched C3-C4-alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the C2-C6-alkyl di-radical or the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical; and
m independently represents an integer from 1 to 6;
or a pharmaceutically acceptable salt thereof.
[0007] An aspect of the invention relates to the aminobenzisoxazole compound represented by Formula (la):
Figure imgf000005_0001
An aspect of the invention relates to the aminobenzisoxazole compound represented by
Figure imgf000005_0002
[0009] An aspect of the invention relates to a single stereoisomer of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
[0010] An aspect of the invention relates to a single enantiomer or a single diastereomer of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
[0011] An aspect of the invention relates to a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0012] An aspect of the invention relates to a method comprising administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0013] Another aspect of the invention provides a method of treating a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0014] Another aspect of the invention provides a method of maintaining, treating, curing and/or improving at least one cognitive function in a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0015] Another aspect of the invention provides a method of maintaining, treating, curing and/or improving at least one cognitive function in a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0016] Another aspect of the invention provides a method of treating a patient diagnosed as having a cognitive impairment, comprising: administering to the an effective dose of an
aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0017] Another aspect of the invention provides a method of treating a patient in need thereof, comprising: administering to the patient, for example, a patient diagnosed with having a cognitive impairment, Limited Cognitive Impairment, Mild Cognitive Impairment, Alzheimer's disease, and/or schizophrenia, an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; such that the patient may derive a benefit therefrom.
[0018] Another aspect of the invention provides a method of treating one or more symptoms associated with a cognitive impairment, comprising administering to a patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the patient suffers from, or has been diagnosed as having, a cognitive impairment.
[0019] Another aspect of the invention provides a method of improving cognition of a patient in need thereof, comprising: administering to the patient an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0020] Another aspect of the invention provides a method of improving cognition in a patient suffering from a cognitive impairment, such as a cognitive impairment associated with either schizophrenia or Alzheimer's disease, for example mild Alzheimer's disease, moderate Alzheimer's disease, severe Alzheimer's disease, or mild-to-moderate Alzheimer's disease, comprising
administering an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0021] Another aspect of the invention provides a method of treating a patient suffering from, diagnosed with having, or suffers from one or more symptoms associated with, a cognitive impairment, for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent. For example, the method of treating a patient suffering from, diagnosed with having, or suffers from one or more symptoms associated with, a cognitive impairment, may provide said patient at least one of the following: (i) treats, minimizes progression of, prevents the deterioration of, or reduces the rate of detioraration of, one or more symptoms associated with the cognitive impairment; (ii) treats the cognitive impairment; (iii) improves cognition in said cognitively impaired patient; (iv) improves one or more behavioral symptoms associated with the cognitive impairment; (v) provides a pro-cognitive effect; (vi) provides a pro-cognitive effect in at least one of the following: visual motor, learning, delayed memory, or executive function, or (vii) provides a positive effect on clinical function in said cognitively impaired patient.
[0022] Another aspect of the invention provides a method of treating a patient previously treated, or currently being treated, with an AChEI, that is suffering from, or has been diagnosed with having, a cognitive impairment, for example, Alzheimer's disease, dementia of an Alzheimer's type, MCI, LCI, or schizophrenia, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents; wherein the method improves one or more symptoms associated with the cognitive impairment in the previously, or currently, AChEI treated patient.
[0023] Another aspect of the invention provides a method of treating a patient suffering from, or diagnosed with having a cognitive impairment, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the method provides a positive effect on cognition or a positive effect on clinical function in said cognitively impaired patient, and wherein said patient has been previously treated or is currently being treated with an AChEI.
[0024] Another aspect of the invention provides a method of improving cognition in a patient diagnosed as having a probable cognitive disease, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0025] Another aspect of the invention provides a method of improving or substantially improving one or more symptoms in a cognitve disease patient, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0026] Another aspect of the invention provides a method of slowing the rate of deterioration of at least one symptom in a cognitve disease patient, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient the pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0027] Another aspect of the invention provides a method of treating one or more symptoms associated with a cognitive disease in a patient suffering therefrom, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent
[0028] Another aspect provides a method of minimizing or substantially halting the rate of progression of one or more cognitive diseases in a patient suffering from a cognitive disease, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0029] Another aspect of the invention provides a method of substantially stopping or reversing progression of one or more cognitive diseases, in a patient suffering therefrom, comprising:
administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0030] Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the effective amount of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein said effective amount is administered in an effective dose.
[0031] Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0032] Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, wherein the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a
pharmaceutically acceptable salt thereof, is administered in the form of a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, excipient or diluent.
[0033] Another aspect of the invention provides a method of treating dementia, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the pharmaceutical composition is in the form of a tablet.
[0034] Another aspect of the invention provides a method of treating a patient having a cognitive disease and being administered an acetylcholine esterase inhibitor, comprising: administering to a patient in need thereof an effective amount of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient an effective dose of a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the treatment comprises halting the administration of the acetylcholine esterase inhibitor prior to treating with the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0035] An embodiment of the present invention provides an aminobenzisoxazole compound represented by Formula (la) or Formula (lb):
Figure imgf000010_0001
R1. R independently represent -H, -D, halogen radical, -CN, an unbranched Ci-C4- alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OCi-C4-alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C -alkyl radical, the branched C3-C -alkyl radical, the C3-C6- cycloalkyl radical, the unbranched -OCi-C -alkyl, the branched or cyclic -OC3-C -alkyl, the -S02Ci-C -alkyl, the -(CH2)mS02Ci-C -alkyl, or the -N(R5)S02Ci-C4-alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02d-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6),
-N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched d- C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4- alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2- haloalkyl radical, or -OCi-C2-haloalkyl radical;
R5 and R6 independently represent -H; an unbranched Ci-C6-alkyl radical, a branched
C3-C6-alkyl radical; a C3-C6-cycloalkyl radical; or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di- radical or a (3-6 membered)-heteroalkyl di -radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci-C -alkyl radical, a branched C3-C - alkyl radical, a C3-C -cycloalkyl radical, -(CO)-unbranched Ci-C -alkyl, -(CO)-branched C3-C4-alkyl, -(S02)-unbranched Ci-C4-alkyl, or
-(S02)-branched C3-C -alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the C2-C6-alkyl di-radical or the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0 an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical; and
m independently represents an integer from 1 to 6;
or a pharmaceutically acceptable salt thereof.
[0036] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1, R2, R3, and R4 independently representing -H, -D, halogen radical, -CN, an unbranched Ci-C3-alkyl radical, a branched C3-C -alkyl radical, a C3-C5-cycloalkyl radical, an unbranched -Od-C4-alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02C!-C2-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C2-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C2-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, the branched C3-C -alkyl radical, the C3-C5-cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C -alkyl, the -S02Ci-C2-alkyl, the
-(CH2)mS02Ci-C2-alkyl, or the -N(R5)S02Ci-C2-alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, halogen radical, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6),
-(CH2)mN(R5)(R6), -S02Ci-C2-alkyl, -S02N(R5)(R6), -(CH2)mS02Ci-C2-alkyl,
-(CH2)mS02N(R5)(R6), -N(R5)S02C1-C2-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched C C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C5-cycloalkyl radical, a Ci-C4-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, halogen radical, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -SO.d-C.-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C2-alkyl, -(CH2)mS02N(R5)(R6), -NiR^SO.d-C.-alkyl, -(CO)(CH2)mR5,
-(CO)N(R5)(R6), an unbranched Ci-C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C5- cycloalkyl radical, a Ci-C4-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6-alkyl radical, such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2, or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3-6 membered)- heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di-radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0037] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 and R2 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C3-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, -CHF2, -CH2F, -CF3, an unbranched -OCi-C3-alkyl, a branched or cyclic -OC3-alkyl, -OCF3, -S02CH3, -S02N(CH3)2, or -N(R5)S02CH3; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, the branched C3-C4-alkyl radical, the C3-C4-cycloalkyl radical, the unbranched -OCi-C3-alkyl, or the branched or cyclic -OC3-alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -OR5, =0, -CH3, -CHF2, -CH2F, -CF3, cyclopropyl radical, cyclobutyl radical, or -OCF3; and wherein R5 may independently represent -H, -CH3, or -CH2CH3.
[0038] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 and R2 independently representing -H, -D, -F, -CI, -CH3, -CH2CH3, a cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCF3, -S02CH3, -S02N(CH3)2, or -N(H)S02CH3.
[0039] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 and R2 independently representing -H, -D, or halogen radical, for example, -F, -CI, or -Br. For example, in certain embodiments, R1 and R2 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F. In certain embodiments, R1 and R2 may independently represent -H or -D. In certain embodiments, R1 may independently represent -H or -D, and R2 may independently represent -F or -CI, such as -F. In certain embodiments, R1 may independently represent -F or -CI, such as -F, and R2 may independently represent -H or -D.
[0040] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R3 independently representing -F, -CI, -Br, -CN, an unbranched Ci- C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OC1-C4- alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02d-C4- alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N^SO^-C.-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C4-alkyl radical, the branched C3-C4-alkyl radical, the C3-C6-cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C4-alkyl, the -S02Ci-C4-alkyl, the -(CH2)mS02Ci-C4-alkyl, or the
-N(R5)S02Ci-C4-alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02Ci-C4-alkyl,
-S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C!-C4-alkyl,
-(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2- haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C!-C4-alkyl, -S02N(R5)(R6), -(CH^SO^-C.-alkyl,
-(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched C C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6-alkyl radical , such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2, or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6- alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3-6 membered)-heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di-radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0041] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R3 independently representing -F, -CI, -Br, -CN, an unbranched Ci- C4-alkyl radical, a branched C3-C -alkyl radical, a C3-C -cycloalkyl radical, an unbranched -OCi-C - alkyl, a branched or cyclic -OC3-C4-alkyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02CH3, -S02N(R5)(R6), -CH.CH.SOzd-C.-alkyl, or -N(R5)S02CH3, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C4-alkyl radical, the branched C3-C -alkyl radical, the C3-C -cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C -alkyl, or the -CH2CH2S02Ci-C -alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C C4-alkyl, -S02N(R5)(R6), -(CH^SO.d-C.-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched C C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -SO.d-C.-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5,
-(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6- cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6-alkyl radical, such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2, or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3-6 membered)- heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di-radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0042] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R3 independently representing -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, -S02CH3, a phenyl radical or a heteroaryl radical, such as an N-pyrazole radical, a furan radical, a thiophene radical, an imidazole radical, an oxazole radical, a thiazole radical, a pyridyl radical, a pyrazine radical, a pyrimidine radical, or an oxadiazole radical; wherein the phenyl radical or the heteroaryl radical, such as the N-pyrazole radical, the furan radical, the thiophene radical, the imidazole radical, the oxazole radical, the thiazole radical, the pyridyl radical, the pyrazine radical, the pyrimidine radical, or the oxadiazole radical, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6-alkyl radical , such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as - CH(CH3)2, or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3-6 membered)-heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di- radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0043] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R3 independently representing -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCF3, -S02CH3, a phenyl radical or a heteroaryl radical, such as an N-pyrazole radical, a furan radical, a thiophene radical, an imidazole radical, an oxazole radical, a thiazole radical, a pyridyl radical, a pyrazine radical, a pyrimidine radical, or an oxadiazole radical; wherein the phenyl radical or the heteroaryl radical, such as the N-pyrazole radical, the furan radical, the thiophene radical, the imidazole radical, the oxazole radical, the thiazole radical, the pyridyl radical, the pyrazine radical, the pyrimidine radical, or the oxadiazole radical, may be substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR5, -CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3. For example, in certain embodiments, R3 may independently represent -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, or -OCF3. In certain embodiments, R3 may independently represent -F, -CI, -Br, -CH3, or -OCH3, such as R3 may independently represent -CI, -CH3, or -OCH3.
[0044] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R4 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OC1-C4-alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -SO.d-C.-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C4-alkyl radical, the branched C3-C4-alkyl radical, the C3-C6-cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C4-alkyl, the -S02Ci-C4-alkyl, the
-(CH2)mS02Ci-C4-alkyl, or the -N(R5)S02Ci-C4-alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6),
-(CH2)mN(R5)(R6), -S02C C4-alkyl, -S02N(R5)(R6), -(CH^SO.d-C.-alkyl,
-(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C1-C4-alkyl,
-S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C!-C4-alkyl,
-(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3, an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi- C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6- alkyl radical, such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2, or a C3- C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3- 6 membered)-heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di-radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0045] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R4 independently representing -H, -D, -F, -CI, -CN, an unbranched Ci-C3-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, unbranched -OCi-C3- alkyl, a branched or cyclic -OC3-C4-alkyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, the branched C3-C -alkyl radical, the C3-C -cycloalkyl radical, the unbranched -OCi-C3-alkyl, or the branched or cyclic -OC3-C -alkyl, may be
independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3, an unbranched d-C6- alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein R5 and R6 may independently represent -H, an unbranched Ci-C6-alkyl radical, such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2, or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical, or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a a C2-C5-alkyl di-radical, or a (3-6 membered)-heteroalkyl di-radical, such as a (3-5 membered)-heteroalkyl di-radical; and wherein m may independently represents an integer from 1 to 6, for example, an integer from 1 to 4, such as 1 to 2, 2 to 3, or 3 to 4.
[0046] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R4 independently representing -H, -D, -F, -CI, -CN, -CH3, cyclopropyl radical, cyclobutyl radical, -CH2F, -CHF2, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, or -OCH2CF3. For example, in certain embodiments, R4 may independently represent -H, -D, -F, -CI, -CN, -CH3, cyclopropyl radical, cyclobutyl radical, -CH2F, -CHF2, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, or -OCF3, such as R4 may independently represent -H, -D, -F, -CI, -CH3, -OCH3, -OCH2CH3, or -CF3.
[0047] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise: R1 and R2 independently representing -H or -D, R2 and R4 independently representing -H or -D, R1 and R4 independently representing -H or -D, or R1, R2, and R4 independently representing -H or -D; and R3 independently representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C3-alkyl radical, for example, -CH3 or -CH2CH3, a branched C3-C -alkyl radical, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, an unbranched -OC1-C3- alkyl, such as -OCH3 or -OCH2CH3, a branched or cyclic -OC3-C4-alkyl, such as -OCH(CH3)2 or -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, -S02CH3, a phenyl radical or a heteroaryl radical, such as an N-pyrazole radical, a furan radical, a thiophene radical, an imidazole radical, an oxazole radical, a thiazole radical, a pyridyl radical, a pyrazine radical, a pyrimidine radical, or an oxadiazole radical; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, branched C3-C4- alkyl radical, unbranched -OCi-C3-alkyl, or the branched or cyclic -OC3-C4-alkyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, =0, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3; and wherein the phenyl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3.
[0048] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R3 independently
representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C3-alkyl radical, for example, -CH3 or -CH2CH3, -CH(CH3)2, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, an unbranched -OCi-C3-alkyl, such as -OCH3 or -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, -S02CH3, a phenyl radical or a heteroaryl radical, such as an N- pyrazole radical or an oxadiazole radical; and R4 independently representing -H, -D, -F, -CI, -CN, an unbranched Ci-C3-alkyl radical, for example, -CH3 or -CH2CH3, -CH(CH3)2, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, an unbranched -OCi-C3-alkyl, such as -OCH3 or -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, -CH(CH3)2, unbranched -OCi-C3-alkyl, -OCH(CH3)2, or -O-cyclopropyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, =0, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3; and wherein the phenyl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, -Br, -CN, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH3,
-CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3. [0049] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R3 independently
representing -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C3-alkyl radical, for example, -CH3 or -CH2CH3, -CH(CH3)2, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, an unbranched -OCi-C3-alkyl, such as -OCH3 or -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, or -S02CH3; and R4 independently representing -H, -D, -F, -CI, -CN, an unbranched Ci-C3-alkyl radical, for example, -CH3 or -CH2CH3, -CH(CH3)2, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, an unbranched -OCi-C3-alkyl, such as -OCH3 or -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, -CH(CH3)2, the cyclopropyl radical, the cyclobutyl radical, the unbranched -OCi-C3-alkyl, -OCH(CH3)2, or -O-cyclopropyl, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, -F, -CI, =0, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3.
[0050] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R1 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R2 independently representing -H, -D, or a halogen radical, for example -H, -D, -F, or -CI, such as -H, -D, or -F; R3 independently
representing -H, -D, -F, -CI, -Br, -CN, -CH3, -CH2CH3, -CH(CH3)2, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, or -O-cyclopropyl, or -OCF3; and R4 independently representing -H, -D, -F, -CI, -CN, -CH3, -CH2CH3, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, or
-O-cyclopropyl, -OCF3.
[0051] For example, in certain embodiments, R1 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F; R2 may independently represent -H, -D, -F, or -CI, such as -H, -D, or -F: R3 may independently represent -F, -CI, -Br, -CN, -CH3, -CH2CH3, a cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, or -O-cyclopropyl, or -OCF3, such as -F, -CI, -Br, -CH3, or -OCH3, or such as -CI, -CH3, or -OCH3; and R4 may independently represent -H, -D, -F, -CI, -CN, -CH3, -CH2CH3, a cyclopropyl radical, a cyclobutyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, or -O-cyclopropyl, -OCF3, such as -H, -D, -F, -CI, -CH3, -OCH3, -OCH2CH3, or -CF3.
[0052] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), at least one of R1, R2, R3, and R4 does not independently represent -H. For example, in certain embodiments, R1 independently represents -H, and at least one of R2, R3, and R4 does not independently represent -H; R2 independently represents -H, and at least one ofR\ R3, and R4 does not independently represent -H; R3 independently represents -H, and at least one ofR\ R2, and R4 does not independently represent -H; or R4 independently represents -H, and at least one of R1, R2, and R3 does not independently represent -H.
[0053] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise R5, R6, or both R5 and R6, independently representing -H; an unbranched Ci-C6-alkyl radical, such as -CH3 or -CH2CH3, a branched C3-C6-alkyl radical, such as -CH(CH3)2; or a C3-C6-cycloalkyl radical, such as a cyclopropyl radical or a cyclobutyl radical. For example, R5 and R6 may independently represent -H, -CH3, -CH2CH3, -CH(CH3)2, a cyclopropyl radical, or a cyclobutyl radical, such as independently represent -H, -CH3, or -CH2CH3.
[0054] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise an N(R5)(R6) moiety, wherein the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical or a (3-6 membered)-heteroalkyl di-radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci- C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, -(CO)-unbranched Ci- C4-alkyl, -(CO)-branched C3-C -alkyl, -(S02)-unbranched Ci-C -alkyl, or -(S02)-branched C3-C - alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the C2-C6-alkyl di-radical or the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, halogen radical, =0, an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical.
[0055] In certain embodiments, the N(R5)(R6) moiety may form a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical, such as a C2-C5-alkyl di-radical or C3-C4-alkyl di-radical; wherein the C2-C6-alkyl di-radical, such as a C2-C5-alkyl di-radical or C3-C4-alkyl di-radical, may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, halogen radical, =0, an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical. For example, the N(R5)(R6) moiety may form a cycle, wherein R5 and R6 taken together represent a C2-alkyl di-radical, a C3-alkyl di-radical, C4-alkyl di-radical, or C5- alkyl di-radical, such as a C2-alkyl di-radical.
[0056] In certain embodiments, the N(R5)(R6) moiety may, for example, form a cycle wherein the R5 and R6 taken together represent a (3-6 membered)-heteroalkyl di-radical, such as (4-5 membered)-heteroalkyl di-radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H; an unbranched Ci-C4-alkyl radical, such as -CH3, -CH2CH3, or -CH2CH2CH3, a branched C3-C4- alkyl radical, such as -CH(CH3)2; a C3-C4-cycloalkyl radical; -(CO)-unbranched Ci-C4-alkyl; -(CO)-branched C3-C4-alkyl; -(S02)-unbranched Ci-C4-alkyl; or -(S02)-branched C3-C -alkyl; and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents, for example, up to 4 radical substituents or up to 3 radical substituents, comprising: -D, halogen radical, =0, an unbranched Ci- C6-alkyl radical, or a branched C3-C6-alkyl radical. For example, the N(R5)(R6) moiety may form a cycle, wherein R5 and R6 taken together represent a (4-5 membered)-heteroalkyl di-radical, wherein the (4-5 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen or nitrogen, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H; -CH3, -CH2CH3, -CH(CH3)2, a cyclopropyl radical. -(CO)CH3, -(CO)CH2CH3, -(S02)CH3, or -(S02)CH2CH3.
[0057] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise racemic mixture of enantiomers, a mixture of diastereomers, a single enantiomer, or a single diastereomer, of the compound, or a pharmaceutically acceptable salt thereof. In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), may comprise a mixture of tautomers, substantially a single tautomer form, or a single tautomer form, such as a tautomer contained within the aminobenzisoxazole ring system or a tautomer resulting from one or more substitutents substituted on the aminobenzisoxazole ring system, for example, a tautomer may be contained within the aminobenzisoxazole ring system or one or more substitutents substituted on the aminobenzisoxazole ring system containing a heteroaryl ring nitrogen adjacent to a heteroaryl ring carbon substituted with a hydroxyl group.
[0058] The chemical names and structure diagrams used herein to describe the compounds of the present invention, supra and infra, were created with the use of ChemBioDraw Ultra® Version 12.0 (available from CambridgeSoft Corp., Cambridge, Mass.).
[0059] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the compounds listed below, and single enantiomers and pharmaceutically acceptable salts thereof:
N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 -chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine;
6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-cyclopropyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
N-(quinuclidin-3 -yl) -6 -(trifluoromethyl)benzo [d] isoxazol -3 -amine ;
6,7-dichloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
4-chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ; 6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
3- (quinuclidin-3-ylamino)benzo[d]isoxazole-6-carbonitrile;
6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6- (tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5.6- dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
N-(quinuclidin-3 -yl) -6 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
7- fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine;
4- fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6.7- difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-chloro-7 -methyl -N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
6- chloro-7-cyclopropyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
4-fluoro-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
4.6- dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7- fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-ethoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6- chloro-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-7-carbonitrile;
7- chloro-6-fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-(lH-pyrazol-l-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6- (5-methyl-l,3,4-oxadiazol-2-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7- methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6.7- dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ; and
6-bromo-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine .
[0060] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the compounds listed below, and single enantiomers and pharmaceutically acceptable salts thereof:
6-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; 6-ethyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
6-chloro-N-(quinuclidin-3 -yl)-7-(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 - fluoro-6-methoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6- methoxy-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
6-chloro-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-isopropoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6- chloro-7-cyclopropoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
7- ethoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-fluoro-7-methoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-methoxy-N-(quinuclidin-3 -yl)-7-(trifluoromethyl)benzo [d] isoxazol-3 -amine ;
5 -fluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
5.6- difluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
5.7- difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
6-chloro-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; 6-chloro-5-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 ,7-difluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6,7-dichloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-chloro-7-ethoxy-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine.
[0061] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
(i?)-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(<S)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(iS) -7 -chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine ;
(i?)-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R)-5 -chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-5-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(<S)-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ; JJ?)-6-cyclopropyl-N -(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
^5)-6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
R) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
S) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
R) -N-(quinuclidin-3 -yl) -6 -(trifluoromethyl)benzo [d] isoxazol-3 -amine ;S) -N-(quinuclidin-3 -yl) -6 -(trifluoromethyl)benzo [d] isoxazol-3 -amine ;
^)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-4-chloro-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
^5)-4-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
R)- -(quinuclidin-3 -ylamino)benzo [d] isoxazole -6 -carbonitrile ;
;5)-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-6-carbonitrile;
^)-6-(methylsulfonyl)-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
;<S)-6-(methylsulfonyl)-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
^)-6-(tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
S) -6 -(tert-butyl) -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
^)-5,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
S)-5 ,6-dichloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
R) -N -(quinuclidin-3 -yl) -6 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;S) -N -(quinuclidin-3 -yl) -6 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
^)-7-fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
^S)-7-fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
R)-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
S)-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
R) -4 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine ;
;5)-4-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
[R)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
[S)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
^)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; ^5)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;S) -6 -chloro-N-(quinuclidin-3 -yl) -7 -(trifluoromethyl)benzo [d] isoxazol-3 -amine ;
^)-6-chloro-7-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-4,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-4,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
R) -6 -ethoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
S) -6 -ethoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
R) -6 -chloro-3 -(quinuclidin-3 -ylamino)benzo [d] isoxazole -7 -carbonitrile ;
S) -6 -chloro-3 -(quinuclidin-3 -ylamino)benzo [d] isoxazole -7 -carbonitrile ;
^)-7-chloro-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
R) -6 -( 1 H-pyrazol- 1 -yl) -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
S)-6-( lH-pyrazol- 1 -yl)-N-(quinuclidin-3 -yl)benzo[d]isoxazol-3 -amine;
;i?)-6-(5-methyl-l,3,4-oxadiazol-2-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;<S)-6-(5 -methyl- 1 ,3 ,4-oxadiazol-2-yl)-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
^)-7-methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (i?)-6-bromo-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
(5)-6-bromo-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine.
[0062] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
(i?)-6-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(<S)-6-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R) -6 -ethyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -ethyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethoxy)benzo[d]isoxazol-3-amine;
(iS) -6 -chloro-N-(quinuclidin-3 -yl) -7 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S)-5 -fluoro-6-methoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(i?)-6-methoxy-7 -methyl -N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-methoxy-7 -methyl -N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(5)-6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-6-chloro-5,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-ethoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-7-ethoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methoxy-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(5)-6-methoxy-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(R)-5 -fluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
(5)-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (R)-5 ,6-difluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-5,6-difluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R)-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(S)-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(i?)-6-chloro-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-5 -fluoro-7-methoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(5)-6-chloro-5-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5,7-difluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-5,7-difluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6,7-dichloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(<S)-6,7-dichloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(i?)-6-chloro-7-ethoxy-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS)-6-chloro-7-ethoxy-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
(5)-5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine.
[0063] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
(i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(iS)-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
(i?)-6-chloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine .
[0064] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof: (i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; and
(i?)-6-chloro-7-fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine .
[0065] In certain embodiments, specific examples of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb) may include, collectively or individually, the single enantiomers listed below, and pharmaceutically acceptable salts thereof:
(iS)-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(R) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(R)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ; and
(i?)-6-chloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine .
[0066] In certain embodiments, the aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be more potent against al nAChR (according to the al nAChR Binding Assay (Ki)) than against a 5- HT3 serotonin receptor (according to the [ H]BRL 43694 competition binding (Ki)). For example, the aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be at least 1.5 times more potent against al nAChR than against a 5-HT3 serotonin receptor, as determined by the a7 nAChR Binding Assay and the [ H]BRL 43694 competition binding assay, respectively, such as at least 2 times more potent, at least 3 times more potent, at least 4 times more potent, at least 5 times more potent, at least 6 times more potent, at least 7 times more potent, at least 8 times more potent, at least 9 times more potent, at least 10 times more potent, at least 15 times more potent, at least 20 times more potent, or at least 25 times more potent against al nAChR than against a 5-HT3 serotonin receptor, as determined by the a7 nAChR Binding Assay and the [ H]BRL 43694 competition binding assay, respectively.
[0067] As used herein, the term "treating" (or "treat" or "treatment"), unless otherwise specified, includes the generally accepted meaning which encompasses improving, modifying, decreasing, prohibiting, preventing, restraining, minimizing, slowing, halting, stopping, curing, and/or reversing a symptom associated with a disease and/or a disease. Treatment may include both therapeutic and prophylactic administration. For example, treatment of a cognitive impairment, in a patient diagnosed as having a cognitive impairment, may include, but is not limited to, curing the cognitive impairment, preventing the deterioration of one or more symptoms associated with the cognitive impairment; improving cognition in a patient suffering from the cognitive impairment, slowing the progression of the cognitive impairment and/or modifying the cognitive impairment.
[0068] As used herein, the term "effective dose" (or "dose"), unless otherwise specified, is understood to include a thereapeutically acceptable dose, a thereapeutically acceptable amount, a thereapeutically effective dose, a thereapeutically effective amount, a pharmaceutically acceptable dose, a pharmaceutically acceptable amount, a pharmaceutically effective dose, or a pharmaceutically effective amount.
[0069] As used herein, the term "cognitive impairment," unless otherwise specified, includes at least one of the following: Limited Cognitive Impairment (LCI), Mild Cognitive Impairment (MCI), Alzheimer's disease (or dementia of an Alzheimer' s-type) or a particular stage of Alzheimer's disease, inclusive of pre-Alzheimer's disease, early Alzheimer's disease, mild Alzheimer's disease, moderate Alzheimer's disease, severe Alzheimer's disease, pre-Alzheimer' s-to-mild Alzheimer's disease, mild-to-moderate Alzheimer's disease, moderate-to-severe Alzheimer's disease,
schizophrenia (for example, paranoid type schizophrenia, disorganized type schizophrenia, catatonic type schizophrenia, undifferentiated type schizophrenia), schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of
schizophrenia, or schizophrenia with dementia.
[0070] Alzheimer's disease may include, unless otherwise specified, any of the sub-diagnostic categories used to characterize the type or degree of cognitive impairment in a patient for treatment purposes. A commonly referenced diagnostic scale for characterizing the degree of cognitive impairment for a patient with Alzheimer's disease includes the 3 -stage Alzheimer Disease Model. The 3-stages consist of: mild stage (also referred to as "early Alzheimer's disease" or "mild
Alzheimer's disease" or "early stage Alzheimer's disease" or "mild dementia of an Alzheimer's- type"), moderate stage (also referred to as "middle Alzheimer's disease" or "moderate Alzheimer's disease" or "middle stage Alzheimer's disease" or "moderate dementia of an Alzheimer's-type"), and severe stage (also referred to as "late Alzheimer's disease" or "severe Alzheimer's disease" or "late stage Alzheimer's disease" or "severe dementia of an Alzheimer's-type"). For patients with a condition that has not progressed to the point of mild stage Alzheimer's disease, they may be diagnosed as having pre-Alzheimer's disease. It is also not uncommon for treatment purposes to characterize stages together, such as pre-Alzheimer's disease-to-mild stage Alzheimer's disease, mild- to-moderate Alzheimer's disease, or moderate-to-severe Alzheimer's disease. Another useful diagnostic scale that is used in characterizing the degree of cognitive impairment for a patient having Alzheimer's disease is the Seven Stage Alzheimer's Disease Model (sometimes known as the "Seven Stage Global Deterioration Scale" or the "Reisberg Scale"). This diagnostic scale divides the progression of the cognitive disorder associated with Alzheimer's disease as follows: Stage 1-no Alzheimer's disease (generally characterized by absence of impairment, no impairment, or normal function), Stage 2-pre-Alzheimer's disease (generally characterized by minimal impairment, normal forgetfulness, or very mild cognitive decline), Stage 3-early-stage Alzheimer's disease (generally characterized by a noticeable cognitive decline, early confusional/mild cognitive impairment, or mild cognitive decline), Stage 4-early-stage/mild Alzheimer's disease (also referred to as late
confusional/mild Alzheimer's, and generally characterized by moderate cognitive decline), Stage 5- middle-stage/moderate Alzheimer's (also referred to as early dementia/moderate Alzheimer's disease and generally characterized by moderately severe cognitive decline), Stage 6-middle
dementia/moderately severe Alzheimer's disease (also referred to as middle -stage/moderate to late- stage/severe Alzheimer's disease and generally characterized by severe cognitive decline), and Stage 7-late-stage/severe Alzheimer's disease (also referred to as severe dementia or failure-to-thrive, and generally characterized by very severe cognitive decline). It is also not uncommon for treatment purposes to characterize stages together, such as pre-Alzheimer's disease-to-mild stage Alzheimer's disease, mild-to-moderate Alzheimer's disease, or moderate-to-severe Alzheimer's disease. As used herein, unless otherwise specified, Alzheimer's disease includes all of the above named diagnostic catagories or disease characterizations. It is also not uncommon for a physician to categorize any one or more of the above noted states of Alzheimer's disease as being probable, for example, probable mild-to-moderate Alzheimer's disease or probable severe Alzheimer's disease, when their diagnosis does not include, for example a physical biopsy or other definitive analysis.
[0071] Mild Cognitive Impairment (MCI) is considered by some to be an intermediate stage between normal aging and the onset of Alzheimer's disease. For example, MCI may be characterized by persistent forgetfulness, but may lack some or many of the more debilitating symptoms of Alzheimer's disease. Another set of criteria that may characterize a patient as having mild cognitive impairment suitable for treatment includes a patient that meets the following: 1) memory complaints corroborated by an informant, 2) objective memory impairment for age and education, 3) normal general cognitive function, 4) intact activities of daily living, and 5) the patient does not meet criteria for dementia. In general, a patient characterized as having mild cognitive impairment may not yet have a clinical cognitive deficit. Mild cognitive impairment may also be distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. On the clinical diagnostic scale, mild cognitive impairment is followed, in increased severity, by Alzheimer's disease.
[0072] Limited Cognitive Impairment (LCI) describes a cognitive impairment (i.e., symptoms or conditions), which precedes mild cognitive impairment on a clinical diagnostic scale, and includes any chronic or temporary impairment in cognition, learning or memory that prevents or reduces the ability of a patient from achieving their individual potential in these areas. For example, LCIs may include minor impairments to memory associated with focus and concentration (e.g., accuracy and speed of learning and recalling information), working memory (e.g., used in decision making and problem solving), cognition, focus, mental quickness, and mental clarity. [0073] The term "stereoisomer" refers to a molecule capable of existing in more than one spatial atomic arrangement for a given atomic connectivity (e.g., enantiomers, meso compounds, and diastereomers). As used herein, the term "stereoisomer" means either or both enantiomers and diastereomers.
[0074] The aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more stereogenic centers. Accordingly, compounds of this invention can exist as either individual stereoisomers or mixtures of two or more stereoisomers. A compound of the present invention will include both mixtures (e.g., racemic mixtures) and also individual respective stereoisomers that are substantially free from another possible stereoisomer. The term "substantially free of other stereoisomers" as used herein means less than 25% of other stereoisomers, less than 10% of other stereoisomers, less than 5% of other stereoisomers, less than 2% of other stereoisomers, or less than "X"% of other stereoisomers (wherein X is a number between 0 and 100, inclusive) are present.
[0075] The aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more tautomeric forms. Accordingly, compounds of this invention can exist as either individual tautomers or mixtures of tautomeric forms. A compound of the present invention will include both mixtures (e.g., mixtures of tautomeric forms) and also individual respective tautomers that are substantially free from another possible tautomer.
[0076] The aminobenzisoxazole compounds of the present invention represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may contain one or more geometric isomers. Accordingly, compounds of this invention can exist as either geometric isomers or mixtures of geometric isomers. A compound of the present invention will include both mixtures (e.g., mixtures of geometric isomers) and also individual respective geometric isomers that are substantially free from another possible geometric isomer.
[0077] The term "haloalkyl" refers to an alky group having from 1 to 5 halogen substituents independently selected from -F, -CI, -Br, and -I. For example, a haloalkyl may represent a -CF3 group, a -CCI3 group, a -CH2CF3 group, or a -CF2CF3 group.
[0078] The term "heteroaryl" refers to an aromatic ring system comprising at least one or more hetero- ring atoms, such as two, three, four, or five hetero- ring atoms, independently selected from N, O, and S. Suitable heteroaryl groups may include a single ring, for example, thienyl, pyridyl, thiazolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, pydridazinyl, triazinyl, oxadiazolyl, and furazanyl. Sutiable heteroaryl groups may include a fused ring system, for example, a six-six fused ring system, a six-five fused ring system, or a five-six fused ring system, such as benzothienyl, quinolyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, isoindolyl, purinyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl.
[0079] Suitable "heterocycloalkyl" groups include those having at least one or more hetero- ring atoms, such as two or three hetero- ring atoms, independently selected from at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci- C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, -(CO)-unbranched Ci- C4-alkyl, -(CO)-branched C3-C4-alkyl, -(S02)-unbranched Ci-C4-alkyl, or -(S02)-branched C3-C4- alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0. Suitable heterocycloalkyl groups may include, for example, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazino, azetidino, azetidinono, oxindolo, oxetano, dihydroimidazolo, and pyrrolidinono.
[0080] The pharmaceutically acceptable salt of the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), according to the present invention may be acid addition salts with inorganic or organic acids. Specific examples of these salts include acid addition salts with, for instance, mineral acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid or phosphoric acid; organic acids, for example carboxylic acids or sulfonic acids, such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, isethionic acid, glucuronic acid, gluconic acid, methane sulfonic acid or ethane sulfonic acid; or acidic amino acids such as aspartic acid or glutamic acid.
[0081] In certain embodiments, a pharmaceutical composition may comprise an
aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0082] In certain embodiments, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, are suitable for use as medicaments for the treatment and/or prophylaxis of diseases in humans and/or animals.
[0083] In certain embodiments, the invention relates to a method comprising administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0084] In certain embodiments, the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, act as ligands, in particular as l- nAChR agonists. [0085] In certain embodiments, a method of treating a patient in need thereof, comprising administering an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof. In certain embodiments, a method of treating a patient in need thereof, comprising administering a pharmaceutical composition comprising an
aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof. For example, the patient may suffer from a cognitive impairment or suffers from one or more symptoms associated with a cognitive impairment, such as Limited Cognitive Impairment (LCI), Mild Cognitive Impairment (MCI), Alzheimer's disease, dementia of an
Alzheimer' s-type, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, or schizophrenia with dementia.
[0086] In certain embodiments, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, can, because of their pharmacological properties, be employed alone or in combination with other active ingredients for the treatment and/or prevention of cognitive impairments, for example, Alzheimer's disease or schizophrenia. Because of their selective effect as a7-nAChR agonists, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, are particularly suitable for improving cognition, providing procognitive effects, improving perception, improving concentration, improving learning or memory, improving one or more aspects of cognition, e.g., one or more of: executive function, memory (e.g., working memory), social cognition, visual learning, verbal learning and speed of processing, especially after or associated with cognitive impairments like those occurring for example in situations/diseases/syndromes such as mild cognitive impairment, age- associated learning and memory impairments, age-associated memory loss, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post-stroke dementia), post-traumatic brain syndrome, general concentration impairments, concentration impairments in children with learning and memory problems, attention deficit hyperactivity disorder, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome,
Parkinson's disease, dyskinesias associated with dopamine agonist therapy in Parkinson's Disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia (e.g., paranoid type, disorganized type, catatonic type, and
undifferentiated type), schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, schizophrenia with dementia, Korsakoff s psychosis, depression, anxiety, mood and affective disorders, traumatic brain injury, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, treatment (including amelioration, prevention or delay of progression) of sleep disorders (e.g., narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/or cataplexy), treatment (including amelioration, prevention or delay) of progression of fatigue, or use for facilitation of emergence from general anesthesia.
[0087] In certain embodiments, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, can be employed alone or in combination with other active ingredients for the prophylaxis and treatment of acute and/or chronic pain (for a classification, see "Classification of Chronic Pain, Descriptions of Chronic Pain
Syndromes and Definitions of Pain Terms", 2nd edition, Meskey and Begduk, editors; IASP Press, Seattle, 1994), especially for the treatment of cancer-induced pain and chronic neuropathic pain like, for example, that associated with diabetic neuropathy, postherpetic neuralgia, peripheral nerve damage, central pain (for example as a consequence of cerebral ischaemia) and trigeminal neuralgia, and other chronic pain such as, for example, lumbago, backache, or rheumatic pain. In addition, these active ingredients are also suitable for the therapy of primary acute pain of any origin and of secondary states of pain resulting therefrom, and for the therapy of states of pain which were formerly acute and have become chronic.
[0088] In certain embodiments, the invention relates to a method comprising administering to a patient in need thereof, such as a patient suffering from, or diagnosed as having, a cognitive impairment or having one or more symptoms associated with a cognitive impairment, an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent. For example, the method may treat and/or improve the one or more symptoms associated with a cognitive impairment and/or the cognitive impairment.
[0089] A certain embodiment of the present invention provides a method of improving one or more cognitive symptoms, improving one or more behavioral symptoms, or both, associated with a cognitive impairment, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0090] In a certain embodiment of the present invention, the method provides a pro-cognitive effect in a patient suffering from, or diagnosed as having, a cognitive disease or dementia, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent; wherein the method provides at least one of the following: visual motor, learning, delayed memory, or executive function; for example provides a pro-cognitive effect, exclusive of attention, in said patient; for example provides a pro-cognitive effect in at least one of the following: visual motor, learning, delayed memory, or executive function.
[0091] A certain embodiment of the present invention provides a method of treating a patient with a cognitive disease, comprising: administering to the patient a daily dose of a pharmaceutical composition comprising an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0092] In a certain embodiment of the present invention, the method provides a pro-cognitive effect in a patient suffering from, or diagnosed as having, schizophrenia, for example, paranoid type schizophrenia, disorganized type schizophrenia, catatonic type schizophrenia, undifferentiated type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, or schizophrenia with dementia, comprising: administering to a patient in need thereof an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to a patient in need thereof, a pharmaceutical composition comprising an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents; wherein the method provides at least one of the following: visual motor, learning, delayed memory, or executive function; for example provides a pro-cognitive effect, exclusive of attention, in said patient; for example provides a pro-cognitive effect in at least one of the following: visual motor, learning, delayed memory, or executive function.
[0093] In an embodiment of the present invention, any one of the above-noted embodiments, includes wherein the daily dose is an initial daily dose.
[0094] In a certain embodiment of the present invention provides a method of improving cognition of a patient in need thereof, comprising: administering to the patient an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluents.
[0095] In a certain embodiment of the present invention provides a method of treating or improving one or more symptoms associated with a cognitive disease and/or a cognitive impairment in a patient in need thereof, comprising: administering to the patient an effective dose of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof; or administering to the patient a pharmaceutical composition comprising the aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.
[0096] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with a cognitive disease.
[0097] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with a cognitive disease.
[0098] In an embodiment of the present invention, an}7 one of the above-noted embodiments, wherein the method specifically includes preventing progression of a cognitive disease.
[0099] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the patient has been diagnosed as having a cognitive disease.
[00100] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the patient has been diagnosed as having Alzheimer's disease.
[00101] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with Alzheimer's disease.
[00102] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with Alzheimer's disease.
[00103] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes preventing progression of Alzheimer's disease.
[00104] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the patient has been diagnosed as having mild-to-moderate Alzheimer's disease.
[00105] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with schizophrenia.
[00106] In an embodiment of the present invention, an)7 one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with schizophrenia.
[00107] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes preventing progression of schizophrenia.
[00108] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the patient has been diagnosed as having schizophrenia.
[00109] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a sy mptom associated with positive symptoms of schizophrenia.
[00110] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with positive symptoms of schizophrenia. [00111] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes preventing progression of positive symptoms of schizophrenia.
[00112] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having positive symptoms of schizophrenia.
[00113] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with negative symptoms of schizophrenia.
[00114] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with negative symptoms of schizophrenia.
[00115] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes preventing progression of negative symptoms of schizophrenia.
[00116] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having negative symptoms of schizophrenia.
[00117] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes treating a symptom associated with schizophrenia with dementia.
[00118] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes improving a symptom associated with schizophrenia with dementia.
[00119] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes preventing progression of schizophrenia with dementia.
[00120] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having schizophrenia with dementia.
[00121] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the method specifically includes the patient has been diagnosed as having a disease associated with chronic inflammation, including atherosclerosis, rheumatoid arthritis and
inflammatory bowel diseases.
[00122] In an embodiment of the present invention, any one of the above-noted embodiments, wherein the pharmaceutical composition is in the form of a tablet.
[00123] Pharmaceutical Compositions [00124] In certain embodiments, the invention also includes pharmaceutical preparations which, besides inert, nontoxic, pharmaceutically suitable excipients, adjuvants and carriers, contain one or more aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a
pharmaceutically acceptable salt thereof, or consist of one or more aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, and processes for producing these preparations.
[00125] An aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be formulated for administration in solid or liquid form. For example, an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be formulated for administration in a capsule, a tablet, or a powder form. For example, an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be formulated alone or as part of a pharmaceutical composition, suitable for oral administration, such as in a capsule or tablet, intravenous administration, parenteral administration, topical administration, or transdermal administration, such as in a patch, to a patient in need thereof.
[00126] An aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be administered as a pharmaceutical composition, for example, in the presence of carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants, and the like, for example, administered as a pharmaceutical composition (e.g., formulation) comprising at least an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, together with one or more
pharmaceutically acceptable carriers, adjuvants, excipients, diluents, or other materials well known to those skilled in the art. As used herein, the term "pharmaceutically acceptable", unless otherwise specified, includes the generally accepted meaning which encompasses combinations, compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for consumption by humans without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[00127] Suitable pharmaceutically acceptable carriers, adjuvants, excipients, and diluents, can include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- poly oxypropylene -block polymers, polyethylene glycol and wool fat.
[00128] The formulations can additionally include, but are not limited to, pharmaceutically acceptable lubricating agents, glidants, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, and/or flavoring agents. The pharmaceutical compositions of the present invention may be formulated so as to provide quick release, immediate release, sustained release, or delayed release of an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, after administration to the patient by employing procedures well-known in the art.
[00129] Another embodiment of the invention further comprises methods of making
Pharmaceutical Composition, comprising admixing at least an aminobenzisoxazole compound represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers, or other materials.
[00130] In certain embodiments, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, are to be present in these preparations in a concentration of from 0.1 to 99.5% by weight, preferably from 0.5 to 95% by weight, of the complete mixture. Besides the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, the pharmaceutical preparations may also contain other active pharmaceutical ingredients.
[00131] In certain embodiments, the novel active ingredients can be converted in a known manner into conventional formulations such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceutically suitable excipients or solvents. In these cases, the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the entire mixture, i.e., in amounts which are sufficient to reach the stated dose range.
[00132] In certain embodiments, the formulations are produced, for example, by extending the active ingredients with solvents and/or excipients, where appropriate with use of emulsifiers and/or dispersants, it being possible for example when water is used as diluent where appropriate to use organic solvents as auxiliary solvents.
[00133] In certain embodiments, administration may take place in a conventional way, for example, orally, transdermally or parenterally, especially perlingually or intravenously. In certain embodiments, administration may also take place by inhalation through the mouth or nose, for example, with the aid of a spray, or topically via the skin.
[00134] In certain embodiments, the aminobenzisoxazole compounds represented by Formula (la) or Formula (lb), or a pharmaceutically acceptable salt thereof, may be administered in amounts of about 0.01 to 10 mg/kg, on oral administration, for example, about 0.05 to 5 mg/kg, of body weight to achieve effective results.
[00135] EXAMPLES
[00136] Analytical instrument model:
Table 1
Figure imgf000039_0001
[00137] LCMS:
[00138] LCMS Conditions A ("LCMS (A)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5 mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 10- 80AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: Boston Green ODS 2.1x30 mm, 3 μπι; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00139] LCMS Conditions B ("LCMS (B)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 1.5 ml TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 5-95AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00140] LCMS Conditions C ("LCMS (C)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 2 mL NH3H20; Mobile phase B: Acetonitrile; Method name: 5-95CD_4.5MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature 50 °C; Wavelength: 220 nm & 254 nm.
[00141] LCMS Conditions D ("LCMS (D)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 1.5 mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 5- 95AB_R_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP- 18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00142] LCMS Conditions E ("LCMS (E)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 1.5 ml TFA, Mobile phase B: 4L ACN\0.75 mL TFA; Method name: 5-95AB_R; Flow Rate: 1.5 mL/min. ; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00143] LCMS Conditions F ("LCMS (F)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 2 ml NH3H20, Mobile phase B: Acetonitrile; Method name: 5-95CD_2MIN_ 2W; Flow Rate: 1.2 mL/min.; Gradient: 5%-95%; Column: XBrige Shield RP-18 2.1x50 mm, 5 μιη; Column temperature: 30 °C; Wavelength: 220 nm & 254 nm.
[00144] LCMS Conditions G ("LCMS (G)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 2 mL NH3H20, Mobile phase B: Acetonitrile; Method name: 10-80CD_4MIN _2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: XBridge C-18 2.1x50 mm, 5μιη; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00145] LCMS Conditions H ("LCMS (H)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 1.5 mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 10- 80AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 10%-80%; Column: Xtimate C-18, 2.1x30 mm, 3μιη; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00146] LCMS Conditions I ("LCMS (I)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 2 mL NH3H20, Mobile phase B: Acetonitrile; Method name:0-60CD_4.5MIN_2W; Flow Rate: 0.8 ml/min.; Gradient: 0%-60%; Column: XBrige Shield RP-18 2.1x50 mm, 5μιη; Column temperature 50 °C; Wavelength: 220 nm & 254 nm.
[00147] LCMS Conditions J ("LCMS (J)"): Instrument: Agilent 1200 Series; Mobile phase A: 4L H20 \ 2mL NH3H20, Mobile phase B: Acetonitrile; Method name: 10-80CD_2MIN_POS_2W; Flow Rate: 1.2ml/min.; Gradient: 10%-80%; Column: Xbridge C-18 2.1x50 mm, 5μιη; Column
temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00148] LCMS Conditions K ("LCMS (K)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 30AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-30%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00149] LCMS Conditions L ("LCMS (L)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA;Method name: 0-30AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00150] LCMS Conditions M ("LCMS (M)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 60AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00151] LCMS Conditions N ("LCMS (N)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 60AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00152] LCMS Conditions O ("LCMS (O)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-30CD_2MIN_POS_2W; Flow Rate: 1.0 mL/min.; Gradient: 0%-30%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00153] LCMS Conditions P ("LCMS (P)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-60CD_2MIN_POS_2W; Flow Rate: 1.0 mL/min.; Gradient: 0%-60%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00154] LCMS Conditions Q ("LCMS (Q)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 2mL NH3H20, Mobile phase B: CAN; Method name: 0-60CD_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-60%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00155] LCMS Conditions R ("LCMS (R)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 10- 80AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 10%-80%; Column: Xtimate C18, 2.1x30mm, 3um; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00156] LCMS Conditions S ("LCMS (S)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 2mL NH3H20, Mobile phase B: CAN; Method name: 30- 90CD_4MIN_POS_2W; Flow Rate: 0.8 mL/min.; Gradient: 30%-90%; Column: Xbridge C18 2.1x50 mm, 5um; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00157] LCMS Conditions T ("LCMS (T)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 5- 95AB_15MIN_YMC; Flow Rate: 1.0 mL/min.; Gradient: 5%-95%; Column: YMC-Pack ODS-A 5μιη 150x4.6mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00158] LCMS Conditions U ("LCMS (U)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 30AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00159] LCMS Conditions V ("LCMS (V)"): Instrument: Agilent 1200 Series LCMS;Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA;Method name: 0- 30AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00160] LCMS Conditions W ("LCMS (W)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 60AB_2MIN_2W; Flow Rate: 1.2 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00161] LCMS Conditions X ("LCMS (X)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 0- 60AB_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 0%-60%; Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00162] LCMS Conditions Y ("LCMS (Y)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5 ml TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 5-95AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP-18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00163] LCMS Conditions Z ("LCMS (Z)"): Instrument: Shimadzu LCMS 2020; Mobile phase A: 4L H20 \ 1.5 mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: 5- 95AB_R_4MIN_2W; Flow Rate: 0.8 mL/min.; Gradient: 5%-95%; Column: Chromolith@Flash RP- 18e 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00164] LCMS Conditions AA ("LCMS (AA)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 2mL NH3 H20, Mobile phase B: ACN; Method name: 10-80CD_2MIN_NEG; Flow Rate: 1.2 mL/min.; Gradient: 10%-80%; Column: Xbridge C18 2.1x50 mm, 5μιη; Column temperature: 40 °C; Wavelength: 220 nm & 254 nm.
[00165] LCMS Conditions BB ("LCMS (BB)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA;Method name: 0- 60AB R 2W; Flow Rate: 1.5 mL/min.; Gradient: 0%-60%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00166] LCMS Conditions CC ("LCMS (CC)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA;Method name: 0- 30AB_R_2W; Flow Rate: 1.5 mL/min.; Gradient: 0%-30%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00167] LCMS Conditions DD ("LCMS (DD)"): Instrument: Agilent 1200 Series LCMS; Mobile phase A: 4L H20 \ 1.5mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA;Method name: 10- 80AB R 2W; Flow Rate: 1.5 mL/min.; Gradient: 10%-80%;Column: Chromolith@Flash RP-18E 25x2 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00168] LCMS Conditions EE ("LCMS (EE)"): Instrument: Agilent 1200 Series; Mobile phase A: 1L H20 \ 0.375mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: WUXIAB00; Flow Rate: 0.6 -l.OmL/min; Gradient: 0%-80%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00169] LCMS Conditions FF ("LCMS (FF)"): Instrument: Agilent 1200 Series; Mobile phase A: 1L H20 \ 0.375mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: WUXIAB01; Flow Rate: 0.8 -l.OmL/min; Gradient: l%-90%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00170] LCMS Conditions GG ("LCMS (GG)"): Instrument: Agilent 1200 Series; Mobile phase A: 1L H20 \ 0.375mL TFA, Mobile phase B: 4L ACN \ 0.75 mL TFA; Method name: WUXIABIO; Flow Rate: 0.8 -l.OmL/min; Gradient: 10%-100%; Column: Agilent 5 TC-C18 50x2.1 mm; Column temperature: 50 °C; Wavelength: 220 nm & 254 nm.
[00171] LCMS Conditions 1 ("LCMS (1)"): Instrument: Agilent 1100 Bin. Pump: G1312A, degasser; autosampler, ColCom, DAD: Agilent G1315B, 210 nm, MSD: Agilent LC/MSD G1956B ESI, pos/neg 100-800; MS parameters: Source: ESI, Capillary voltage: 3000V, Drying gas flow: 12 L/min., Nebulizer Pressure 60 psig, Drying Gas Temperature: 350°C, Fragmentor 70, MS scan: MS range 100-800 (positive and negative mode), Flow into MS 0.4 mL/min.; Mobile phase A: 95% acetonitrile + 5% 10 mM ammonium bicarbonate in water; Mobile phase B: 10 mM ammonium bicarbonate in water pH = 9.0; Flow Rate: 0.8 mL/min; Linear Gradient: t=0 min 5% A, t = 3.5 min 98% A, t=6 min 98% A; Column: Phenomenex Gemini NX (C18, 50x2.0 mm, particle size: 3 μιη); Column temperature: 25°C; Detection DAD: Wavelength 220-320 nm.
[00172] LCMS Conditions 2 ("LCMS (2)"): Instrument Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315D, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800, ELSD Alltech 3300 gas flow 1.5 mL/min., Gas
Temperature: 40°C; MS parameters: Source: ESI, Capillary voltage: 3000V, Drying gas flow: 12 L/min., Nebulizer Pressure 60 psig, Drying Gas Temperature: 350°C, Fragmentor 70, MS scan: MS range 100-800 (positive and negative mode), Flow into MS 0.4 mL/min.; Mobile phase A: 0.1% formic acid in acetonitrile; Mobile phase B: 0.1% formic acid in water; Flow Rate: 1 mL/min; Linear gradient: t=0 min 5% A, t=1.6min 98% A, t=3 min 98% A; Column: Waters XSelect (C18, 30x2.1 mm, particle size 3.5μιη); Column temperature: 35°C; Detection DAD: Wavelength 220-320 nm.
[00173] GCMS:
[00174] GCMS Conditions Instrument: SHIMADZU GCMS-QP2010 Ultra; Carrier gas: He; Column Flow: 1.5mL/min; Injector: 250 °C; Split Ratio: 100: 1; Column: HP-5MS
15mx0.25mmx0.25um; FILM From: 40 °C (holding 3min) to 250 °C (holding 3min) at the rate of 25°C/min.
[00175] cSFC Analytical:
[00176] cSFC Analytical Conditions: Flow rate: 3mL/min; Wavelength: 220 nm; and Column temperature: 35°C, were used for each of the specified conditions below: [00177] cSFC Analytical Conditions A ("cSFC analytical (A)"): Column: Chiralpak OD-3
100x4.6mm I.D., 3um; Mobile phase: ethanol (0.05% diethylamine ("DEA") in C02 from 5% to 40%.
[00178] cSFC Analytical Conditions B ("cSFC analytical (B)"): Column: Chiralpak OD-3
100x4.6mm I.D., 3um; Mobile phase: methanol (0.05% DEA) in C02 from 5% to 40%.
[00179] cSFC Analytical Conditions C ("cSFC analytical (C)"): Column: Chiralpak OD-3
100x4.6mm I.D., 3um; Mobile phase: 40% ethanol (0.05% DEA) in C02.
[00180] cSFC Analytical Conditions D ("cSFC analytical (D)"): Column: Chiralpak AY-3
100x4.6mm I.D., 3um; Mobile phase: ethanol (0.05% DEA) in C02 from 5% to 40%.
[00181] cSFC Analytical Conditions E ("cSFC analytical (E)"): Column: Chiralpak OJ-3
100x4.6mm I.D., 3um; Mobile phase: ethanol (0.05% DEA) in C02 from 5% to 40%.
[00182] cSFC Analytical Conditions F ("cSFC analytical (F)"): Column: Chiralpak OJ-3
100x4.6mm I.D., 3um; Mobile phase: methanol (0.05% DEA) in C02 from 5% to 40%.
[00183] cSFC Analytical Conditions G ("cSFC analytical (G)"): Column: Chiralpak AD-3
100x4.6mm I.D., 3um; Mobile phase: ethanol (0.05% DEA) in C02 from 5% to 40%.
[00184] cSFC Analytical Conditions H ("cSFC analytical (H)"): Column: Chiralpak AD-3
100x4.6mm I.D., 3um; Mobile phase: methanol (0.05% DEA) in C02 from 5% to 40%.
[00185] For each final compound prepared below that indicates the presence of a salt associated with the final compound (i.e., a salt complex), the specific molar equivalence of salt included in the final compound, unless specified, was not determined.
[00186] General .
Figure imgf000044_0001
N"hydroxyimjdOy|
chloride
[00187] A mixture of aldehyde (1 eq.), hydroxylamine hydrochloride (1.3-2 eq.) and triethylamine (2 eq.) in dichloromethane (1.2-2.5 mL/mmol aldehyde) was stirred at room temperature for 16 hours. On completion, the reaction mixture was diluted with water and extracted with dichloromethane (3 χ 20 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give the oxime intermediate. This intermediate was either purified by silica gel chromatography or used without further purification in the next step.
[00188] To a solution of oxime intermediate (1 eq.) in dichloromethane (10 mL) at 0 °C was added a solution of N-chlorosuccinimide (1.2 eq.) in N, N-dimethylformamide (0.5 mL). The mixture was stirred at 30 °C for 1 hour. On completion, the reaction mixture was diluted with water and extracted with dichloromethane (3 x 10 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give Ν- hydroxyimidoyl chloride intermediate, which was used crude in the next reaction without further purification.
[00189] General Procedure A2: Synthesis of N-hydroxyimidoyl chloride.
Figure imgf000045_0001
[00190] To a solution of aldehyde in ethanol/water (8/1, v/v) at room temperature was added hydroxylamine hydrochloride (2 eq.) and sodium acetate (3 eq.). The reaction was stirred for 1-2 hour until TLC showed the reaction was complete. The mixture was concentrated in vacuo, and the residue was triturated from water, collected by filtration, washed with water and dried in vacuo to afford the oxime product, which was used as such in the next step.
[00191] To a solution of oxime in N,N-dimethylformamide at room temperature was added N- chlorosuccinimide (1 eq.). The reaction was stirred for 1 or more hours until TLC showed the reaction was complete. The solution was diluted with ethyl acetate and water and filtered through Celite to remove particles. The layers were separated, and the organic layer was washed with water and brine (2x), dried with sodium sulfate, filtered, and concentrated in vacuo to afford the N- hydroxybenzimidoyl chloride product, which was used as such in the next step.
[00192] Example 1A: -chlorobenzo[d]isoxazol-3-amine
Figure imgf000045_0002
[00193] To a solution of N-hydroxyacetamide (3.6 g, 48 mmol) in dry N,N-dimethylformamide (60 mL ) at room temperature was added potassium 7-butoxide (5.4 g, 48 mmol). After stirring for 30 minutes, 3-chloro-2-fluorobenzonitrile (5.0 g, 32 mmol) was added, and stirring was continued for another 4.5 hours. On completion, the reaction mixture was poured into a mixture of brine (60 mL) and ethyl acetate (60 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by silica gel chromatography
[petroleum ether: ethyl acetate = 3: 1] to afford compound A-l (3.9 g, 73% yield) as a pale yellow solid. i-NMR (DMSO- 6, 400 MHz): δ 7.82-7.80 (d, J=7.6 Hz, 1H), 7.65-7.63 (d, J=7.2 Hz, 1H), 7.30-7.26 (m,lH), 6.61 (s, 2H). [00194] Example 2A -chlorobenzo[d]isoxazol-3-amine
Figure imgf000046_0001
[00195] To a solution of N-hydroxyacetamide (3.1 g, 41 mmol) in dry N,N-dimethylformamide
(60 mL ) at room temperature was added potassium 7-butoxide (4.6 g, 41 mmol). After stirring for 30 minutes, 4-chloro-2-nitrobenzonitrile (5.0 g, 27 mmol) was added, and stirring was continued for another 4.5 hours. On completion, the reaction mixture was poured into a mixture of brine (60 mL) and ethyl acetate (60 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by silica gel chromatography
[petroleum ether: ethyl acetate = 3: 1] to afford compound A-2 (3.1 g, 66% yield) as a pale yellow solid. i-NMR (DMSO- 6, 400 MHz): δ 7.84-7.82 (d, J=8.8 Hz, 1H), 7.65-7.64 (d, J=1.2 Hz, 1H),
7.33-7.31 (dd, J=1.2 Hz, J=8.8 Hz, 1H), 6.52 (s, 2H).
[00196] Example 3A: 5-chlorobenzo[d]isoxazol-3-amine (A-3)
Figure imgf000046_0002
[00197] To a solution of N-hydroxyacetamide (2.2 g, 29 mmol) in dry N,N-dimethylformamide (30 mL ) at room temperature was added potassium 7-butoxide (3.2 g, 29 mmol). After stirring for 30 minutes, 5-chloro-2-fluorobenzonitrile (3.0 g, 19 mmol) was added, and stirring was continued for another 4.5 hours. On completion, the reaction mixture was quenched with water and extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were washed with water and brine (5 x 50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 1: 1] to afford compound A-3 (1.5 g, 31% yield) as a white solid.
[00198] Example 4A: 6-cyclopropylbenzo[d]isoxazol-3-amine (A-4)
Figure imgf000046_0003
[00199] To a solution of 6-bromobenzo[d]isoxazol-3 -amine (1.0 g, 4.7 mmol) and
cyclopropylboronic acid (0.81 g, 9.4 mmol) in a mixture of toluene (10 mL) and water (1.0 mL) under nitrogen at room temperature were added potassium phosphate (1.0 g, 9.4 mmol), palladium acetate (53 mg, 0.2 mmol) and tricyclohexylphosphine (0.11 g, 0.4 mmol). The resulting mixture was stirred at 100 °C for 6 hours, then diluted with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vaccuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 5: 1] to afford compound A-4 (0.59 g, 72% yield) as a off-white solid. LCMS (B): tR=0.684 min., (ES+) m/z (M+H)+ = 175.1. ¾-NMR (CD3OD,, 400 MHz): δ 7.40-7.38 (d, J=8.0 Hz, 1H), 7.09 (s, 1H), 6.99-6.97 (d, J=8.4 Hz, 1H), 4.37 (s, 2H), 2.05-2.01 (m, 1H), 1.10-1.05 (m, 2H), 0.81-0.77 (m, 2H).
[00200] Example 5A: 6-methoxybenzo[d]isoxazol-3-amine (A-5)
Figure imgf000047_0001
[00201] To a solution of N-hydroxyacetamide (3.2 g, 42 mmol) in dry N,N-dimethylformamide (50 mL ) at room temperature was added potassium 7-butoxide (6.6 g, 59 mmol). After stirring for 30 minutes, 4-methoxy-2-nitrobenzonitrile (3.0 g, 17 mmol) was added, and stirring was continued for another 16 hours. On completion, the reaction mixture was quenched with water and extracted with ethyl acetate (3 100 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, concentrated in vacuo and purified by silica gel chromatography
[petroleum ether: ethyl acetate = 1: 1] to give compound A-5 (2.0 g, 72% yield) as a yellow solid. LCMS (J): (ES+) m/z (M+H)+ = 165.1, tR= 1.164 min.
[00202] Example 6A: 3 4-dichloro-2-fluorobenzaldehyde oxime (A-6)
Figure imgf000047_0002
[00203] A mixture of 3,4-dichloro-2-fluorobenzaldehyde (2.0 g, 9.5 mmol), hydroxylamine hydrochloride (0.98 g, 14 mmol.) and triethylamine (2.0 mL, 14 mmol.) in dichloromethane (10 mL) was stirred at room temperature for 12 hours. On completion, the reaction mixture was diluted with water and extracted with dichloromethane (3 20 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give compound A-6 (1.5 g, white solid, 69% yield). LCMS (B): (ES+) m/z (M+H)+ = 208.0. tR=0.81 min.
[00204] Example 7A: 3,4-dichloro-2-fluorobenzonitrile (A- 7)
Figure imgf000047_0003
[00205] To a solution of compound A-6 (1.5 g, 7.2 mmol) in toluene (50 mL) was added slowly thionyl chloride (0.90 g, 7.6 mmol). The mixture was stirred at 120 °C for 2 hours, then concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1] to give compound A-7 (0.80 g, 58% yield) as a white solid. ¾-NMR (CD3OD, 400 MHz): δ 7.81- 7.73 (m, 1H), 7.62-7.60 (m, 1H). [00206] Example 8A: 6,7-dichlorobenzo[d]isoxazol-3-amine
Figure imgf000048_0001
A"7 A 8
[00207] To a solution of N-hydroxyacetamide (1.4 g, 19 mmol) in dry N,N-dimethylformamide (20 mL) at room temperature was added potassium 7-butoxide (2.1 g, 19 mmol). After stirring for 0.5 hour, compound A-7 was added, and stirring was continued for another 12 hours. On completion the reaction mixture was poured into brine and extracted with ethyl acetate (2x 25 mL).The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting solid was recrystallized from dichloromethane / petroleum ether to give compound A-8 (1.0 g, 50% yield) as a white solid. LCMS (B): (ES+) m/z (M+H)+ = 203.1. tR=0.73 min.
[00208] Exam -chloro-6-fluoro-N-hydroxybenzimidoyl chloride (A-10)
Figure imgf000048_0002
A 9 A 10
[00209] Following general procedure Al, compound A-10 was prepared from 2-chloro-6- fluorobenzaldehyde :
[00210] Compound A-9 (790 mg, white solid, 72% yield) was prepared from 2-chloro-6- fluorobenzaldehyde (1.0 g, 6.37 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1].
[00211] Compound A-10 (0.3 g, white solid, crude) was prepared from compound A-9 (0.4 g, 2.3 mmol). TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.7.
[00212] Exam -difluoro-N-hydroxybenzimidoyl chloride (A-12)
Figure imgf000048_0003
A 11 A 12
[00213] Following general procedure Al, compound A-12 was prepared from 2,4- difluorobenzaldehyde :
[00214] Compound A-ll (2.0 g, white solid, 90% yield) was prepared from 2,4- difluorobenzaldehyde (2.0 g, 14 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (B): (ES+) m/z (M+H)+ = 158.1, tR=0.598 min.
[00215] Compound A-12 (1.4 g, white solid, crude) was prepared from compound A-ll (1.0 g,
6.4 mmol). TLC [petroleum ether: ethyl acetate = 5: 1]: Rf= 0.6.
[00216] Example 11 A: 4-cyano-2-fluoro-N-hydroxybenzimidoyl chloride (A-14)
Figure imgf000049_0001
A"13
[00217] Following general procedure Al, compound A-14 was prepared from 3-fluoro-4- formylbenzonitrile :
[00218] Compound A-13 (2.7 g, white solid, 82% yield) was prepared from 3-fluoro-4- formylbenzonitrile (3.0 g, 20 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (B): (ES+) m/z (M+H)+ = 165.1, tR=0.538 min.
[00219] Compound A-14 (0.30 g, white solid, crude) was prepared from compound A-13 (0.40 g, 2.4 mmol). TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.6.
[00220] Example 12A: 2-fluoro-N-hydroxy-4-(methylsulfonyl)benzi 16)
Figure imgf000049_0002
[00221] Following general procedure Al, compound A-16 was prepared from 2-fluoro-4- (methylsulfonyl) benzaldehyde:
[00222] Compound A-15 (1.8 g, white solid, 81% yield) was prepared from 2-fluoro-4-
(methylsulfonyl) benzaldehyde (2.0 g, 9.9 mmol) and purified by silica gel chromatography
[petroleum ether: ethyl acetate = 8: 1]. LCMS (B): (ES+) m/z (M+H)+ = 218.1, tR=0.798 min.
[00223] Compound A-16 (0.6 g, white solid, crude) was prepared from compound A-15 (1.0 g,
4.6 mmol). TLC [petroleum ether: ethyl acetate = 10: 1]: Rf = 0.5.
[00224] Example 13A: l-(tert-butyl)-3-fluorobenzene (A- 17)
Figure imgf000049_0003
[00225] To 40% fluoroboric acid (40 mL) was added 3-tert-butylaniline (5.5 g, 37 mmol) portion- wise. The mixture was stirred at 25 °C for 0.5 hour and then cooled to 0 °C. Sodium nitrite (4.1 g, 59 mmol) in water (10 mL) was added, and the solution was stirred at 0 °C for 0.5 hour and at 25°C for 20 mins, resulting in formation of a sold. The solid was collected by filtration, washed with 40% fluoroboric acid (10 mL), ethanol (5 mL) and n-hexane (10 mL), dried, dissolved in tetrahydrofuran (60 mL) and stirred at 40 °C for 12 hours. On completion, the mixture was concentrated, and the residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 1:0] to afford compound A- 17 (4.0 g, 71% yield) as a yellow oil. [00226] Example 14 -(tert-butyl)-2-fluorobenzaldeh
Figure imgf000050_0001
[00227] To a solution of compound A-17 (1.9 g, 12 mmol) in anhydrous tetrahydrofuran (25 mL) at -70 °C was added dropwise sec-butyllithium (12 mL, 1.3 N in pentane, 15 mmol). The reaction was stirred at -70 °C for lh. Then N,N-dimethylformamide (3.6 g, 49 mmol) was added, and stirring was continued at -70 °C for another lh. On completion, the mixture was poured into aqueous ammonium chloride (20 mL) and extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The reside was purified by silica gel chromatography [petroleum ether: ethyl acetate = 15: 1] to give compound A-18 (2.0 g, 91% yield) as a yellow oil.
[00228] Exa -20)
Figure imgf000050_0002
A"18 A"19
[00229] Following general procedure Al, compound A-20 was prepared from compound A-18:
[00230] Compound A-19 (0.35 g, white solid, 73% yield) was prepared from compound A-18 (0.45 g, 2.5 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (DD): (ES+) m/z (M+H)+ = 196.2, tR=0.835 min.
[00231] Compound A-20 (0.30 g, white solid, crude) was prepared from compound A-19 (0.35 g, 1.8 mmol).
[00232] Example 16A: (4,5-dichloro-2-fluorophenyl)methanol (A-21)
Figure imgf000050_0003
[00233] To a solution of 4, 5-dichloro-2-fluoro-benzoic acid (5.0 g, 24 mmol) in tetrahydrofuran (50 mL) at 0 °C was added borane -tetrahydrofuran complex (1 M, 60 mL, 60 mmol) dropwise over 30 minutes. The resulting solution was stirred at 30 °C for 14 hours until TLC analysis showed the reaction was complete. The reaction was quenched carefully with methanol (10 mL) and then concentrated in vacuo to give compound A-21 (4.50 g, 85% yield) as a yellow oil, which was used in the next step without further purification. LCMS (DD): (ES+) m/z (M+H)+ = 176.9, tR=0.859 min. [00234] Example 17A: 4,5-dichloro-2-fluorobenzaldehyde (A-22)
Figure imgf000051_0001
[00235] A mixture of compound A-21 (2.8 g, 14 mmol) and manganese dioxide (12 g, 143 mmol) in dichloromethane (40 mL) was stirred at 30 °C for 16 hours until TLC analysis showed the starting material was consumed. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 5: 1] to afford compound A-22 (2.0 g, 73% yield) as a white solid.
[00236] Ex 24)
Figure imgf000051_0002
A 22 A 23 A 24
[00237] Following general procedure Al, compound A-24 was prepared from compound A-22:
[00238] Compound A-23 (3.0 g, white solid, 80% yield) was prepared from compound A-22 (3.5 g, 18 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (DD): (ES+) m/z (M+H)+ = 207.9, tR=0.931 min.
[00239] Compound A-24 (0.30 g, white solid, crude) was prepared from compound A-23 (0.30 g,
1.4 mmol).
[00240] Example 19A: 2-fluoro-N-hydroxy-4-(trifluoromethoxy)benzimidoyl chloride (A-26)
Figure imgf000051_0003
[00241] Following general procedure Al, compound A-26 was prepared from 2-fluoro-4- (trifluoromethoxy) benzaldehyde:
[00242] Compound A-25 (0.93 g, white solid, crude) was prepared from 2-fluoro-4- (trifluoromethoxy)benzaldehyde (1.0 g, 4.8 mmol) and hydroxylamine hydrochloride (1.0 g, 14 mmol) using a mixture of ethanol (12 mL) and water (2.4 mL) without triethylamine as the solvent instead of dichloromethane. The reaction time was 2.5 hours. The product was used directly for the next step without further purification. LCMS (DD): (ES+) m/z (M+H)+ = 224.0, tR=0.953 min.
[00243] Compound A-26 (0.63 g of yellow oil, crude) was prepared from compound A-25 (0.55 g, 2.5 mmol) and N-chlorosuccinimide (0.40g, 3.0 mmol). The reaction time was 3 hours. LCMS (B): tR=0.836 min, (ES+) m/z (M+H)+ = 258.0. [00244] Exa
Figure imgf000052_0001
[00245] Following general procedure Al, compound A-28 was prepared from 2,3- difluorobenzaldehyde :
[00246] Compound A-27 (1.0 g, white solid, 90% yield) was prepared from 2,3- difluorobenzaldehyde (1.0 g, 7.0 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1].
[00247] Compound A-28 (1.2 g, white solid, crude) was prepared from compound A-27 (1.0 g, 6.4 mmol).
[00248] Example 21A: 2,5-difluoro-N-hydroxybenzimidoyl chloride (A-30)
Figure imgf000052_0002
[00249] Following general procedure Al, compound A-30 was prepared from 2,5- difluorobenzaldehyde :
[00250] Compound A-29 (1.0 g, white solid, crude) was prepared from 2,5 -difluorobenzaldehyde (1.0 g, 7.0 mmol) with a reaction time of 14 hours and used in next step without further purification. LCMS (B): (ES+) m/z (M+H)+ = 158.0, tR= 0.559 min.
[00251] Compound A-30 (1.0 g, white solid, crude) was prepared from compound A-29 (1.0 g, 6.4 mmol) with a reaction time of 12 hours, [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.7.
[00252] Exam
Figure imgf000052_0003
[00253] Following general procedure Al, compound A-32 was prepared from 2,6- difluorobenzaldehyde :
[00254] Compound A-31 (1.1 g, white solid, 99% yield) was prepared from 2,4- difluorobenzaldehyde (1.0 g, 7.0 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (J): (ES+) m/z (M+H)+ = 158.1, tR=0.838 min.
[00255] Compound A-32 (0.60 g, white solid, crude) was prepared from compound A-31 (0.50 g, 3.2 mmol). The reaction time was 16 hours. TLC [petroleum ether: ethyl acetate = 10: 1]: Rf = 0.45. [00256] Example 23A: 2,3-difluoro-N-hydroxy-4-methylbenzimidoyl chloride (A-34)
Figure imgf000053_0001
A 33 A"34
[00257] Following general procedure Al, compound A-34 was prepared from 2,3-difluoro-4- methylbenzaldehyde :
[00258] Compound A-33 (1.0 g, white solid, 91% yield) was prepared from 2,3-difluoro-4- methylbenzaldehyde (1.0 g, 6.4 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (J): (ES+) m/z (M+H)+ = 172.1, tR=1.279 min.
[00259] Compound A-34 (0.60 g, white solid, crude) was prepared from compound A-33 (0.50 g, 3.2 mmol). The reaction time was 16 hours. TLC [petroleum ether: ethyl acetate = 10: 1]: Rf = 0.5.
[00260] Exam -trifluoro-N-hydroxybenzimidoyl chloride (A-36)
Figure imgf000053_0002
[00261] Following general procedure Al, compound A-36 was prepared from 2, 3, 4- trifluorobenzaldehyde :
[00262] Compound A-35 (0.80 g, white solid, 73% yield) was prepared from 2,3,4- trifluorobenzaldehyde (1.0 g, 6.3 mmol) (reaction time was 12 hours), and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (B): (ES+) m/z (M+H)+ = 176.1, tR=0.68 min.
[00263] Compound A-36 (0.35 g, white solid, crude) was prepared from compound A-35 (0.40 g, 2.3 mmol) with a reaction time of 12 hours. TLC [petroleum ether: ethyl acetate = 7: 1]: Rf = 0.6.
[00264] Example 25A: (2,5-difluoro-4-methylphenyl)methanol (A-37)
Figure imgf000053_0003
[00265] To a solution of 4, 5-dichloro-2-fluoro-benzoic acid (2.75 g, 16 mmol) in tetrahydrofuran (30 mL) at 0 °C was added borane -tetrahydrofuran complex (1 M, 40 mL, 40 mmol) drop-wise over 30 minutes. The resulting solution was stirred at 30 °C for 2.5 hours. On completion, the reaction was quenched carefully with methanol (10 mL) and then concentrated in vacuo to give compound A-37 (2.0 g, crude) as a yellow solid, which was used in next step without further purification. LCMS (J): (ES+) m/z (M+H)+ = 159.1, tR=1.12 min. [00266] Example 26A: 2, 5-difluoro-4-methylbenzaldehy
Figure imgf000054_0001
[00267] A mixture of compound A-37 (2.5 g, 16 mmol) and manganese dioxide (14 g, 0.16 mol) in dichloromethane (20 mL) was stirred at 30 °C for 46 hours. On completion, the reaction mixture was filtered, and the filtrate was concentrated in vacuo to give compound A-38 (2.0 g, crude) as a white solid. LCMS (J): (ES+) m/z (M+H)+ = 157.1, tR=1.28 min.
[00268] Exa 40)
Figure imgf000054_0002
A"38 A"39 A"40
[00269] Following general procedure Al, compound A-40 was prepared from compound A-38.
[00270] Compound A-39 (2.3 g, crude) was prepared from compound A-38 (2.5 g, 16 mmol). The reaction time was 15 hours.
[00271] Compound A-40 (1.2 g, white solid, crude) was prepared from compound A-39 (1.0 g, 5.8 mmol). The reaction time was 14 hours. TLC [petroleum ether: ethyl acetate = 8: 1]: Rf = 0.5.
[00272] Example 28A: 4-chloro-2-fluoro-3-methylbenzaldehyde (A-41)
Figure imgf000054_0003
A 41
[00273] To a solution of l-chloro-3-fluoro-2-methylbenzene (10 g, 69 mmol) in anhydrous tetrahydrofuran (20 mL) at -78 °C was added lithium diisopropylamide (2 M in tetrahydrofuran, 0.10 mol, 50 mL). The reaction was stirred for 0.5 hr, thenN, N-dimethylformamide (0.21 mol, 15 g) was added, and stirring was continued -78 °C for 1.5 hrs. On completion, the reaction mixture was quenched with water and extracted with ethyl acetate (3 χ 200 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give A-41 (12 g, crude) as a white solid.
[00274] Exa de (A-43)
Figure imgf000054_0004
[00275] Following general procedure Al, compound A-43 was prepared from compound A-41. [00276] Compound A-42 (1.1 g crude) was prepared from compound A-41 (12 g, 70 mmol). 1H- NMR (CD3OD, 400 MHz): δ 11.68 (m, 1 H), 8.21-8.19 (m, IH), 7.61-7.57 (m, IH), 7.34-7.32(m, IH), 2.28 (s, 3H).
[00277] Compound A-43 (0.52 g, white solid, crude) was prepared from compound A-42 (0.50 g, 2.7 mmol). The reaction time was 14 hours. TLC [petroleum ether: ethyl acetate = 8: 1]: Rf = 0.5.
[00278] Example 30A: 4-chloro-2-fluoro-N-hydroxy-3-methoxybenzimidoyl chloride (A-45)
Figure imgf000055_0001
[00279] Following general procedure Al, compound A-45 was prepared from 4-chloro-2-fluoro- 3 -methoxybenzaldehyde :
[00280] Compound A-44 (0.49 g, white solid,crude) was prepared from 4-chloro-2-fluoro- 3- methoxybenzaldehyde (0.50 g, 2.7 mmol) with a reaction time of 15 hours.
[00281] Compound A-45 (0.47 g, white solid, crude) was prepared from compound A-44 (0.45 g, 2.2 mmol) with a reaction time of 16 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.7.
[00282] Example 31A: 4-chloro-2-fluoro-3-(trifluoromethyl)benzaldehyde (A-46)
Figure imgf000055_0002
A 46
[00283] To a solution of l-chloro-3-fluoro-2-(trifluoromethyl)benzene (0.50 g, 2.5 mmol) at - 70 °C was added dropwise lithium diisopropylamide (2 M in tetrahydrofuran, 3.8 mmol, 1.9 mL). The reaction was stirred at -70 °C for 0.5 hour, then N, N - dimethylformamide (0.55 g, 7.6 mmol) was added slowly, and stirring was continued at -70 °C for another hour. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were concentrated in vacuo, and the residue was purified by silica gel chromatography
[petroleum ether: ethyl acetate = 10: 1] to give A-46 (0.40 g, 70% yield) as a yellow solid. 1H-NMR (CDCI3, 400 MHz): 510.28 (s, IH), 7.95-7.90 (t, J=10.0 Hz, IH), 7.40-7.37 (d, J=l 1.2 Hz, IH).
[00284] Example 32A: 4-chloro-2-fluoro-N-hydroxy-3-(trifluoromethyl)benzimidoyl chloride (A-
48)
Figure imgf000055_0003
[00285] Following general procedure Al, compound A-48 was prepared from compound A-46:
[00286] Compound A-47 (0.40 g, yellow solid, 62% yield) was prepared from compound A-46
(0.60 g, 2.7 mmol) with a reaction time of 14 hours and used in next step without further purification. [00287] Compound A-48 (0.40 g, white solid, crude) was prepared from compound A-47 (0.38 g,
1.6 mmol). TLC [petroleum ether: ethyl acetate = 8: 1]. Rf = 0.6.
[00288] Example 33A: ( -bromo-4-chloro-2-fluorophenyl)methanediol (A-49)
Figure imgf000056_0001
A"49
[00289] To a solution of 2-bromo-l-chloro-3-fluorobenzene (6.0 g, 29 mmol) in tetrahydrofuran (30 mL) at -70 °C was added dropwise lithium diisopropylamide (2 M in tetrahydrofuran/n-heptane, 22 mL, 43 mmol). The resulting solution was stirred at -70 °C for 0.5 hour. Then N, N - dimethylformamide (4.2 g, 57 mmol) was added slowly, and stirring was continued at -70 °C for another 0.5 hour. On completion of the reaction by TLC [petroleum ether: ethyl acetate = 10: 1, Rf=0.6], the reaction was quenched with saturated aqueous ammonium chloride (2 mL) at 0 °C and extracted with acetate ethyl (3 χ 20 mL). The combined organic extracts were concentrated to give compound A-49 (4.0 g, 58% yield) as a yellow solid. ¾-NMR (CD3OD, 400 MHz): δ 7.64-7.57 (m, 1H), 7.21-7.17 (m, 1H), 6.02 (s, 1H).
[00290] Example 34A: (3-bromo-4-chloro-2-fluorophenyl)methanol (A-50)
Figure imgf000056_0002
[00291] To a solution of compound A-49 (2.0 g, 8.4 mmol) in methanol (10 mL) at 0 °C was added sodium borohydride (0.64 g, 17 mmol). The reaction was allowed to warm to room temperature and stirred for another 1 hour, until TLC showed the reaction was complete [petroleum ether: ethyl acetate = 10: 1, Rf=0.4]. The reaction was quenched at 0 °C with 2 N hydrochloric acid (2 mL) and extracted with ethyl acetate (3x 200 mL). The combined organic phase was dried over anhydrous sodium sulfate and concentrated to afford compound A-50 (2.0 g, crude) as a yellow oil. ¾-NMR (CD3OD, 400 MHz): δ 7.50-7.46 (m, 1H), 7.17-7.13 (m, 1H), 4.89 (s, 2H).
[00292] Example 35A: (4-chloro-3-cyclopropyl-2-fluorophenyl)methanol (A-51)
Figure imgf000056_0003
A"50 di°xane/H20' 80 °C 4 h
[00293] To a solution of compound A-50 (2.0 g, 8.4 mmol) in dioxane (8.0 mL) and water (1.0 mL) was added potassium phosphate (5.3 g, 25 mmol) , [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.61 g, 0.84 mmol) and cyclopropylboronic acid (1.1 g, 13 mmol). The mixture was stirred at 80 °C for 4 hours, then concentrated and purified by silica gel chromatography [petroleum ether: ethyl acetate = 5 : 1] to afford compound A-51 ( 1.2 g, 72% yield over two steps) as a yellow oil. GCMS: tR=9.103 min, 199.9, (EI) m/z (M)+.
[00294] Example 36 -52)
Figure imgf000057_0001
[00295] A mixture of compound A-51 (1.2 g, 6.0 mmol) and manganese dioxide (11 g, 0.12 mol) in toluene (40 mL) was stirred at 100 °C for 16 hours until TLC analysis showed the starting material was consumed. The reaction mixture was filtered, and the filtrate was concentrated in vacuo.
The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 5: 1] to afford compound A-52 (0.6 g, crude) as a yellow oil. LCMS (B): (ES+) m/z (M+H)+ = 199.0, tR= 0.827 min.
[00296] Example 37A: 4-chloro-3-cyclopropyl-2-fluoro-N-hydroxybenzimidoyl chloride (A-54)
Figure imgf000057_0002
[00297] Following general procedure Al, compound A-54 was prepared from compound A-52:
[00298] Compound A-53 (0.45 g, white solid, 93% yield over two steps) was prepared from compound A-52 (0.45 g, 2.3 mmol). IH-NMR (CDC13, 400 MHz): 59.23 (s, IH), 8.47 (s, IH), 7.15- 7.12 (d, J=8.4 Hz, IH), 6.87-6.83 (d, J=8.0 Hz, IH), 2.16-2.07 (m, IH), 1.05-0.97 (m, 2H), 0.73-0.68 (m,2H).
[00299] Compound A-54 (0.50 g, colorless oil, crude) was prepared from compound A-53 (0.40 g, 1.7 mmol) with a reaction time of 16 hours. TLC [petroleum ether: ethyl acetate = 10: 1]: Rf = 0.5.
[00300] Example 38A: 4-chloro-2,6-difluoro-N-hydroxybenzimidoyl chloride (A-56)
Figure imgf000057_0003
A"55 A"56
[00301] Following general procedure Al, compound A-56 was prepared from 4-chloro-2,6- difluorobenzaldehyde :
[00302] Compound A-55 (0.50 g, white solid, 92% yield) was prepared from 4-chloro-2,6- difluorobenzaldehyde (0.50 g, 2.8 mmol) with a reaction time of 12 hours and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (B): tR=0.678 min., 192.1 m/z (M+l); IH-NMR (CDC13, 400 MHz): 5 8.27 (s, IH), 8.21 (s, IH), 7.03-7.00 (m, 2H).
[00303] Compound A-56 (0.80 g of colorless oil, crude) was prepared from compound A-55 (0.80 g, 4.2 mmol) with a reaction time of 16 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.70. [00304] Example 39A: 2,4-dichloro-6-fluorobenzaldehyde (A-57)
Figure imgf000058_0001
A"57
[00305] To a solution of l,3-dichloro-5-fluorobenzene (2.0 g, 12 mmol) in tetrahydrofuran (20 mL) at -70 °C was added dropwise lithium diisopropylamide (2 M in tetrahydrofuran, 18 mmol., 9.1 mL). The reaction was stirred at -70 °C for 0.5 hr, then N, N - dimethylformamide (1.8 g, 24 mmol) was added slowly, and stirring was continued at -70 °C for another 0.5 hr. The reaction was quenched with water (20 mL) and extracted with acetate ethyl (3 x 20 mL). The combined organic layers were concentrated in vacuo and purified by silica gel chromatography [petroleum ether: ethyl acetate = 30 : 1] to give A-57 (1.5 g, 64% yield) as a yellow solid. IH-NMR (CDC13, 400 MHz): 510.41 (s, 1H), 7.934 (s, 1H), 7.18-7.16 (d, J=10.0 Hz, 1H).
[00306] Example 40A: 2,4-dichloro-6-fluoro-N-hydroxybenzimidoyl chloride (A-59)
Figure imgf000058_0002
[00307] Following general procedure Al, compound A-59 was prepared from compound A-57:
[00308] Compound A-58 (0.75 g, white solid, 90% yield) was prepared from compound A-57 (0.77 g, 7.0 mmol) with a reaction time of 3 hours and used in the next step without further purification. LCMS (B): (ES+) m/z (M+H)+ = 207.9, tR=0.628 min.
[00309] Compound A-59 (0.35 g, white solid, crude) was prepared from compound A-58 (0.30 g, 1.4 mmol) with a reaction time of 12 hours. TLC [petroleum ether: ethyl acetate = 5: l]: Rf= 0.8.
[00310] -61)
Figure imgf000058_0003
A"60
[00311] Following general procedure Al, compound A-61 was prepared from 2,3-difluoro-4- methoxybenzaldehyde :
[00312] Compound A-60 (0.50 g, white solid, 92% yield) was prepared from 2,3-difluoro-4- methoxyben zaldehyde (0.50 g, 2.9 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 8: 1].
[00313] Compound A-61 (0.50 g, white solid, crude) was prepared from compound A-60 (0.40 g,
2.1 mmol). TLC [petroleum ether: ethyl acetate = 3: 1]: Rf = 0.5.
[00314] Example 42A: 3-chloro-2-fluoro- 4-methoxybenzaldehyde (A-62)
Figure imgf000059_0001
A 62
[00315] To a solution of 2-chloro-l-fluoro-3-methoxy-benzene (1.5 g, 9.3 mmol) in
tetrahydrofuran (10 mL) at -78 °C was added lithium diisopropylamide (2M in tetrahydrofuran, 7.0 mL, 14 mmol). The reaction was stirred for 0.5 hour, then N N-dimethylformamide (2.1 g, 28 mmol) was added, and stirring was continued at -78 °C for 2.5 hours. On completion, the reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give compound A-62 (0.40 g, 23% yield) as a white solid.
[00316] Example 43A: 3-chloro-2-fluoro-N-hydroxy-4-methoxybenzimidoyl chloride (A-64)
Figure imgf000059_0002
[00317] Following general procedure Al, compound A-64 was prepared from compound A-62:
[00318] Compound A-63 (0.43 g, white solid, crude) was prepared from compound A-62 (0.40 g, 2.1 mmol) with a reaction time is 12 hours.
[00319] Compound A-64 (0.45 g, white solid, crude) was prepared from compound A-63 (0.43 g, 2.1 mmol) with a reaction time is 15 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf= 0.7.
[00320] Example 44A: 3-chloro-2-fluoro-4-methylbenzaldehyde (A-65)
Figure imgf000059_0003
[00321] To a solution of 2-chloro-l-fluoro-3-methyl-benzene (1.0 g, 6.9 mmol) in tetrahydrofuran (30 mL) at -70 °C was added dropwise n-butyllithium (2.5 N in hexane, 3.3 mL, 8.3 mmol). The reaction was stirred at -70 °C for 0.5 h, then N, N - dimethylformamide (2.0 g, 28 mmol) was added, and stirring was continued at -70 °C for another 0.5 h. On completion, the mixture was poured into ammonium chloride (40 mL) solution and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give compound A-65 (1.2 g, 86% yield) as yellow solid, which was used in the next step without further purification. LCMS (J): (ES+) m/z (M+H)+ = 173.0, tR=0.508 min.
[00322] (A-67)
Figure imgf000059_0004
[00323] Following general procedure Al, compound A-67 was prepared from compound A-65: [00324] Compound A-66 (1.1 g, white solid, 85% yield) was prepared from compound A-65 (1.2 g, 7.0 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 8: 1]. 1H- NMR (CD3OD, 400 MHz): δ 8.20 (s, 1H), 7.61-7.57 (t, J=7.2 Hz, 1H), 7.09-7.07 (d, J=8.0 Hz, 1H).
[00325] Compound A-67 (0.60 g, white solid, crude) was prepared from compound A-66 (0.50 g, 2.7 mmol). TLC [petroleum ether: ethyl acetate = 3: 1]: Rf = 0.5.
[00326] Example 46A: l-bromo-2-fluoro-4-isopropoxybenzene A-68)
Figure imgf000060_0001
[00327] A mixture of 4-bromo-3-fluoro-phenol (5.0 g, 26 mmol), 2-bromopropane (6.4 g, 52 mmol) and potassium carbonate (29 g, 0.21 mol) in N, N - dimethylformamide (50 mL) was stirred at 80 °C for 16 hrs. On completion, the reaction was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were concentrated in vacuo, and the residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 30: 1] to give compound A-68 (5.0 g, 82% yield) as colourless oil. IH-NMR (CDC13, 400 MHz): 57.42-7.38 (t, J=8.8 Hz, 1H), 6.71- 6.68 (dd, J=10.8Hz, J=2.8 Hz, 1H), 6.62-6.59 (dd, J=8.8 Hz, J=1.6 Hz, 1H), 4.55-4.46 (m, 1H), 1.36- 1.34 (d, J=6.0 Hz, 6H).
[00328] Example 47 -fluoro-4-isopropoxybenzaldehyd
Figure imgf000060_0002
[00329] To a solution of A-68 (1.5 g, 6.4 mmol) in tetrahydrofuran (20 mL) at -70 °C was added dropwise n-butyllithium (2.5 M in hexanes, 3.1 mL, 7.8 mmol). The reaction was stirred at -70 °C for 0.5 hr., then N, N - dimethylformamide (1.4 g, 19 mmol) was added slowly, and stirring was continued at -70 °C for another 0.5 hr. On completion, the reaction was quenched slowly with saturated aqueous ammonium chloride (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic phases were concentrated in vacuo to give compound A-69 (1.0 g, 85% yield) as a light yellow solid.
[00330]
Figure imgf000060_0003
^
[00331] Following general procedure Al, compound A-71 was prepared from compound A-69:
[00332] Compound A-70 (0.90 g, light yellow solid, 83% yield) was prepared from compound A- 69 (1.0 g, 5.5 mmol) with a reaction time of 14 hours and and purified by silica gel chromatography [petroleum ether: ethyl acetate = 20: 1]. IH-NMR (CDC13, 400 MHz): 58.31 (s, 1H), 7.83 (s, 1H), 7.67-7.62 (t, J=8.4 Hz, 1H), 6.72-6.69 (dd, J=8.4 Hz, J=2.4 Hz, 1H), 6.64-6.60 (m, 1H), 4.62-4.52 (m, 1H), 1.38-1.37 (m, 6H).
[00333] Compound A-71 (0.80 g, yellow solid, crude) was prepared from compound A- 70 (0.60 g, 3.0 mmol) with a reaction time of 16 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.5.
[00334] Example 49A: 4-ethoxy-2-fluorobenzaldehyde (A-72)
Figure imgf000061_0001
[00335] To a mixture of 2-fluoro-4-hydroxybenzaldehyde (3.0 g, 21 mmol) and iodoethane(5.0 g, 32 mmol) in N, N - dimethylformamide (0.5 mL) was added potassium carbonate (4.4 g, 32 mmol). The reaction mixture was stirred at 50 °C for 16 hours. On completion, the reaction mixture was diluted with water and extracted with ethyl acetate (3 χ 150 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give compound A-72 (3.4 g, crude) as a yellow solid. LCMS (B): (ES+) m/z (M+H)+ = 169.2, tR=0.649 min.
[00336] Example 50A: 4-ethoxy-2-fluoro-N-hydroxybenzimidoyl chloride (A- 74)
Figure imgf000061_0002
[00337] Following general procedure Al, compound A- 74 was prepared from compound A-72:
[00338] Compound A- 73 (1.0 g, white solid, 92% yield over two steps) was prepared from compound A-72 (1.0 g, 6.0 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (B): (ES+) m/z (M+H)+ = 184.2, tR=0.757 min.
[00339] Compound A- 74 (0.60 g, white solid, crude) was prepared from compound A- 73 (0.50 g, 2.9 mmol) with a reaction time of 16 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.7.
[00340] Example 51A: 6-chloro-2-fluoro-3-formylbenzonitrile (A- 75)
Figure imgf000061_0003
[00341] To a mixture of 2-chloro-6-fluorobenzonitrile (5.0 g, 32 mmol) in anhydrous
tetrahydrofuran (50 mL) at -70 °C under nitrogen was added dropwise lithium diisopropylamide (2.0 M in tetrahydrofuran n-heptane, 24 mL, 48 mmol). The mixture was stirred at -70 °C for 0.5 hour, and N, N-dimethylformamide (3.5 g, 48 mmol) was added dropwise. The reaction was stirred at -70 °C for another 0.5 hour, then quenched with saturated ammonium chloride solution (500 mL) at 0 °C and extracted with ethyl acetate (2 χ 200 mL). The combined organic layers were dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 30: 1] to give compound A-75 (1.0 g, 17% yield) as a yellow solid. ¾-NMR (CDC13, 400 MHz): δ 10.33 (s, 1H), 8.07 (t, J=8.0 Hz, lH), 7.50 (d, J=8.4 Hz, 1H).
[00342] Example 52A: 4-chloro-3-cyano-2-fluoro-N-hydroxybenzimidoyl chloride (A-77)
Figure imgf000062_0001
A 75 A 76
[00343] Following general procedure Al, compound A-77 was prepared from compound A-75:
[00344] Compound A- 76 (0.36 g, white solid, 33% yield) was prepared from compound A-75 (0.20 g, 1.1 mmol, 5 batches) with a reaction time of 2 hours and 0 °C and purified by prep-TLC
[petroleum ether: ethyl acetate = 5: 1]. 1H-NMR (CDC13, 400 MHz): δ 8.31 (s, 1H), 8.00 (t, J=8.0 Hz, 1H), 7.71 (s, 1H), 7.36 (d, J=8.8Hz, 1H).
[00345] Compound A-77 (0.50 g of yellow oil, crude) was prepared from compound A- 76 (0.31 g, 1.3 mmol), in dichlomethane and stirred at 20 °C for 12 hours. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf= 0.61.
[00346] Example 53A: 3-chloro-2,4-difluoro-N-hydroxybenzimidoyl chloride (A- 79)
Figure imgf000062_0002
[00347] Following general procedure Al, compound A- 79 was prepared from 3-chloro-2,4- difluorobenzaldehyde :
[00348] Compound A- 78 (0.90 g, white solid, 83% yield) was prepared from 3-chloro-2,4- difluorobenzaldehyde (1.0 g, 5.7 mmol) and used in the next step without further purification.
[00349] Compound A- 79 (0.80 g, white solid, crude) was prepared from compound A- 78 (0.90 g, 4.7 mmol) with a reaction of 16 hours. TLC [petroleum ether: ethyl acetate = 8: 1]: Rf = 0.75.
[00350] Example 54A: 2-fluoro-4-(lH-pyrazol-l-yl)benz )
Figure imgf000062_0003
[00351] A mixture of 2,4-difluorobenzaldehyde (14 g, 1.0 mol), lH-pyrazole (6.8 g, 1.0 mmol) and potassium carbonate (14 g, 1.0 mmol) inN,N-dimethylacetamide (200 mL) was stirred at 200 °C for 10 mins. TLC [petroleum ether: ethyl acetate = 5: 1] showed starting material consumed and two new spots formed. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 x 150 mL). The combined organic phases were washed with water (5 x 150 mL) and brine (150 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by Prep-HPLC (TFA, Instrument: HPLC-B. column :Phenomenex Synergi Max-RP 250x50mmxl0 μιη. Condition: 0.1%TFA-ACN) and lyophilization to give compound A-80 (3.5 g, 18% yield) as a white solid. LCMS (D): (ES+) m/z (M+H)+ = 191.1, tR= 1.271 min.
[00352] -82)
Figure imgf000063_0001
[00353] Following general procedure Al, compound A-82 was prepared from compound A-80:
[00354] Compound A-81 (0.75 g, white solid, 90% yield) was prepared from compound A-80 (1.0 g, 5.3 mmol) with a reaction time of 3 hours and purified by silica gel chromatography [petroleum ether: ethyl acetate = 10: 1]. LCMS (Y): (ES+) m/z (M+H)+ = 206.2, tR= 0.666 min.
[00355] Compound A-82 (0.40 g, white solid, crude) was prepared from compound A-81 (0.30 g, 1.5 mmol) with a reaction time of 12 hours, [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.62.
[00356] Example 5
Figure imgf000063_0002
[00357] To a solution of 4-bromo-3-fluoro-benzoic acid (10 g, 46 mmol) in methanol (120 mL) was added thionyl chloride (33 g, 0.28 mol). The reaction was stirred at 80 °C for 5 hours, then concentrated in vacuo to give compound A-83 (11 g, crude) as yellow solid, which was used in the next step without further purification. TLC [petroleum ether: ethyl acetate = 10: 1]: Rf = 0.80.
[00358] Example 57A: 4-bromo-3-fluorobenzoh drazide (A-84)
Figure imgf000063_0003
[00359] A mixture of compound A-83 (11 g, crude) and hydrazine hydrate (23 g, 0.46 mol) in methanol (200 mL) was stirred at 70 °C for 12 hours. On completion, the mixture was concentrated in vacuo, diluted with ethyl acetate (60 mL), washed with water (50 mL) and brine (2 χ 20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford compound A-84 (5.0 g, crude) as a yellow solid.
[00360] Example 58A: 2-(4-bromo-3-fluorophenyl)-5-methyl-l,3,4-oxadiazole (A-85)
Figure imgf000063_0004
[00361] A mixture of compound A-84 (4.0 g, crude) and triethylorthoacetate (2.5 g, 17 mmol) was stirred at 100 °C for 18 hours. On completion, the mixture was poured into water (40 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic phase was washed with brine (2 χ 20 mL), dried with anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 3: 1] to give compound A-85 (3.7 g, 39% yield over three steps) as a yellow solid. i-NMR (CD3OD, 400 MHz): δ 7.88-7.85 (m, 2H), 7.79- 7.77 (m, 1H), 2.65 (m, 3H).
[00362] Example 59A: 2-(3-fluoro-4-vinylphenyl)-5-methyl-l,3,4-oxadiazole (A-86)
Figure imgf000064_0001
PPh3' PdCI2' CS2C03 HF'H20
A 85 A"86
[00363] To a solution of compound A-85 (3.3 g, 13 mmol), potassium trifluoro(vinyl)boranuide (2.1 g, 15 mmol) and cesium carbonate (13 g, 39 mmol) in tetrahydrofuran (9.0 mL) and water (1.0 mL) was added triphenylphosphine (0.34 g, 1.3 mmol) and palladium chloride (0.23 g, 1.3 mmol). The reaction was stirred at 80-90°C for 16 hours, then poured into water (20 mL) and extracted with ethyl acetate (2 χ 20 mL). The combined organic phase was washed with brine, dried with anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 3: 1] to give compound A-86 (2.3 g, 88% yield) as a yellow solid. LCMS (B): (ES+) m/z (M+H)+ = 205.1, tR=0.730 min.
[00364] Example -fluoro-4-(5-methyl-l,3,4-oxadi e (A-87)
Figure imgf000064_0002
[00365] To a solution of compound A-86 (1.5 g, 7.2 mmol), sodium periodate (3.1 g, 14 mmol) and 4-methylmorpholine (2.5 g, 21 mmol) in tetrahydrofuran (50 mL) and water (25 mL) was added osmium tetroxide (18 mg, 72 umol). The reaction was stirred at 25 °C for 5 hours, then poured into aqueous sodium thiosulfate (20 mL) and extracted with ethyl acetate (2 χ 20 mL). The combined organic phase was washed with brine, dried with anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 3: 1] to give compound A-87 (1.3 g, 88% yield) as a yellow solid. LCMS (M): (ES+) m/z (M+H)+ = 207.1, tR=0.705 min.
[00366] Example 61A: 2-fluoro-N-hydroxy-4-(5-methyl-l,3,4-oxadiazol-2-yl)benzimidoyl chloride (A-
Figure imgf000064_0003
A"87 A"88 A"89
[00367] Following general procedure Al, compound A-89 was prepared from compound A-87: [00368] Compound A-88 (0.50 g, yellow solid, 34% yield) was prepared from compound A-87 ( 1.4 g, 6.6 mmol) and purified by silica gel chromatography [petroleum ether: ethyl acetate = 2: 1]. LCMS (B): (ES+) m/z (M+H)+ = 222.1, tR=0.657 min.
[00369] Compound A-89 (0.60 g, yellow solid, crude) was prepared from compound A-88 (0.50 g, 2.3 mmol). TLC [petroleum etherethyl acetate = 3: 1]: Rf = 0.60.
[00370] Ex
Figure imgf000065_0001
[00371] To a solution of 4-bromo-2-fluoro-3-methoxy-benzaldehyde (3.0 g, 13 mmol), 2,4,6- trimethyl-l,3,5,2,4,6-trioxatriborinane (2.1 g, 17 mmol) and potassium phosphate (5.5 g, 26 mmol) in water (10 mL) and tetrahydrofuran (30 mL) was added dicyclohexyl-[3 -(2,4,6- triisopropylphenyl)phenyl]phosphane [2-(2-aminophenyl)phenyl]-chloro-palladium (0.5 lg, 0.64 mmol). The mixture was stirred at 80 °C for 12 hours. On completion, the mixture was poured into water (20 mL) and extracted with ethyl acetate (2 χ 20 mL). The combined organic phase was washed with brine (2 χ 20 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo to give compound A-90 ( 1.60 g, crude) as a yellow solid, which was used in the next step without further purification. LCMS (B): (ES+) m/z (M+H)+ = 169.2, tR=0.640 min.
[00372] Exam -fluoro-N-hydroxy-3-methoxy-4-methylbenzimidoyl chloride (A-92)
Figure imgf000065_0002
[00373] Following general procedure Al, compound A-92 was prepared from compound A-90:
[00374] Compound A-91 (0.70 g, yellow solid, 40% yield over two steps) was prepared from compound A-90 (1.6 g, 9.5 mmol) with a reaction time of 12 hours and purified by silica gel chromatography [petroleum ether: ethyl acetate = 5: 1]. LCMS (B): (ES+) m/z (M+H)+ = 184.2, tR=0.641 min.
[00375] Compound A-92 (0.50 g, yellow solid, crude) was prepared from compound A-91 (0.50 g, 2.7 mmol) with a reaction time of 12 hours and dichloromethane as the solvent. TLC [petroleum ether thyl acetate = 3: 1]: Rf = 0.70.
[00376] Example 64A: l
Figure imgf000065_0003
[00377] A mixture of 2-chloro-6-fluoro-phenol (2.0 g, 14 mmol, iodoethane (4.3 g, 27 mmol) and potassium carbonate (3.8 g, 27 mmol) in N, N - dimethylformamide (20 mL) was stirred at 50 °C for 16 hrs. On completion, the reaction was diluted with water (30 mL) and extracted with methyl t-butyl ether (3 x 20 mL). The combined organic phases were washed with water (10 mL) and brine (10 mL), dried with anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography [petroleum ether: ethyl acetate = 30:1] to give compound A-93 (1.5 g, 63% yield) as light yellow oil.
[00378] Example 65A: l-chloro-2-ethoxy-3-fluorobenzene (A-94)
Figure imgf000066_0001
A 93 A 94
[00379] To a solution of Compound A-93 (1.0 g, 5.7 mmol) at -70 °C was added dropwise lithium diisopropylamide (2 M in tetrahydrofuran, 4.3 mL, 8.6 mmol). The reaction was stirred at - 70 °C for 0.5 hr. Then N, N - dimethylformamide ( 1.7 g, 23 mmol) was added slowly, and stirring was continued at -70 °C for another 0.5 hr. The reaction was quenched with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic extracts were concentrated in vacuo and purified by silica gel chromatography [petroleum ether: ethyl acetate = 8: 1] to give compound A- 94 (0.80 g, 69% yield) as a yellow solid.
[00380] Example 66A: 4-chloro-3-ethoxy-2-fluoro-N-hydroxybenzimidoyl chloride (A-96)
Figure imgf000066_0002
[00381] Following general procedure Al, compound A-96 was prepared from compound A-94:
[00382] Compound A-95 (90 mg, yellow solid, 84% yield) was prepared from compound A-94 (0.10 g, 0.49 mmol), reaction was stirred at 20 °C, and purified by silica gel chromatography
[petroleum ether: ethyl acetate = 20: 1]. 1H-NMR (CDC13, 400 MHz): 58.33 (s, IH), 7.79 (s, IH), 7.45-7.41 (dd, J=7.2 Hz, J=1.2 Hz, IH), 7.20-7.17 (dd, J=8.4 Hz, J=1.6 Hz, IH), 4.23-4.18 (dd, J=14 Hz, J=7.2 Hz, IH), 1.47-1.44 (t, J=7.2 Hz, IH).
[00383] Compound A-96 (0.60 g, white solid, crude) was prepared from compound A-95 (0.45g, 2.1 mmol), reaction was stirred at 20 °C. TLC [petroleum ether: ethyl acetate = 8: 1]: Rf = 0.52.
[00384] Example 67A: 2-fluoro-3,4-dimethylbenzaldehyde (A-97)
Figure imgf000066_0003
[00385] To a mixture of tetramethylethylenediamine (2.1 g, 18 mmol) in anhydrous
tetrahydrofuran (20 mL) at -70°C under nitrogen was added tert-butyllithium (1.3 M in pentane solution, 14 mL, 18 mmol) dropwsie. The resulting yellow solution was stirred at -70°C for 0.5 hour. Then a solution of l-fluoro-2,3-dimethyl-benzene (2.0 g, 16 mmol) in anhydrous tetrahydrofuran (12 mL) was added dropwise. The mixture was stirred at -70 °C for 1 hour. Then a solution of N, N- dimethylformamide (1.3 g, 18 mmol) in anhydrous tetrahydrofuran (8.0 mL) was added, and the reddish-brown mixture was stirred at -70°C for an additional 1 hour. On completion, the reaction mixture was quenched with acetic acid (2.0 mL) and water (20 mL) at 0 °C and extracted with ethyl acetate (3 30 mL). The combined organic layers were washed with water (2 20 mL), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound A-97 (1.5 g, 61% yield) as a yellow oil. TLC [petroleum ether: ethyl acetate = 5: 1]: Rf = 0.61.
[00386] Exa 99)
Figure imgf000067_0001
[00387] Following general procedure Al, compound A-99 was prepared from compound A-97:
[00388] Compound A-98 (1.5 g, yellow solid, 90% yield) was prepared from compound A-97 (1.5 g, 9.9 mmol) with a reaction time of 12 hours and purified by silica gel chromatography [petroleum ether: ethyl acetate = 50: 1-5: 1]. i-NMR (CDC13, 400 MHz): δ 8.35 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 2.30 (s, 3H), 2.20(s, 3H).
[00389] Compound A-99 (1.9 g, yellow solid, crude) was prepared from compound A-98 (1.0 g, 6.0 mmol) using dichloromethane and a reaction time of 12 hours. TLC [petroleum ether: ethyl acetate = 10: 1]: Rf= 0.43.
[00390] Example 69A: 4-chloro-2,3-difluoro-N-hydroxybenzimidoyl chloride (compound-A-101)
Figure imgf000067_0002
[00391] Following general procedure A2, compound A-101 was prepared from 4-chloro-2,3- difluorobenzaldehyde :
[00392] Compound A-100 (0.5 g, 92% yield, 11: 1 mixture of (E)/(Z) isomers) was prepared as a white solid from 4-chloro-2,3-difluorobenzaldehyde (0.5 g, 2.8 mmol) using 9 mL of ethanol/water and a reaction time of 2 hours. LCMS (2): tR=1.910 min., (ES+) m/z (M+H)+ = 191.9. ¾NMR (300 MHz, DMSO-d6, major isomer) δ 11.90 (s, 1H), 8.21 (s, 1H), 7.61 - 7.51 (m, 1H), 7.51 - 7.42 (m, 1H).
[00393] Compound A-101 (99 mg, 95% yield) was prepared as a white solid from compound A- 100 (100 mg, 0.5 mmol) using 1 mL of N,N-dimethylformamide and a reaction time of 2 hours. 1H NMR (300 MHz, DMSO-d6) δ 12.91 (s, 1H), 7.61 - 7.53 (m, 2H).
[00394] Example 70A: 4-chloro-2,5-difluoro-N-hydroxybenzimidoyl chloride (compound-A-103)
Figure imgf000068_0001
[00395] Following general procedure A2, compound A-103 was prepared from 4-chloro-2,5- difluorobenzaldehyde :
[00396] Compound A-102 (0.5 g, 92% yield, 8: 1 mixture of (E)/(Z) isomers) was prepared as a white solid from 4-chloro-2,5-difluorobenzaldehyde (0.5 g, 2.8 mmol) using 7 mL of ethanol/water and a reaction time of 2 hours. LCMS (2): tR=1.907 min., (ES+) m/z (M+H)+ = 192.0. ¾ NMR (300 MHz, DMSO-d6, major isomer) δ 11.89 (s, 1H), 8.15 (s, 1H), 7.84 - 7.58 (m, 2H).
[00397] Compound A-103 (99 mg, 84% yield) was prepared as a white solid from compound A- 102 (100 mg, 0.5 mmol) using 1 mL of N,N-dimethylformamide and a reaction time of 16 hours. 1H NMR (300 MHz, DMSO-d6) δ 12.87 (s, 1H), 7.89 - 7.74 (m, 2H).
[00398] Exam ound-A-105)
Figure imgf000068_0002
[00399] Following general procedure A2, compound A-105 was prepared from 4-bromo-2- fluorobenzaldehyde :
[00400] Compound A-104 (2.5 g, 93% yield, 9: 1 mixture of (E)/(Z) isomers) was prepared as a white solid from 4-bromo-2-fluorobenzaldehyde (2.5 g, 12.3 mmol) using 45 mL of ethanol/water and a reaction time of 2 hours. 1H NMR (300 MHz, DMSO-d6, major isomer) δ 11.69 (s, IH), 8.15 (s, 1H), 7.69 - 7.60 (m, 2H), 7.48 - 7.42 (m, IH).
[00401] Compound A-105 (2.3 g, 82% yield) was prepared as a white solid from compound A- 104 (2.4 g, 11.0 mmol) using 20 mL of N,N-dimethylformamide and a reaction time of 3 days. IH NMR (300 MHz, DMSO-d6) δ 12.73 (s, IH), 7.73 (dd, J= 10.4, 1.8 Hz, IH), 7.66 - 7.52 (m, 2H).
[00402] Exam -chloro-2-fluoro-N-hydroxybenzimidoyl chloride (compound-A-107)
Figure imgf000068_0003
[00403] Following general procedure A2, compound A-107 was prepared from 4-chloro-2- fluorobenzaldehyde :
[00404] Compound A-106 (2.7 g, 96% yield) was prepared as a white solid from 4-chloro-2- fluorobenzaldehyde (2.6 g, 16.4 mmol) using 45 mL of ethanol/water and a reaction time of 1 hour. LCMS (2): tR=1.856 min., (ES+) m/z (M+H)+ = 174.0. ¾ NMR (300 MHz, DMSO-d6) δ 11.83 (s, IH), 8.16 (s, IH), 7.87 - 7.63 (m, IH), 7.62 - 7.41 (m, IH), 7.31 (d, J= 7.9 Hz, IH). [00405] Compound A-107 (2.7 g, 84% yield) was prepared as a white solid from A-106 (2.7 g, 15.6 mmol) using 25 mL of N,N-dimethylformamide and a reaction time of 1.5 hours. 1H NMR (300 MHz, DMSO-d6) δ 12.73 (s, 1H), 7.75 - 7.65 (m, 1H), 7.65 - 7.57 (m, 1H), 7.47 - 7.37 (m, 1H).
[00406] General Procedure Bl: Synthesis and chiral separation of amino-benzoisoxazoles.
Figure imgf000069_0001
benzojc jjsoxazo|~3~amjne amjnobenzojsoxazoie
products
[00407] To a solution of benzo[d]isoxazol-3-amine (1 eq.) and quinuclidin-3-one (1.1 eq.) in toluene (7 mL/mmol benzo[d]isoxazol-3-amine) at 25 °C was added portion-wise titanium(IV) isopropoxide (9 eq.). The resulting solution was stirred at 100 °C for 12 hours. On completion, the mixture was cooled to 0 °C, and ethanol (1 mL/mmol benzo[d]isoxazol-3-amine) was added via syringe, followed by sodium borohydride (3.7 eq.) in portions. The reaction was stirred at 25 °C for 3 hours, then quenched with saturated aqueous potassium carbonate solution, resulting in the formation of a solid. The mixture was filtered, and the filtrate was extracted with dichloromethane (5 χ 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The filter cake from the original filtration was slurried with methanol, and the mixture was filtered. The filtrate was directly evaporated to dryness. The combined residue from both batches was dissolved in 4N hydrochloric acid (20 mL) and stirred at room temperature for 4 hours. The mixture was made basic by addition of saturated potassium carbonate solution and extracted with dichloromethane (5 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC to give the racemic aminobenzoisoxazole product.
[00408] Chiral Separation: A solution of racemic aminobenzoisoxazole product in 3-5 mL of methanol was separated by cSFC (Waters SFC Prep 80, Column temperature: 25 °C, back pressure: 100 bar, and wavelength: 220 nm). Each set of collected fractions was concentrated at room temperature. The residue was dissolved in 0.2 M hydrochloric acid and lyophilized to give each enantiomer of the aminobenzoisoxazole product.
[00409] General Procedure CI: Synthesis of Aminobenzoisoxazole s.
Figure imgf000069_0002
N hydroxyimjdOyi N hydro yimjdamjde Amjnobenzojsoxazoie
chloride [00410] N-hydroxybenzimidoyl chloride intermediate (1 eq.) in methanol (7 mL/mmol imidoyl chloride intermediate) was added dropwise over 30 min. to a solution of amine A-NH2 (1.2-2 eq.) and triethylamine (2 eq) in methanol (5-10 mL/mmol imidoyl chloride intermediate) at room temperature. The resulting mixture was stirred at room temperature for 30 min. On completion, the reaction mixture was concentrated in vacuo and purified by prep-HPLC to give the N-hydroxyimidamide intermediate.
[00411] A mixture of N-hydroxyimidamide intermediate and base, in an appropriate solvent, was heated until the reaction was judged complete by LCMS. The mixture was filtered, concentrated in vacuum and purified by prep-HPLC to give the the aminobenzoisoxazole product.
[00412] General Procedure C2: Synthesis of Aminobenzoisoxazole s.
Figure imgf000070_0001
N'hydiOXyjmjdOyi N'hydiOXyjmjdamjcie Amjnobenzojsoxazoie
chloride
[00413] To a solution of amine A-NH2 (1 eq.) and triethylamine (1 eq.) in methanol (3-5 mL/mmol amine A-NH2) at room temperature was added dropwise a solution of -N- hydroxybenzimidoyl chloride (1 eq) in methanol (3-5 mL/mmol N-hydroxybenzimidoyl chloride). The mixture was stirred for 1 or more hours, then filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography to afford the Ν-hydroxyimidamide intermediate.
[00414] A mixture of N-hydroxyimidamide intermediate and base, in an appropriate solvent, was heated until the reaction was judged complete by LCMS. The mixture was filtered, concentrated in vacuum and purified by silica gel column chromatography to give the aminobenzoisoxazole product.
[00415] Example 1: N-(quinuclidin-3-yl)benzo[d]isoxazol-3 -amine (rac-1)
Figure imgf000070_0002
[00416] Following general procedure Bl, rac-1 was prepared from benzo[d]isoxazol-3 -amine (0.40 g, 3.0 mmol). The product was purified by prep-HPLC [Instrument: GX-A; Column:
Phenomenex Gemini C18 150x25 mm, particle size: 10 μπι; Mobile phase: 44-74% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-1 (70 mg, 9% yield) as a yellow solid. LCMS (B):
tPv=1.179 min., (ES+) m/z (M+H)+ = 244.2.
[00417] Chiral Separation: [00418] rac-1 (27 mg, 0.11 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μιη; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00419] N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 1- Pl) (11 mg, 41% yield) as a white solid: cSFC analytical (A) tR=5.521 min., purity: 100.00%; LCMS (B): tR=0.115 min., (ES+) m/z (M+H)+ = 244.1; ¾-NMR (CD3OD, 400 MHz): δ 7.88-7.86 (d, J=7.6 Hz, IH), 7.58-7.54 (m, IH), 7.42-7.40 (d, J=8.4 Hz, IH), 7.30-7.26 (t, J=7.6 Hz, IH), 4.20-4.18 (m, IH), 3.87-3.84 (m, IH), 3.43-3.35 (m, 5H), 2.58-2.56 (m, IH), 2.38-2.35 (m, IH), 2.16-2.10 (m, 2H), 1.99-1.93 (m, IH); and
[00420] N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 1- P2) (11 mg, 41% yield) as a white solid: cSFC analytical (A) tR=7.926 min., purity: 98.82%; LCMS (J): tR=1.150 min., (ES+) m/z (M+H)+ = 244.1; ¾-NMR (CD3OD, 400 MHz): δ 7.90-7.88 (d, J=8.0 Hz, IH), 7.61-7.57 (t, J=7.6 Hz, IH), 7.45-7.43 (d, J=8.4 Hz, IH), 7.32-7.29 (t, J=8.0 Hz, IH), 4.20- 4.18 (m, IH), 3.90-3.86 (m, IH), 3.48-3.33 (m, 5H), 2.58-2.56 (m, IH), 2.38-2.36 (m, IH), 2.16-2.10 (m, 2H), 1.97-1.96 (m, IH).
[00421] Example 2: 7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-2)
Figure imgf000071_0001
[00422] Following general procedure Bl, rac-2 was prepared from A-l (0.30 g, 1.8 mmol). The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μπι; Mobile phase: 40-70% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-2 (170 mg, 34% yield) as an off-white solid. LCMS (B): tR=0.617 min., (ES+) m/z (M+H)+ = 278.1. ¾-NMR (CD3OD, 400 MHz): 57.81-7.78 (d, J=8.4 Hz, IH), 7.55 (m, IH), 7.34-7.32 (d, J=7.2 Hz, IH), 4.18-4.15 (m, IH), 3.90-3.84 (td, J=2.0 Hz, J=13.2 Ηζ,ΙΗ), 3.44-3.38 (m, 4H), 3.29-3.26 (m, IH), 2.55-2.53 (m, IH), 2.35-2.34 (m, IH), 2.16-2.12 (m, 2H), 2.09-1.97 (m, IH).
[00423] Chiral Separation:
[00424] rac-2 (170 mg, 0.6 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μπι; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00425] 7-chloro- N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 2-P1) (40 mg, 47% yield) as a white solid: cSFC analytical (A) tR=6.113 min., purity: 100%; LCMS (B): tR=0.633 min., (ES+) m/z (M+H)+ = 278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.80- 7.78 (d, J=8.0 Hz, IH), 7.61-7.59 (d, J=7.6 Hz, IH), 7.69-7.67 (t, J=8.0 Hz, IH), 4.19-4.17 (m, IH), 3.89-3.83 (m, IH), 3.44-3.35 (m, 4H), 3.28-3.27 (m, IH), 2.56-2.54 (m, IH), 2.34-2.33 (m, 2H), 2.14- 2.10 (m, IH), 2.08-1.96 (m, IH); and [00426] 7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 2-P2) (35 mg, 41% yield) as a white solid: cSFC analytical (A) tR=7.304 min., purity: 100.00%; LCMS (B): tR=0.636 min., (ES+) m/z (M+H)+ = 278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.81-7.79 (d, J=8.0 Hz, IH), 7.61-7.59 (d, J=7.2 Hz, IH), 7.69-7.67 (t, J=8.0 Hz, IH), 4.19-4.17 (m, IH), 3.89-3.83 (m, IH), 3.45-3.35 (m, 4H), 3.29-3.28 (m, IH), 2.55-2.53 (m, IH), 2.34-2.33 (m, 2H), 2.14-2.11 (m, IH), 1.99-1.96 (m, IH).
[00427] Example 3:
[00428] Preparation of 6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-3)
Figure imgf000072_0001
[00429] Following general procedure Bl, rac-3 was prepared from A-2 (0.30 g, 1.8 mmol). The product was purified by prep-HPLC [Instrument: PREP -A; Column: Phenomenex Gemini C18 150 21.2 mm, particle size: 5 μιη; Mobile phase: 30-55% acetonitrile in H20 (add 0.05% NH3 H20, v/v)] to give rac-3 (210 mg, 43% yield) as an off-white solid. LCMS (B): tR=0.631 min., (ES+) m/z (M+H)+ = 278.1. ¾-NMR (CD3OD, 400 MHz): δ 7.79-7.77 (d, J=8.0 Hz, IH), 7.63-7.61 (d, J=7.6 Hz IH), 7.32-7.28 (m, IH), 4.21-4.18 (m, IH), 3.92-3.88 (m,lH), 3.45-3.37 (m, 4H), 3.33-3.30 (m, IH), 2.58-2.55 (m, IH), 2.36-2.34 (m, IH), 2.16-2.12 (m, 2H), 2.10-1.98 (m, IH);
[00430] Chiral Separation:
[00431] rac-3 (170 mg, 0.6 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μιη; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00432] 6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 3-P1) (50 mg, 59% yield) as a white solid: cSFC analytical (A) tR=5.617 min., purity: 99.33%; LCMS (B): tR=0.683 min., (ES+) m/z (M+H)+ = 278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.85-7.83 (d, J=8.8 Hz, IH), 7.52-7.51 (d, J=1.6 Hz, IH), 7.32-7.29 (dd, J=1.6 Hz, J=8.8 Hz, IH), 4.20-4.18 (m, IH), 3.87-3.84 (m, IH), 3.43-3.35 (m, 5H), 2.58-2.56 (m, IH), 2.38-2.35 (m, IH), 2.16- 2.10 (m, 2H), 1.99-1.93 (m, IH); and
[00433] 6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 3-P2) (32 mg, 38% yield) as a white solid: cSFC analytical (A) tR=8.069 min., purity: 100.00%; LCMS (B): tR=0.681 min., (ES+) m/z (M+H)+ = 278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.85-7.83 (d, J=8.4 Hz, IH), 7.54-7.53 (d, J=1.6 Hz, IH), 7.34-7.31 (dd, J=1.6 Hz, J=8.4 Hz, IH), 4.18-4.16 (m, IH), 3.90-3.83 (m, IH), 3.36-3.33 (m, 4H), 3.46-3.37 (m, IH), 2.56-2.54 (m, IH), 2.36 (m, IH), 2.15-2.11 (m, 2H), 1.98-1.97 (m, IH).
[00434] Preparation of (i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((i?)-3)
Figure imgf000073_0001
[00435] Following general procedure C2, compound (i?)-3 was prepared from compound A-107:
[00436] Compound (i?)-A-107-l (144 mg, 61% yield) was prepared as a white solid from A-107 (165 mg, 0.8 mmol) and (i?)-quinuclidin-3 -amine (100 mg, 0.8 mmol) using 5 mL of methanol and a reaction time of 1 hour. The product was purified by silica gel column chromatography [chloroform: methanol = 1:0 to 17:3]. LCMS (1): tR=2.965 min., (ES+) m/z (M+H)+ = 298.1.
[00437] To a solution of compound (i?)-A-107-l (101 mg, 0.3 mmol) in NN-dimethylacetamide (5 mL) was added potassium tertbutoxide (57 mg, 0.5 mmol). The mixture was stirred at room temperature for 20 hours. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 3.5 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 1/0 to 9/1]. The resulting product was lyophilized to afford:
[00438] Compound (R)-3 (23 mg, 24% yield) as a white solid: cHPLC analytical [cHPLC analytical conditions: Column: Chiralcel OD-H, 250x4.6 mm, particle size: 5 μπι; Flow: 1.0 mL/min; Column temp: 25 °C; Mobile phase: 0.1% diethylamine in Heptane/Ethanol = 8/2; detection: DAD (220-320 nm)] tR=4.505 min., purity: 100%; LCMS (1): tR=3.132 min., (ES+) m/z (M+H)+ = 278.0; 1HNMR (400 MHz, CDC13), δ 7.48 - 7.40 (m, 2H), 7.24 - 7.19 (m, 1H), 4.28 (d, J = 4.6 Hz, 1H), 3.90 - 3.81 (m, 1H), 3.55 - 3.45 (m, 1H), 3.01 - 2.78 (m, 4H), 2.70 - 2.60 (m, 1H), 2.28 - 2.21 (m, 1H), 1.88 - 1.63 (m, 3H), 1.58 - 1.38 (m, 1H).
[00439] Exam -chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-4)
Figure imgf000073_0002
[00440] Following general procedure Bl, rac-4 was prepared from A-3 (0.20 g, 1.2 mmol). The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μιη; Mobile phase: 44-74% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-4 (45 mg, 14% yield) as a white solid. LCMS (J): tR=l .346 min., (ES+) m/z (M+H)+ = 278.1.
[00441] Chiral Separation:
[00442] rac-4 (45 mg, 0.16 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μπι; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00443] 5 -chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine-enantiomer 1 hydrochloride (compound 4-P1) (13 mg, 29% yield) as a white solid: cSFC analytical (D) tR=5.053 min., purity: 100%; LCMS (B): tR=0.615min., (ES+) m/z (M+H)+ = 278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.94 (s, IH), 7.56-7.50 (m, IH), 7.44-7.38 (m, IH), 4.19-4.17 (m, IH), 3.89-3.83 (m, IH), 3.49-3.36 (m, 5H), 2.56-2.55 (m, IH), 2.36-2.36 (m, IH), 2.13-2.12 (m, 2H), 1.99-1.96 (m, IH); and
[00444] 5-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 4-P2) (10 mg, 22% yield) as a white solid: cSFC analytical (D) tR=6.445 min., purity: 98.3%; LCMS (B): tR=0.616 min., (ES+) m/z (M+H)+ = 2278.1; ¾-NMR (CD3OD, 400 MHz): δ 7.92-7.92 (d, J=1.6 Hz, IH), 7.57-7.55 (dd, J=8.8 Hz, J=1.6 Hz, IH), 7.45-7.43 (d, J=8.8 Hz, IH), 4.19-4.17 (m, IH), 3.89-3.83 (m, IH), 3.51-3.36 (m, 5H), 2.56-2.55 (m, IH), 2.36-2.33 (m, IH), 2.15- 2.11 (m, 2H), 2.10-1.97 (m, IH).
[00445] Example 5: 6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3 -amine (rac-5)
Figure imgf000074_0001
[00446] Following general procedure Bl, rac-5 was prepared from 6-methylbenzo[d]isoxazol -3- amine (0.50 g, 3.4 mmol) using 4 equivalents sodium borohydride and a reaction time of 16 hours for the first step. The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μιη; Mobile phase: 44-74% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-5 (0.70 g, 14% yield) as a white solid. LCMS (G): (ES+) m/z (M+H)+ = 258.0, tR=2.749 min.
[00447] Chiral Separation:
[00448] rac-5 (0.10 g, 0.46 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μπι; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00449] 6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 5-P1) (40 mg, 40% yield) as a white solid: cSFC analytical (G) tR=2.61 min., purity: 96.98%; LCMS (J): tR=1.21 min., (ES+) m/z (M+H)+ = 258; ¾-NMR (CD3OD, 400 MHz): δ 7.72 (d, J=8.4 Hz, IH), 7.24 (s, IH), 7.14 (d, J=8.4 Hz, IH), 4.17-4.15 (m, IH), 3.88-3.82 (m, IH), 3.48-3.27 (m, 5H), 2.56-2.53 (m, IH), 2.50 (m, 3H), 2.37-2.34 (m, IH), 2.15-2.09 (m, 2H), 1.98-1.92 (m, IH); and
[00450] 6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 5-P2) (45 mg, 45% yield) as a white solid: cSFC analytical (G) tR=3.05 min., purity: 96.94%; LCMS (J): tR=1.22 min., (ES+) m/z (M+H)+ = 258; ¾-NMR (CD3OD, 400 MHz): δ 7.71 (d, J=8.4 Hz, IH), 7.25 (s, IH), 7.14 (d, J=8.4 Hz, IH), 4.17-4.16 (m, IH), 3.87-3.82 (m, IH), 3.48-3.27 (m, 5H), 2.56-2.53 (m, IH), 2.50 (m, 3H), 2.37-2.34 (m, IH), 2.15-2.09 (m, 2H), 1.98-1.93 (m, IH).
[00451] Example 6: 6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-6)
Figure imgf000075_0001
[00452] Following general procedure Bl, rac-6 was prepared from A-4 (0.20 g, 1.1 mmol) using 10 eq. of titanium(IV) isopropoxide. The product was purified by prep-HPLC [Instrument: GX-I; Column: Xtimate C18 150x25 mm, particle size: 5 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.1% TFA, v/v)] to give rac-6 (150 mg, 40% yield) as a white solid. LCMS (J): tR=1.425 min., (ES+) m/z (M+H)+ = 278.1. i-NMR (CD3OD, 400 MHz): δ 7.70-7.68 (d, J=8.4 Hz, 1H), 7.06 (m, 1H), 7.00-6.98 (d, J=8.4 Hz, 1H), 3.79-3.77 (m, 1H), 3.39-3.35 (m, 1H), 2.98-2.95 (m, 1H), 2.88-2.81 (m, 3H), 2.77-2.72 (m, 1H), 2.21-2.19 (m, 1H), 2.07-2.03 (m, 2H), 1.97-1.95 (m, 1H), 1.78-1.76 (m, 1H), 1.55-1.49 (m, 1H), 1.07-1.05 (m, 2H), 0.79-0.77 (m, 2H);
[00453] Chiral Separation:
[00454] rac-6 (60 mg, 0.2 mmol) was separated by SFC (Column: Chiralpak AD-3 -100x4.6mm, I.D., 3 μπι; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00455] 6-cyclopropyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine -enantiomer 1 hydrochloride (compound 6-P1) (21 mg, 67% yield) as a white solid: cSFC analytical (A) tR=1.010 min., purity: 98.24%; LCMS (B): tR=0.649 min., (ES+) m/z (M+H)+ = 284.2; ¾-NMR (CD3OD, 400 MHz): δ 7.73-7.70 (m, 1H), 7.09 (s, 1H), 7.02-7.00 (d, J=8.0 Hz, 1H), 4.15-4.12 (m, 1H), 3.86-3.83 (m, 1H), 3.46-3.33 (m, 5H), 2.53-2.52 (m, 1H), 2.29 (m, 1H), 2.10-2.06 (m, 3H), 2.04 (m, 1H), 1.07-1.05 (m, 2H), 0.79-0.78 (m, 2H); and
[00456] 6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 6-P2) (22 mg, 73% yield) as a white solid: cSFC analytical (A) tR=1.633 min., purity: 95.20%; LCMS (B): tR=0.652 min., (ES+) m/z (M+H)+ = 284.2; ¾-NMR (CD3OD, 400 MHz): δ 7.73-7.71 (d, J=8.4 Hz, 1H), 7.09 (s, 1H), 7.02-7.00 (d, J=8.0 Hz, 1H), 4.15-4.12 (m, 1H), 3.85-3.80 (m, 1H), 3.46-3.33 (m, 5H), 2.53-2.52 (m, 1H), 2.34-2.33 (m, 1H), 2.10-2.06 (m, 3H), 1.93 (m, 1H), 1.08-1.04 (m, 2H), 0.80-0.77 (m, 2H).
[00457] Example 7: 6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine rac-l)
Figure imgf000075_0002
[00458] Following general procedure Bl, rac-l was prepared from compound A-5 (0.50 g, 3.1 mmol) . The first step was run at 110 °C for 48 hours, and the second step at 25 °C for 16 hours. The product was purified by prep-HPLC [Instrument: GX-B; Column: YMC-pack ODS-AQ 150x30mm, particle size: 5 μπι; Mobile phase: 10-40% acetonitrile in H20 (add 0.1% TFA, v/v)] to give rac-l (0.60 g, 70% yield) as a white solid. LCMS (J): tR=1.135 min., (ES+) m/z (M+H)+ = 274.1. [00459] Chiral Separation:
[00460] rac-1 (0.30 g, 1.1 mmol) was separated by SFC (Column: Chiralpak AD-3 100x4.6mm, I.D., 10 μιη; Mobile phase: 40% ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00461] 6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 7-P1) (40 mg, 13% yield) as a white solid: cSFC analytical (B) tR=2.479 min., purity: 98.09%; LCMS (Q): tR=2.777 min., (ES+) m/z (M+H)+ = 274.1; ¾-NMR (CD3OD, 400 MHz): δ 7.73-7.71 (d, J=8.4 Hz, 1H), 6.97-6.96 (d, J=1.6 Hz, 1H), 6.91-6.88 (dd, Jx=8.8 Hz, J2=2.0 Hz, 1H), 4.16-4.12 (m, lH), 3.89(s, 3H), 3.85-3.82 (m, lH), 3.51-3.37 (m, 4H), 3.33-3.30 (m, 1H), 2.54-2.52 (m, 1H), 2.36-2.35 (m, 1H), 2.15-2.09 (m, 2H), 1.96-1.92 (m, 1H); and
[00462] 6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 7-P2) (40 mg, 13% yield) as a white solid: cSFC analytical (B) tR=2.771 min., purity: 97.76%; LCMS (Q): tR=2.770 min., (ES+) m/z (M+H)+ = 2740.1; ¾-NMR (CD3OD, 400 MHz): δ 7.75-7.73 (d, J=8.8 Hz, 1H), 6.97-6.96 (d, J=2.0 Hz, 1H), 6.91-6.88 (dd, Jx=8.8 Hz, J2=2.0 Hz, 1H), 4.15-4.13 (m, lH), 3.89(s, 3H), 3.85-3.82 (m, lH), 3.52-3.37 (m, 4H), 3.33-3.30 (m, 1H), 2.55-2.52 (m, 1H), 2.39-2.35 (m, 1H), 2.15-2.08 (m, 2H), 1.98-1.92 (m, 1H).
[00463] Ex (rac-8)
Figure imgf000076_0001
[00464] Following general procedure Bl, rac-8 was prepared from 6-(trifluoromethyl)benzo[d] isoxazol-3 -amine (0.40 g, 2.0 mmol) using 4 equivalents of sodium borohydride and a reaction time of 16 hours for the first step. The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μπι; Mobile phase: 28-58% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-8 (0.15 g, 24% yield) as a white solid. LCMS (G): (ES+) m/z (M+H)+ = 312.1, tR=2.84 min.
[00465] Chiral Separation:
[00466] rac-8 (0.12 g, 0.46 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μπι; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00467] N-(quinuclidin-3-yl)-6-(trifluoromethyl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 8-P1) (35 mg, 35% yield) as a white solid: cSFC analytical (G) tR=2.66 min., purity: 99.42%; LCMS (J): tR=1.42 min., (ES+) m/z (M+H)+ = 312.1; TT-NMR (CD3OD, 400 MHz): δ 8.09-8.04 (m, 1H), 7.84 (s, 1H), 7.61 (d, J=8 Hz, 1H), 4.24-4.20 (m, 1H), 3.92-3.86 (m, 1H), 3.47-3.37 (m, 5H), 2.58-2.57 (m, 1H), 2.38-2.37 (m, 1H), 2.20-2.11 (m, 2H), 2.01-1.98 (m, 1H); and
[00468] N-(quinuclidin-3-yl)-6-(trifluoromethyl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 8-P2) (45 mg, 45% yield) as a white solid: cSFC analytical (G) tR=3.70 min., purity: 99.39%; LCMS (J): tR=1.42 min., (ES+) m/z (M+H)+ = 312.1; ¾-NMR (CD3OD, 400 MHz): 58.09-8.05 (m, 1H), 7.83 (s, 1H), 7.61 (d, J=8 Hz, 1H), 4.23-4.20 (m, 1H), 3.91-3.86 (m, 1H), 3.47-3.37 (m, 5H), 2.59-2.56 (m, 1H), 2.38-2.34 (m, 1H), 2.19-2.11 (m, 2H), 2.01-1.95 (m, 1H).
[00469] Example 9: 6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (rac-9)
Figure imgf000077_0001
[00470] Following general procedure Bl, rac-9 was prepared from A-8 (0.26 g, 1.3 mmol) using 3 equivalents of sodium borohydride and a reaction time of 10 hours for the first step and 2 hours for the second. The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μιη; Mobile phase: 44-74% acetonitrile in H20 (add 0.5% NH3 H20, v/v)] to give rac-9 (0.10 g, 40% yield) as a white solid. LCMS (B): (ES+) m/z (M+H)+ = 311.9. tR=0.71 min.
[00471] Chiral Separation:
[00472] rac-9 (0.10 g, 0.49 mmol) was separated by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μιη; Mobile phase: ethanol (0.05% DEA) in C02) according to the chiral separation of general procedure Bl to give:
[00473] 6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomerl hydrochloride (compound 9-P1) (50 mg, 50% yield) as a white solid: cSFC analytical (G) tR= 2.70 min., purity: 98.53%; LCMS (B): tR=0.68 min., (ES+) m/z (M+H)+ = 312.1; ¾-NMR (CD3OD, 400 MHz): δ 7.80 (d, J=8.4 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 4.19-4.17 (m, 1H), 3.90-3.84 (m, 1H), 3.51-3.37 (m, 5H), 2.57-2.54 (m, 1H), 2.38-2.34 (m, 1H), 2.16-2.09 (m, 2H), 1.99-1.94 (m, 1H); and
[00474] 6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine-enantiomer2 hydrochloride (compound 9-P2) (40 mg, 40% yield) as a white solid: cSFC analytical (G) tR=3.44 min., purity: 99.72%; LCMS (B): tR=0.69 min., (ES+) m/z (M+H)+ = 312.1; ¾-NMR (CD3OD, 400 MHz): δ 7.81 (d, J=8.4 Hz, 1H), 7.45 (d, J=8 Hz, 1H), 4.19-4.17 (m, 1H), 3.90-3.84 (m, 1H), 3.50-3.45 (m, 5H), 2.57-2.54 (m, 1H), 2.39-2.35 (m, 1H), 2.16-2.09 (m, 2H), 2.00-1.97 (m, 1H).
[00475] Example 10: (i?)-4-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-10)
Figure imgf000077_0002
[00476] Following general procedure CI, compound (i?)-10 was prepared from compound A-10:
[00477] Compound (i?)-A-10-l (0.1 g, white solid, 42% yield over two steps) was prepared from compound A-10 (0.3 g, 1.46 mmol) and (i?)-quinuclidin-3 -amine (0.25 g, 2.0 mmol). The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 22-52% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 298, tR=0.866 min.
[00478] A mixture of compound (i?)-A-10-l (100 mg, 0.34 mmol) and potassium carbonate (186 mg, 1.4 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 120 °C for 2 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 38-68% acetonitrile in H20 (add 0.05%ammonia-ACN, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00479] Compound (R)-1 (30 mg, 29% yield) as a white solid: cSFC analytical tR=2.97 min., purity: 96.01%; LCMS (EE): tR=2.55 min., 278.1 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 7.54- 7.53 (t, J=8 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 4.23-4.20 (m, 1H), 3.89-3.82 (m, 1H), 3.51-3.37 (m, 5H), 2.63-2.61 (m, 1H), 2.36-2.31 (m, 1H), 2.16-2.10 (m, 2H), 2.00-1.99 (m, 1H).
[00480] Example 11: (i?)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydochloride ((i?)-ll)
Figure imgf000078_0001
[00481] Following general procedure CI, compound (i?)-ll was prepared from compound A-12:
[00482] Compound (i?)-A-12-l (0.10 g, white solid, 31% yield over two steps) was prepared from compound A-12 (0.20 g, 1.0 mmol) and (i?)-quinuclidin-3 -amine (0.25 g, 2.0 mmol), using N, N- dimethylformamide as the solvent instead of methanol. The product was purified by prep-HPLC
[Instrument: GX-A; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 19-49% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. LCMS (B): (ES+) m/z (M+H)+ = 282.1, tR=2.387 min.
[00483] A mixture of compound (i?)-A-12-l (0.10 g, 0.36 mmol) and potassium tert-butoxide (60 mg, 0.53 mmol) in N,N-dimethylacetamide (5 mL) was stirred at room temperature for 1 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 5 μπι; Mobile phase: 12-42% acetonitrile in H20 (add 0.1% TFA, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00484] Compound (R)-ll (10 mg, 10% yield) as a yellow solid: cSFC analytical (A) tR=4.76 min., purity: 100%; LCMS (J): tR=1.259 min., (ES+) m/z (M+H)+ = 262.2; TT-NMR (CD3OD, 400 MHz): δ 7.88-7.84 (m, 1H), 7.25-7.23 (d, J=8.8 Hz, 1H), 7.13-7.09 (t, J=8.8 Hz, 1H), 4.16-4.15 (m, 1H), 3.89-3.83 (t, J=11.6 Hz, 1H), 3.42-3.38 (m, 4H), 3.29 (m, lH), 2.55-2.54 (m, 1H), 2.36 (m, 1H), 2.13-2.12 (m, 2H), 1.96 (m, 1H). [00485] Example 12: (i?)-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-6-carbonitrile
Figure imgf000079_0001
[00486] Following general procedure CI, compound (i?)-12 was prepared from compound A-14:
[00487] Compound (i?)-A-14-l (0.15 g, white solid, 42% yield over two steps) was prepared from compound A-14 (0.30 g, 1.0 mmol) and (i?)-quinuclidin-3 -amine (0.25 g, 2.0 mmol). The product was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 19-49% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. LCMS (B): (ES+) m/z (M+H)+ = 289.2, tR=0.928 min.
[00488] A mixture of compound (i?)-A-14-l (0.13 g, 0.45 mmol) and potassium carbonate (0.19 g, 1.4 mmol) in N N-dimethylformamide (3.0 mL) was stirred at 110 °C for 2 hours. On completion, the reaction mixture was was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 5 μιη; Mobile phase: 17-74% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00489] Compound (i?)-12 (30 mg, 23% yield) as a white solid: cSFC analytical (D) tR=2.15 min., purity: 99.44%; LCMS (EE): tR=2.39 min., 269.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 8.08 (d, J=8 Hz, 1H), 7.94 (s, 1H), 7.64-7.62 (dd, J=8 Hz, J=0.8 Hz, 1H), 4.22-4.20 (m, 1H), 3.91- 3.85 (m, 1H), 3.51-3.35 (m, 5H), 2.58-2.56 (m, 1H), 2.37-2.35 (m, 1H), 2.16-2.10 (m, 2H), 1.99-1.97 (m, 1H).
[00490] Example 13:
[00491] Preparation: (i?)-6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
Figure imgf000079_0002
[00492] Following general procedure CI, compound (i?)-13 was prepared from compound A-16:
[00493] Compound (i?)-A-16-l (0.35 g, pale yellow solid, 49% yield over two steps) was prepared from compound A-16 (0.30 g, 1.2 mmol) and (i?)-quinuclidin-3 -amine (0.18 g, 1.4 mmol), using N N-dimethylformamide as the solvent instead of methanol. The product was purified by silica gel chromatography [DCM : Me OH = 5: 1]. LCMS (B): (ES+) m/z (M+H)+ = 342.1, tR=0.894 min.
[00494] A mixture of compound (i?)-A-16-l (0.10 g, 0.29 mmol) and potassium tert-butoxide (36 mg, 0.32 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 6 hour. On completion, the reaction mixture was was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX-G; Column: Phenomenex Synergi Max-RP C18 250x80 mm, particle size: 10 μιη; Mobile phase: 1-31% acetonitrile in H20 (add 0.2% TFA, v/v)]. The product was lyophilized, dissolved in 0.2 N hydrochloric acid and again lyophilized to give:
[00495] Compound (R)-13 (15 mg, 14% yield) as a white solid: cSFC analytical (A) tR=6.79 min., purity: 100%; LCMS (W): tR=0.740 min., (ES+) m/z (M+H)+ = 322.1; ¾-NMR (CD3OD, 400 MHz): δ 8.12-8.09 (d, J=8.4 Hz, IH), 8.07 (s, IH), 7.88-7.87 (dd, J=1.2 Hz, J=8.4 Hz, IH), 4.21-4.19 (m, IH), 3.90-3.85 (m, IH), 3.45-3.34 (m, 5H), 3.21 (s, 3H), 2.57-2.54 (m, IH), 2.36-2.35 (m, IH), 2.14-2.10 (m, 2H), 2.04-1.93 (m, IH).
[00496] Preparation: (5)-6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hyd
Figure imgf000080_0001
[00497] Following general procedure CI, compound ( )-13 was prepared from compound A-16:
[00498] Compound (S)-A-16-l (0.15 g, pale yellow solid, 36% yield over two steps) was prepared from compound A-16 (0.30 g, 1.2 mmol) and (S)-quinuclidin-3 -amine (0.18 g, 1.4 mmol), using Ν, N-dimethylformamide as the solvent instead of methanol. The product was purified by silica gel chromatography [DCM / MeOH = 5/1]. LCMS (B): (ES+) m/z (M+H)+ = 342.1, tR=0.852 min.
[00499] A mixture of compound ( )-A-16-l (0.30 g, 0.88 mmol) and potassium tert-butoxide (0.11 g, 0.97 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 12 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-G; Column: Phenomenex Synergi Max-RP C18 250x80 mm, particle size: 10 μπι; Mobile phase: 1-31% acetonitrile in H20 (add 0.2% TFA, v/v)]. The resulting solid was dissolved in 0.2 N hydrochloric acid and again lyophilized to give:
[00500] Compound (S)-13 (25 mg, 9% yield) as a white solid: cSFC analytical (A) tR=8.80 min., purity: 100%; LCMS (W): tR=0.708 min., (ES+) m/z (M+H)+ = 322.1; ¾-NMR (CD3OD, 400 MHz): 5 8.11-8.09 (d, J=8.4 Hz, IH), 8.07 (s, IH), 7.88-7.86 (d, J=8.4 Hz, IH), 4.16-4.14 (m, IH), 3.84-3.78 (m, IH), 3.35-3.25 (m, 5H), 3.20 (s, 3H), 2.52-2.50 (m, IH), 2.30-2.29 (m, IH), 2.10-2.06 (m, 2H), 1.91-1.89 (m, IH).
[00501] Example 14: (i?)-6-(tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydro
Figure imgf000080_0002
[00502] Following general procedure CI, compound (i?)-14 was prepared from compound A-20: [00503] Compound (i?)-A-20-l (60 mg, white solid, 14% yield over two steps) was prepared from compound A-20 (0.30 g, 1.3 mmol) and (i?)-quinuclidin-3 -amine (0.16 g, 1.3 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Synergi C18 250x50 mm, particle size: 10 μιη; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 320.2, tR=1.301 min.
[00504] A mixture of compound (i?)-A-20-l (50 mg, 0.16 mmol) and potassium carbonate (66 mg, 0.48 mmol) in N, N-dimethylformamide (4.0 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 5 μπι; Mobile phase: 17-74% acetonitrile in H20 (add 0.5% HCI, v/v)]. The product was lyophilized to give:
[00505] Compound (i?)-14 (6.5 mg, 14% yield) as a white solid: cSFC analytical (D) tR=2.62 min., purity: 100%; LCMS (EE): tR=2.99 min., 300.2 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 7.79-7.77 (d, J=8.4 Hz, 1H), 7.44-7.43 (s, 1H), 7.40-7.40 (m, 1H), 4.17-4.15 (m, 1H), 3.89-3.83 (t, J=11.6 Hz, 1H), 3.43-3.33 (m, 5H), 2.55-2.54 (m, 1H), 2.36 (m, 1H), 2.15-2.11 (m, 2H), 1.96 (m, 1H), 1.40-1.36 (m, 9H).
[00506] Example 15:
[00507] Preparation: (i?)-5,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
hydrochloride ((i?)-15)
Figure imgf000081_0001
[00508] Following general procedure CI, compound (i?)-15 was prepared from compound A-24:
[00509] Compound (i?)-A-24-l (30 mg, white solid, 22% yield over two steps) was prepared from compound A-24 (0.10 g, 0.41 mmol) and (i?)-quinuclidin-3 -amine (62 mg, 0.49 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Synergi C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (X): (ES+) m/z (M+H)+ = 332.1, tR=1.178 min.
[00510] A mixture of compound (i?)-A-24-l (75 mg, 0.23 mmol) and potassium carbonate (94 mg, 0.68 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 110 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 5 μπι; Mobile phase: 17-74% acetonitrile in H20 (add 0.5% HCI, v/v)]. The product was lyophilized to give:
[00511] Compound (i?)-15 (30 mg, 43% yield) as a white solid: cSFC analytical tR=5.47 min., purity: 100%; LCMS (X): tR=0.16 min., 312.0 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 8.09 (s, 1H), 7.73 (s, 1H), 4.18-4.16 (m, 1H), 3.89-3.83 (m, 1H), 3.51-3.31 (m, 5H), 2.55-2.53 (m, 1H), 2.38- 2.34 (m, 1H), 2.16-2.09 (m, 2H), 2.08-1.96 (m, 1H). [00512] Preparation: (5)-5,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochlo
Figure imgf000082_0001
[00513] Following general procedure CI, compound ( )-15 was prepared from compound A-24:
[00514] Compound (S)-A-24-l (0.30 g, white solid, 44% yield over two steps) was prepared from compound A-24 (0.50 g, 2.1 mmol) and (<S)-quinuclidin-3 -amine (0.26 g, 2.1 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 332.1, tR= 1.166 min.
[00515] A mixture of compound ( )-A-24-l (0.20 g, 0.60 mmol) and potassium carbonate (0.25 g, 1.8 mmol) in N,N-dimethylacetamide (8.0 mL) was stirred at 110 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00516] Compound (S)-15 (0.12 g, 64% yield) as a white solid: cSFC analytical (D) tR=l .977 min., purity: 99.16%; LCMS (B): tR=0.683 min., (ES+) m/z (M+H)+ = 312.1; 1H-NMR (CD3OD, 400 MHz): δ 8.06 (s, 1H), 7.75 (s, 1H), 4.18-4.15 (m, 1H), 3.89-3.83 (m, 1H), 3.49-3.27 (m, 5H), 2.55- 2.53 (m, 1H), 2.38-2.34 (m, 1H), 2.16-2.09 (m, 2H) , 1.99-1.96 (m, 1H).
[00517] Example 16: (i?)-N-(quinuclidin-3-yl)-6-(trifluoromethoxy)benzo[£/]isoxazol-3-amine hydrochl
Figure imgf000082_0002
[00518] Following general procedure CI, compound (i?)-16 was prepared from compound A-26:
[00519] Compound (i?)-A-26-l (0.22 g, white solid, 30% yield over three steps) was prepared from compound A-26 (0.55 g, 2.5 mmol), triethylamine (0.42 g, 4.2 mmol) and (i?)-quinuclidin-3- amine (0.26 g, 2.1 mmol), usingN N-dimethylformamide as the solvent instead of methanol. The reaction time was 10 hours. The product was purified by prep-HPLC [Instrument: GX-H; Column: Waters Xbridge C18 150x25 mm, particle size: 5 μπι; Mobile phase: 26-56% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. ¾-NMR (CDC13, 400 MHz): δ 7.43 (t, J=8.0 Hz, 1H), 7.05 (m, 2H), 5.63 (d, J=8.0 Hz, 1H), 3.13-3.09 (m, 2H), 2.93-2.77 (m, 3H), 2.63-2.57 (m, 2H), 1.99-1.84 (m, 2H), 1.68-1.60 (m, 2H), 1.48-1.46 (m, 1H), 1.34-1.33 (m, 1H). LCMS (J): (ES+) m/z (M+H)+ = 348.0, tR= 1.052 min. [00520] A mixture of compound (i?)-A-26-l (0.25 g, 0.52 mmol) and potassium tert-butoxide (88 mg, 0.79 mmol) in N, N-dimethylacetamide (26 mL) was stirred at 25 °C for 2 hours. The mixture was diluted with ethyl acetate (260 mL), washed with brine (6 χ 40 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The product was purified twice by prep-HPLC [Instrument: GX-D; Column: Boston Green ODS 150x30 mm, particle size: 5 μπι; Mobile phase: 6- 42% acetonitrile in H20 (add 0.225% FA, v/v), and Instrument: GX-B; Column: Phenomenex Synergi CI 8 150x30 mm, particle size: 4 μιη; Mobile phase: 23-53% acetonitrile in H20 (add 0.1% TFA, v/v)], treated with 0.2 M hydrochloric acid and lyophilized to give:
[00521] Compound(i?)-16 (32 mg, 17% yield) as a yellow solid : cSFC analytical (D) tR=l .64 min., purity: 100%; LCMS (EE): tR=2.820 min., (ES+) m/z (M+H)+ = 328.1; i-NMR (CD3OD, 400 MHz): δ 7.95 (d, J=8.4 Hz, IH), 7.38 (s, IH), 7.19 (d, J=8.4 Hz, IH), 4.14 (t, J=9.2 Hz, IH), 3.82 (t, J=10.6 Hz, IH), 3.47-3.28 (m, 5H), 2.51 (d, J=3.2 Hz, IH), 2.34-2.32 (m, IH), 2.13-2.07 (m, 2H), 1.95-1.92 (m, IH).
[00522] Example 17: (i?)-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride
((i?)-17)
Figure imgf000083_0001
[00523] Following general procedure CI, compound (i?)-1 was prepared from compound A-28:
[00524] Compound (i?)-A-28-l (0.20 g, white solid, 27% yield over two steps) was prepared from compound A-28 (0.50 g, 2.6 mmol) and (i?)-quinuclidin-3 -amine (0.40 g, 3.1 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 20-50% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 282.1, tR= 0.999 min.
[00525] A mixture of compound (i?)-A-28-l (0.20 g, 0.71 mmol) and potassium tert-butoxide (0.30 g, 2.0 mmol) in N, N-dimethylacetamide (5.0 mL) was stirred at 110 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-B; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 10-40% acetonitrile in H20 (add 0.5% HCI, v/v)]. The product was lyophilized to give:
[00526] Compound (i?)-17 (0.10 g, 47% yield) as a white solid: cSFC analytical (D) tR=2.22 min., purity: 94%; LCMS (EE): tR=2.50 min., 262.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): 57.69-7.67 (d, J=8.0 Hz, IH), 7.39-7.34 (m, IH), 7.30-7.26 (m, IH), 4.21-4.18 (m, IH), 3.91-3.85 (m, IH), 3.49-3.31 (m, 5H), 2.58-2.56 (m, IH), 2.40-2.35 (m,lH) , 2.16-2.10 (m, 2H), 1.99-1.97 (m,lH).
[00527] Example 18: (i?)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-18) and (5)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride (( )-18)
Figure imgf000084_0001
[00528] Following general procedure CI, compound (i?)-18 was prepared from compound A-30:
[00529] Compound (i?)-A-30-l (0.20 g, white solid, 27% yield over three steps) was prepared from compound A-30 (0.50 g, 2.6 mmol) and (i?)-quinuclidin-3 -amine (0.40 g, 3.1 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 20-50% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 282.2, tR= 0.964 min.
[00530] A mixture of compound (i?)-A-30-l (0.30 g, 1.1 mmol) and potassium carbonate (0.44 g, 3.2 mmol) in N, N- dimethylformamide (5.0 mL) was stirred at 110 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 12-42% acetonitrile in H20 (add 0.5% HCI, v/v)]. The product was lyophilized to give:
[00531] Compound (i?)-18 (0.15 g, 37% yield) as a white solid: cSFC analytical (D) tR=2.027 min., chiral purity: 90%;
[00532] Chiral Purification:
[00533] A solution of (i?)-18 at 90% chiral purity (0.12 g, 0.46 mmol) in 3 mL of methanol was purified by cSFC (Instrument: SFC A; Column: AY-10 μπι; Mobile phase: 50% methanol (0.01% NH3 H20) in C02) at room temperature. In addition to the major product compound (R)-18, the minor product compound (S)-18 was also collected. Each set of collected fractions was concentrated at room temperature and lyophilized. The resulting solids were dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00534] Compound (i?)-18 (80 mg, 59% yield) as a white solid : cSFC analytical (D) tR=2.038 min., purity: 100%; LCMS (EE): tR=2.464 min., (ES+) m/z (M+H)+ = 262.1; 1H-NMR (CD3OD, 400 MHz): 57.59-7.56 (dd, J=8.0 Hz, J=2.4 Hz, 1Η),7.47-7.44 (dd, J=8.8 Hz, J=4.0 Hz, 1H), 7.40-7.35 (m, 1H), 4.19-4.16 (m, 1H), 3.90-3.84 (m, 1H), 3.47-3.29 (m, 5H), 2.56-2.54 (m, 1H), 2.37-2.33 (m,lH) , 2.16-2.10 (m, 2H), 1.99-1.95 (m,lH); and
[00535] Compound (S)-18 (8.0 mg, 6% yield) as a white solid : cSFC analytical (D) tR=2.673 min., purity: 97.2%; LCMS (EE): tR=2.438 min., (ES+) m/z (M+H)+ = 262.1; 1H-NMR (CD3OD, 400 MHz): 57.61-7.58 (dd, J=8.0 Hz, J=2.4 Hz, 1Η),7.47-7.44 (dd, J=8.4 Hz, J=4.0 Hz, 1H), 7.40-7.35 (m, 1H), 4.19-4.16 (m, 1H), 3.90-3.83 (m, 1H), 3.48-3.30 (m, 5H), 2.56-2.54 (m, 1H), 2.39-2.33 (m,lH) , 2.18-2.09 (m, 2H), 1.98-1.96 (m,lH);
[00536] cSFC analytical conditions: Column: Chiralcel AY-3 100x4.6mm, I.D., 3 μπι; Mobile phase: ethanol (0.05% DEA) in C02 from 5% to 40%; Flow rate: 3 mL/min.; Back pressure: 120 bar. Example 19: (i?)-4-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride
Figure imgf000085_0001
[00538] Following general procedure CI, compound (i?)-19 was prepared from compound A-32:
[00539] Compound (i?)-A-32-l (0.60 g, white solid, crude) was prepared from compound A-32 (0.40 g, 2.1 mmol) and (i?)-quinuclidin-3 -amine (0.26 g, 2.1 mmol). The reaction time was 2 hours. LCMS (Q): (ES+) m/z (M+H)+ = 282.1, tR= 2.310 min.
[00540] A mixture of compound (i?)-A-32-l (0.30 g, 1.1 mmol) and potassium carbonate (0.44 g, 3.2 mmol) in N, N- dimethylformamide (10 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- A; Column: Phenomenex Gemini C18 250x50, particle size: 10 μπι; Mobile phase: 29-59%
acetonitrile in H20 (add 0.05% NH3 Ή20, v/v)]. The resulting solid was dissolved in 0.2 N
hydrochloric acid and again lyophilized to give:
[00541] Compound (i?)-19 (90 mg, 28% yield over three steps) as a yellow solid: cSFC analytical (D) tR=2.672 min., purity: 97.27%; LCMS (EE): tR=2.383 min., (ES+) m/z (M+H)+ = 262.1; ¾- NMR (CD3OD, 400 MHz): δ 7.61-7.56 (m, 1H), 7.30-7.28 (d, J=8.0 Hz, 1H), 7.03-7.98 (t, J=10.0 Hz, 1H), 4.21-4.18 (m, 1H), 3.87-3.81 (m, 1H), 3.50-3.35 (m, 5H), 2.61-2.59 (m, 1H), 2.34-2.32 (m, 1H), 2.15-2.09 (m, 2H), 1.98-1.92 (m, 1H).
[00542] Example 20: (i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((K)-20)
Figure imgf000085_0002
[00543] Following general procedure CI, compound (i?)-20 was prepared from compound A-34:
[00544] Compound (i?)-A-34-l (0.11 g, white solid, 26% yield over two steps) was prepared from compound A-34 (0.30 g, 1.5 mmol) and (i?)-quinuclidin-3 -amine (0.18 g, 1.5 mmol). The product was purified by prep-HPLC [Instrument: GX-H; Waters Xbridge 150x25, particle size: 5 μπι; Mobile phase: 20-50% acetonitrile in H20 (add 0.05% NH3 H20, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 296.1, tR=l.108 min.
[00545] A mixture of compound (i?)-A-34-l (80 mg, 0.27 mmol) and potassium carbonate (0.11 g, 0.81 mmol) in N, N- dimethylformamide (10 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- C; Column: Phenomenex Gemini C18 250x50, particle size: 10 μπι; Mobile phase: 30-60% acetonitrile in H20 (add 0.05% NH3 Ή20, v/v)]. The resulting product was lyophilized, dissolved in 0.2 N hydrochloric acid and again lyophilized to give:
[00546] Compound (R)-2 (30 mg, 36% yield) as a yellow solid: cSFC analytical (D) tR=2.377 min., purity: 96.68%; LCMS (EE): tR=2.659 min., (ES+) m/z (M+H)+ = 276.1; ¾-NMR (CD3OD, 400 MHz): δ 7.52-7.50 (d, J=8.0 Hz, 1H), 7.18-7.15 (t, J=7.6 Hz, 1H), 4.18-4.15 (m, 1H), 3.90-3.83 (m, 1H), 3.46-3.38 (m, 4H), 3.29-3.28 (m, 1H), 2.56-2.54 (m, 1H), 2.43-2.42 (m, 3H), 2.38-2.34 (m, 1H), 2.16-2.09 (m, 2H), 1.99-1.95 (m, 1H).
[00547] Example 21: (i?)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochlo
Figure imgf000086_0001
[00548] Following general procedure CI, compound (R)-21 was prepared from compound A-36:
[00549] Compound (i?)-A-36-l (0.11 g, white solid, 77% yield over two steps) was prepared from compound A-36 (0.10 g, 0.48 mmol) and (i?)-quinuclidin-3 -amine (0.12 g, 1.0 mmol) with a reaction time of 3 hours. The product was purified by prep-HPLC [Instrument: GX-H; Column: Waters Xbridge 150x25 mm, particle size: 5 μπι; Mobile phase: 20-5% acetonitrile in H20 (add
0.05%ammonia-ACN, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 300.1, tR=l.lmin.
[00550] A mixture of compound (i?)-A-36-l (0.11 g, 0.45 mmol) and potassium carbonate (0.19 g, 1.4 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered. The reaction mixture was concentrated in vacuo and purified by prep-HPLC [Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 5 μπι; Mobile phase: 17-74% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00551] Compound (R)-21 (35 mg, 34% yield) as a white solid: cSFC analytical tR=1.87 min., purity: 97.57%; LCMS (GG): tR=1.74 min., 280.1 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 7.70- 7.86 (m, 1H), 7.28-7.22 (m, 1H), 4.18-4.16 (m, 1H), 3.90-3.83 (m, 1H), 3.58-3.36 (m, 5H), 2.57-2.54 (m, 1H), 2.38-2.35 (m, 1H), 2.17-2.09 (m, 2H), 1.98-1.95 (m, 1H).
[00552] Example 22: (i?)-5-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((R)-22)
Figure imgf000086_0002
[00553] Following general procedure CI, compound (i?)-22 was prepared from compound A-40:
[00554] Compound (i?)-A-40-l (0.14 g, white solid, 16% yield over four steps) was prepared from compound A-40 (0.50 g, 2.4 mmol) and (i?)-quinuclidin-3 -amine (0.31 g, 2.4 mmol). The reaction time was 0.5 hours. The product was purified by prep-HPLC [Instrument: GX-C; Column:
Phenomenex Synergi C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.05%ammonia-ACN, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 296.2, tR=1.092 min.
[00555] A mixture of compound (i?)-A-40-l (90 mg, 0.30 mmol) and potassium phosphate (0.19 g, 0.91 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 150 °C for 0.5 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-B; Column: YMC-Actus Pro C18 150x30 mm, particle size: 4 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.1%TFA-ACN, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00556] Compound (R)-22 (35 mg, 37% yield) as a white solid: cSFC analytical (D) tR=5.47 min., purity: 98.28%; LCMS (FF): tR=2.07 min., 276.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 7.54 (d, J=8.8 Hz, 1H), 7.32 (d, J=5.6 Hz, 1H), 4.17-4.14 (m, 1H), 3.88-3.82 (m, 1H), 3.47-3.36 (m, 4H), 3.31-3.30 (m, 1H), 2.55-2.53 (m, 1H), 2.38-2.35 (m, 1H), 2.15-2.08 (m, 2H), 1.97-1.92 (m, 1H).
[00557] Example 23: (i?)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochl
Figure imgf000087_0001
[00558] Following general procedure CI, compound (i?)-23 was prepared from compound A-43:
[00559] Compound (i?)-A-43-l (0.14 g, white solid, 20% yield over four steps) was prepared from compound A-43 (0.45 g, 2.3 mmol) and (i?)-quinuclidin-3 -amine (0.29 g, 2.3 mmol). The reaction was stirred at 18 °C for 2 hours. The product was purified by prep-HPLC [Instrument: GX-C;
Column: Phenomenex Synergi C18 250x50 mm, particle size: 10 μπι; Mobile phase: 27-58% acetonitrile in H20 (add 0.05%ammonia-ACN, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 312.2, tR=1.172 min.
[00560] A mixture of compound (i?)-A-43-l (90 mg, 0.30 mmol) and potassium phosphate (0.19 g, 0.91 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 150 °C for 0.5 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC
[Instrument: GX-I; Column: Welch Ultimate AQ-C18 150x30mm, particle size: 5 μπι; Mobile phase: 30-60% acetonitrile in H20 (add 0.1%TFA-ACN, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00561] Compound (R)-23 (55 mg, 65% yield) as a white solid: cSFC analytical (D) tR=2.74 min., purity: 100.00%; LCMS (FF): tR=2.30 min., 292.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 7.65 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 4.19-4.16 (m, 1H), 3.90-3.83 (m, 1H), 3.50-3.36 (m, 4H), 3.30-3.29 (m, 1H), 2.56-2.54 (m, 1H), 2.50 (m, 3H), 2.36-2.32 (m, 1H), 2.16-2.09 (m, 2H), 2.00- 1.93 (m, 1H). [00562] Example 24: (i?)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hyd
Figure imgf000088_0001
[00563] Following general procedure CI, compound (R)-24 was prepared from compound A-45:
[00564] Compound (i?)-A-45-l (0.15 g, white solid, 23% yield over three steps) was prepared from compound A-45 (0.45 g, 1.89 mmol) and (i?)-quinuclidin-3 -amine (0.24 g, 2.0 mmol) with a reaction time of 0.5 h. The product was purified by prep-HPLC [Instrument: GX-H; Column: Waters Xbridge 150x25 mm, particle size: 5 μπι; Mobile phase: 20-50% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 328.1, tR=1.04 min.
[00565] A mixture of compound (i?)-A-45-l (0.14 g, 0.43 mmol) and potassium carbonate (0.19 g, 1.4 mmol) in N N-dimethylformamide (3.0 mL) was stirred at 120 °C for 3 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 37-67% acetonitrile in H20 (add 0.05% ammonia-ACN, v/v)]. The residue solid was dissolved in 0.2 N hydrochloric acid and lyophilized again to give:
[00566] Compound (i?)-24 (45 mg, 33% yield) as a white solid: cSFC analytical tR=2.51 min., purity: 97%; LCMS (FF): tR=2.25 min., (ES+) m/z (M+H)+ = 308.1; 1H-NMR (CD3OD, 400 MHz): δ 7.48 (d, J=8.8 Hz, 1H), 7.30 (d, J=8.0 Hz, 1H), 4.20-4.16 (m, 4H), 3.90-3.83 (m, 1H), 3.50-3.31 (m, 5H), 2.57-2.55 (m, 1H), 2.36-2.35 (m, 1H), 2.16-2.10 (m, 2H), 1.98-1.94 (m, 1H).
[00567] Example 25: (i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3- amine
Figure imgf000088_0002
[00568] Following general procedure CI, compound (R)-25 was prepared from compound A-48:
[00569] Compound (i?)-A-48-l (0.20 g, white solid, 39% yield over two steps) was prepared from compound A-48 (0.39 g, 1.4 mmol) and (i?)-quinuclidin-3 -amine (0.21 g, 1.7 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 30-60% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 366.2, tR= 1.239 min.
[00570] A mixture of compound (i?)-A-48-l (0.15 g, 0.41 mmol) and potassium carbonate (0.17 g, 1.2 mmol) inN N-dimethylformamide (4.0 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μιη; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00571] Compound (R)-25 (60 mg, 38% yield) as a white solid: cSFC analytical (D) tR=l .977 min., purity: 100%; LCMS (EE): tR=2.154 min., 346.1 m/z (M+l); 1H-NMR (D20, 400 MHz):
57.66-7.63 (d, J=8.4 Hz, 1Η),7.25-7.23 (d, J=8.0 Hz, 1H), 4.00-3.98 (m, 1H), 3.75-3.69 (m, 1H), 3.36-3.15 (m, 5H), 2.40-2.39 (m, 1H), 2.18-1.85 (m, 4H).
[00572] Example 26: (i?)-6-chloro-7-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
((i?)-26)
Figure imgf000089_0001
[00573] Following general procedure CI, compound (R)-26 was prepared from compound A-54:
[00574] Compound (i?)-A-54-l (0.25 g, white solid, 36% yield over two steps) was prepared from compound A-54 (0.50 g, 2.0 mmol) and (i?)-quinuclidin-3 -amine (0.25 g, 2.0 mmol). The product was purified by prep-HPLC [Instrument: GX-H; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 27-57% acetonitrile in H20 (add 0.5% NH3OH H20, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 338.1 , tR= 1.159 min.
[00575] A mixture of compound (i?)-A-54-l (0.15 g, 0.44 mmol) and potassium phosphate (0.28 g, 1.3 mmol) in N, N- dimethylformamide (20 mL) was stirred at 150 °C for 0.5 hour. On completion, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC [Instrument: GX-I; Column: Welch Ultimate AQ-C18 150x30 mm; particle size: 5 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.1% TFA, v/v)]. The resulting solid was dissolved in 0.2 Ν hydrochloric acid and again lyophilized to give:
[00576] Compound (R)-26 (80 mg, 50% yield) as awhite solid: cSFC analytical (D) tR=3.728 min., purity: 99.57%; LCMS (GG): tR=2.152 min., (ES+) m/z (M+H)+ = 318.1; ¾-NMR (CD3OD, 400 MHz): δ 7.18-7.13 (m, 2H), 4.22-4.20 (m, 1H), 3.89-3.83 (m, 1H), 3.50-3.36 (m, 5H), 2.63-2.60 (m, 1H), 2.35-2.31 (m, 1H), 2.21-2.10 (m, 3H), 2.00-1.98 (m, 1H), 1.12-1.07 (m, 2H), 0.95-0.93 (m, 2H).
[00577] Example 27: (i?)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((K)-27)
Figure imgf000089_0002
[00578] Following general procedure CI, compound (R)-21 was prepared from compound A-56: [00579] Compound (i?)-A-56-l (1.1 g, white solid, 90% yield over two steps) was prepared from compound A-56 (0.80 g, 3.5 mmol) and (R)-quinuclidin-3 -amine (0.45 g, 3.5 mmol). The product was purified by silica gel chromatography (dichloromethane/methanol=100: 1-10:1). LCMS (J): tR=1.144 min., 316.0 m/z (M+l).
[00580] A mixture of compound (i?)-A-56-l (0.30 g, 0.86 mmol) and potassium carbonate (0.35 g, 2.6 mmol) in N N-dimethylformamide (3.0 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 17-47% acetonitrile in H20 (add 0.1%TFA-ACN, v/v)]. The resulting solid was dissolved in 0.2 M
hydrochloric acid and again lyophilized again to give:
[00581] Compound (R)-21 (70 mg, 14% yield) as a yellow solid: cSFC analytical (D) tR=l .1 min., purity: 98%; LCMS (EE): tR=2.101 min., 296.0 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 7.43 (s, 1H), 7.14-7.12 (d, J=9.2 Hz, 1H), 4.19-4.17 (m, 1H), 3.86-3.80 (m, 1H), 3.46-3.35 (m, 5H), 2.59-2.58 (m, 1H), 2.31 (m, 1H), 2.14-2.08 (m, 2H), 1.95 (m, 1H).
[00582] Example 28: (i?)-4,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
hydrochloride ((R)-28)
Figure imgf000090_0001
[00583] Following general procedure CI, compound (i?)-28 was prepared from compound A-59:
[00584] Compound (i?)-A-59-l (0.20 g, white solid, 27% yield over two steps) was prepared from compound A-59 (0.35 g, 1.4 mmol) and (R)-quinuclidin-3 -amine (0.22 g, 1.7 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 22-52% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 332.1, tR= 1.125 min.
[00585] A mixture of compound (i?)-A-59-l (0.10 g, 0.30 mmol) and potassium carbonate (0.12 g, 0.90 mmol) in N N-dimethylformamide (4.0 mL) was stirred at 150 °C for 0.5 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 10 μπι; Mobile phase: 16-46% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00586] Compound (R)-28 (0.15 g, 37% yield) as a white solid: cSFC analytical (D) tR=3.25 min., purity: 99%; LCMS (EE): tR=2.776 min., 312.0 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): 57.57-7.60 (d, J=1.6 Hz, 1Η),7.40-7.39 (d, J=1.2 Hz, 1H), 4.21-4.19 (m, 1H), 3.87-3.81 (m, 1H), 3.50-3.36 (m, 5H), 2.62-2.60 (m, 1H), 2.35-2.29 (m,lH) , 2.16-2.09 (m, 2H), 1.99-1.94 (m,lH).
[00587] Example 29: (i?)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((R)-29)
Figure imgf000091_0001
[00588] Following general procedure CI, compound (R)-29 was prepared from compound A-61:
[00589] Compound (i?)-A-61-l (0.12 g, white solid, 17% yield over two steps) was prepared from compound A-61 (0.50 g, 2.1 mmol) and (i?)-quinuclidin-3 -amine (0.26 g, 2.3 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Synergi C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 312.1, tR= 1.161 min.
[00590] A mixture of compound (i?)-A-61-l (0.10 g, 0.32 mmol) and potassium carbonate (0.13 g, 0.56 mmol) in N, N-dimethylformamide (4.0 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Synergi C18 100x21.2mm, particle size: 4 μπι; Mobile phase: 15-45% acetonitrile in H20 (add 0.1%TFA, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00591] Compound (R)-29 (15 mg, 16 % yield) as a yellow solid: cSFC analytical tR=2.83 min., purity: 100.00%; LCMS (FF): tR=2.08 min., 292.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 7.59-7.57 (m, 1H), 7.16-7.12 (m, 1H), 4.16-4.14 (m, 1H), 4.00-3.98 (m, 3H), 3.89-3.85 (m, 1H), 3.43- 3.29 (m, 5H), 2.55-2.53 (m, 1H), 2.35-2.34 (m, 1H), 2.15-2.10 (m, 2H), 1.99-1.97 (m, 1H).
[00592] Example 30: (i?)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-30) and (5)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
Figure imgf000091_0002
[00593] Following general procedure CI, compound (i?)-30 was prepared from compound A-64:
[00594] Compound (i?)-A-64-l (0.35 g, white solid, 51% yield over three steps) was prepared from compound A-64 (0.45 g, 1.9 mmol) and (i?)-quinuclidin-3 -amine (0.24 g, 2.0 mmol). The product was purified by prep-HPLC [Instrument: GX-H; Column: Waters Xbridge 150x25 mm, particle size: 5 μπι; Mobile phase: 20-5% acetonitrile in H20 (add 0.05% ammonia-ACN, v/v)].
LCMS (J): (ES+) m/z (M+H)+ = 328.1, tR=1.03 min.
[00595] A solution of compound (i?)-A-64-l (250 mg, 0.76 mmol) and potassium carbonate (186 mg, 1.35 mmol) in N N-dimethylformamide (3.0 mL) was stirred at 120 °C for 1 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 37-67% acetonitrile in H20 (add 0.05% ammonia-ACN, v/v)]. The residue was dissolved in 0.2 M hydrochloric acid and lyophilized to give:
[00596] Compound (R)-3 (50 mg, 21% yield) as a white solid: cSFC analytical (D) tR=1.045 min., chiral purity: 87%.
[00597] A solution of (i?)-30 at 87% chiral purity (50 mg, 0.46 mmol) in 3 mL of methanol was purified by cSFC (Instrument: SFC A; Column: AY-10 μπι; Mobile phase: 50% methanol (0.01% NH3 H20) in C02) at room temperature. In addition to the major product compound (R)-3 , the minor product compound (S)-30 was also collected. Each set of collected fractions was concentrated at room temperature and lyophilized. The resulting solids were dissolved in 0.2 M hydrochloric acid solution and again lyophilized to give:
[00598] Compound (R)-3 (35 mg, 70%) as a white solid. cSFC analytical (D) tR=l .085 min., purity: 100.00%; LCMS (FF): tR=2.15 min., (ES+) m/z (M+H)+ = 308.1; 1H-NMR (CD3OD, 400 MHz): δ 7.78 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.8 Hz, 1H), 4.16-4.14 (m, 1H), 4.01 (m, 3H), 3.88-3.83 (m, 1H), 3.51-3.30 (m, 5H), 2.55-2.54 (m, 1H), 2.36-2.35 (m, 1H), 2.19-2.09 (m, 2H), 1.99-1.93 (m, 1H); and
[00599] Compound (S)-30 (4 mg, 10% yield) as a white solid: cSFC analytical (D) tR=2.65 min., purity: 96.44%; LCMS (FF): tR=2.15 min., (ES+) m/z (M+H)+ = 308.1; 1H-NMR (CD3OD, 400 MHz): δ 7.79 (d, J=8.8 Hz, 1H), 7.12 (d, J=8.8 Hz, 1H), 4.19-4.14 (m, lH), 4.01 (s, 3H), 3.88-3.83 (m, 1H), 3.60-3.37 (m, 5H), 2.55-2.54 (m, 1H), 2.36-2.35 (m, 1H), 2.15-2.10 (m, 2H), 1.99-1.93 (m, 1H).
[00600] Example 31: (i?)-7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochl
Figure imgf000092_0001
[00601] Following general procedure CI, compound (R)-31 was prepared from compound A-67:
[00602] Compound (i?)-A-67-l (0.10 g, white solid, 15% yield over two steps) was prepared from compound A-67 (0.50 g, 2.3 mmol) and (i?)-quinuclidin-3 -amine (0.28 g, 2.3 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Synergi C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 312.1, tR= 1.152 min.
[00603] A mixture of compound (i?)-A-67-l (80 mg, 0.26 mmol) and potassium carbonate (0.11 g, 0.77 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 120 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Phenomenex Synergi C18 100x21.2mm, particle size: 4 μπι; Mobile phase: 20-50% acetonitrile in H20 (add 0.1%TFA, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give: [00604] Compound (i?)-31 (20 mg, 26 % yield) as a white solid: cSFC analytical tR=2.90 min., purity: 94.51%; LCMS (FF): tR=2.31 min., 292.1 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 7.68- 7.66 (m, IH), 7.26-7.24 (d, J=8.0 Hz, IH), 4.18-4.16 (m, IH), 3.89-3.84 (m, IH), 3.45-3.33 (m, 5H), 2.56-2.54 (m, IH), 2.53 (s, 3H),2.35-2.35 (m, IH), 2.16-2.12 (m, 2H), 1.99-1.96 (m, IH).
[00605] Example 32: (i?)-6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-32) and (5)-6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine h drochloride ((S)-32)
Figure imgf000093_0001
[00606] Following general procedure CI, compound (i?)-32 was prepared from compound A-71:
[00607] Compound (i?)-A-71-l (0.40 g, white solid, 68% yield over two steps) was prepared from compound A-71 (0.40 g, 1.7 mmol) and (i?)-quinuclidin-3 -amine (0.26 g, 2.1 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 22-52% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 322.2, tR= 1.166 min.
[00608] A mixture of compound (i?)-A-71-l (0.16 g, 0.50 mmol) and potassium phosphate (0.32 g, 1.5 mmol) in N,N-dimethylformamide (4.0 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 10 μπι; Mobile phase: 16-46% acetonitrile in H20 (add 0.5% HC1, v/v)]. The product was lyophilized to give:
[00609] Compound (i?)-32 (80 mg, 53% yield) as a white solid: cSFC analytical (D) tR=2.760 min., chiral purity: 90%;
[00610] Chiral Purification:
[00611] A solution of compound (i?)-32 at 90% chiral purity (80 mg, 0.27 mmol) in 4 mL of methanol was purified by cSFC (Instrument: SFC A; Column: AY-10 μπι; Mobile phase: 50% methanol (0.01% NH3 H20) in C02) at room temperature. In addition to the major product compound (R)-32, the minor product compound (S)-32 was also collected. Each set of collected fractions was concentrated at room temperature and lyophilized. The resulting solids were dissolved in 0.2 M hydrochloric acid and again lyophilized to give:
[00612] Compound (R)-32 (60 mg, 67% yield) as a yellow solid : cSFC analytical ( D) tR=2.684 min., purity: 100%; LCMS (EE): tR=2.264 min., (ES+) m/z (M+H)+ = 302.2; IH-NMR (CD3OD, 400 MHz): 57.71-7.69 (d, J=8.4 Hz, IH), 6.94-6.94 (d, J=1.6 Hz, IH), 6.87-6.84 (dd, J=8.4 Hz, J=2.0 Hz, IH), 4.74-4.68 (m, IH), 4.14-4.12 (m, IH), 3.87-3.81 (m, IH), 3.49-3.30 (m, 5H), 2.54-2.52 (m,lH) , 2.36-2.34 (m, IH), 2.15-2.08 (m, 2H) , 1.97-1.95 (m, IH), 1.38-1.36 (d, J=7.0 Hz, 6H); and [00613] Compound (S)-32 (6.0 mg, 7% yield) as a yellow solid : cSFC analytical ( D) tR=4.131 min., purity: 97.12%; LCMS (EE): tR=2.281 min., (ES+) m/z (M+H)+ = 302.1; 1H-NMR (CD3OD, 400 MHz): 57.71-7.69 (d, J=8.4 Hz, IH), 6.94-6.94 (d, J=1.6 Hz, IH), 6.87-6.84 (dd, J=8.4 Hz, J=2.0 Hz, IH), 4.74-4.68 (m, IH), 4.14-4.12 (m, IH), 3.87-3.82 (m, IH), 3.47-3.28 (m, 5H), 2.54-2.52 (m,lH) , 2.36-2.32 (m, IH), 2.15-2.08 (m, 2H) , 1.98-1.92 (m, IH), 1.38-1.36 (d, J=7.0 Hz, 6H).
[00614] Example 33: (i?)-6-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((i?)-33) and -6-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine (( )-33)
Figure imgf000094_0001
[00615] Following general procedure CI, compound (i?)-33 was prepared from compound A- 74:
[00616] Compound (i?)-A-74-l (0.30 g, white solid, 42% yield over two steps) was prepared from compound A- 74 (0.50 g, 2.3 mmol) and (i?)-quinuclidin-3 -amine (0.29 g, 2.3 mmol). The product was purified by base prep-HPLC [Instrument: GX-A; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 24-54% acetonitrile in H20 (add 0.5% NH3 H20, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 308.2, tR=l.l 17 min.
[00617] A mixture of compound (i?)-A-74-l (0.15 g, 0.49 mmol) and potassium carbonate (0.20 g, 1.5 mmol) in N, N- dimethylformamide (20 mL) was stirred at 150 °C for 2 hours. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Welch Ultimate AQ-C18 150x30 mm, particle size: 5 μπι; Mobile phase: 17-47% acetonitrile in H20 (add 0.1% TFA, v/v)]. The resulting solid was dissolved in 0.2 M hydrochloric acid and again lyophilized to give compound (i?)-33 (0.12 g, 81% chiral purity).
[00618] A solution of compound (i?)-33 at 81% chiral purity (0.12 g, 0.39 mmol) in 5 mL ethanol was purified by SFC (Column: Chiralpak AY-H -150x4.6mm, I.D., 5 μπι; Mobile phase: ethanol (0.05% DEA) in C02) at room temperature. In addition to the major product compound (i?)-33, the minor product compound ( )-33 was also collected. Each set of collected fractions was concentrated at room temperature. The residue was dissolved in 0.2 M hydrochloric acid and lyophilized to give:
[00619] Compound (i?)-33 (40 mg, 32% yield) as a yellow solid: cSFC analytical (A) tR=2.73 min., purity: 100%; LCMS (GG): tR=1.969 min., (ES+) m/z (M+H)+ = 288.1; ¾-NMR (CD3OD, 400 MHz): 5 7.70-7.68 (d, J=8.8 Hz, IH), 6.94-6.93 (d, J=1.6 Hz, IH), 6.89-6.87 (m, IH), 4.14-4.09 (m, 3H), 3.87-3.81 (m, IH), 3.47-3.36 (m, 4H), 3.33-3.30 (m, IH), 2.54-2.52 (m, IH), 2.36-2.34 (m, IH), 2.15-2.08 (m, 2H), 1.97-1.95 (m, IH), 1.46-1.43(t, J=7.2 Hz, 3H); and
[00620] Compound (S)-33 (10 mg, 8% yield) as a yellow solid: cSFC analytical (A) tR=3.86 min., purity: 100%; LCMS (GG): tR=1.935 min., (ES+) m/z (M+H)+ = 288.1; ¾-NMR (CD3OD, 400 MHz): 5 7.71-7.69 (d, J=8.4 Hz, IH), 6.94-6.93 (d, J=1.6 Hz, IH), 6.89-6.86 (m, IH), 4.14-4.09 (m, 3H), 3.87-3.81 (m, 1H), 3.50-3.37 (m, 4H), 3.33-3.28 (m, 1H), 2.54-2.52 (m, 1H), 2.36-2.34 (m, 1H), 2.15-2.08 (m, 2H), 1.97-1.95 (m, 1H), 1.46-1.43(t, J=7.2 Hz, 3H).
[00621] Example 34: (i?)-6-chloro-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-7-carbonitrile
Figure imgf000095_0001
[00622] Following general procedure CI, compound (i?)-34 was prepared from compound A-77:
[00623] Compound (i?)-A-77-l was prepared as follows: A solution of (i?)-quinuclidin-3 -amine (0.27 g, 2.2 mmol) in methanol (5 mL) was added dropwise to a solution of 4-chloro-3-cyano-2- fluoro-N-hydroxybenzimidoyl chloride compound A-77 (0.50 g, 2.2 mmol) in methanol (5 mL) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. On completion, the reaction mixture was concentrated in vacuo and purified by prep-HPLC[Instrument: GX-B;
Column: Atlantis Hilic Silica C18 150x 19 mm, particle size: 5 μπι; Mobile phase: 11-41%
acetonitrile in H20 (add 0.1% TFA-ACN, v/v)] to give compound (R)-A-77-l (0.20 g, 28% yield over two steps) as a yellow solid. LCMS (M): tR=0.540 min., 323.1 m/z (M+1).
[00624] A solution of compound (i?)-A-77-l (0.18 g, 0.41 mmol) and potassium carbonate (0.17 g, 1.2 mmol) in N, N-dimethylformamide (2.0 mL) was stirred at 150 °C for 2 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC[Instrument: GX- E; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 12-42% acetonitrile in H20 (add 0.05% HC1-ACN, v/v)]. The resulting solution was lyophilized to give:
[00625] Compound (i?)-34 (20 mg, 16% yield) as a white solid: cSFC analytical (D) tR=2.8 min., purity: 97%; LCMS (GG): tR=1.942 min.,303.1 m/z (M+1); IH-NMR (CD3OD, 400 MHz): δ 8.17 (d, J=8.8 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 4.21-4.18 (m, 1H), 3.91-3.88 (m, 1H), 3.47-3.36 (m, 5H), 2.57- 2.55 (m, 1H), 2.34 (m, 1H), 2.16-2.10 (m, 2H), 1.99-1.98 (m, 1H).
[00626] Example 35: (i?)-7-chloro-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydro
Figure imgf000095_0002
[00627] Following general procedure CI, compound (i?)-35 was prepared from compound A- 79:
[00628] Compound (i?)-A-79-l (0.30 g, white solid, 54% yield over two steps) was prepared from compound A- 79 (0.40 g, 1.8 mmol) and (i?)-quinuclidin-3 -amine (0.22 g, 1.8mmol). The product was purified by prep-HPLC [Instrument: GX-H; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μηι; Mobile phase: 24-54% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES ) m/z (M+H)+ = 316.1, tR= 1.084 min.
[00629] A mixture of compound (i?)-A-79-l (0.10 g, 0.32 mmol) and potassium phosphate (0.20 g, 0.95 mmol) in N, N- dimethylformamide (10 mL) was stirred at 150 °C for 0.5 hour. On completion, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC [Instrument: GX-I; Column: Xtimate C18 150x25 mm; particle size: 5 μπι; Mobile phase: 12-42% acetonitrile in H20 (add 0.1% TFA, v/v)]. The resulting solid was dissolved in 0.2 Ν hydrochloric acid and again lyophilized to give:
[00630] Compound (R)-35 (70 mg, 66% yield) as a white solid: cSFC analytical (D) tR=2.375 min., purity: 98.24%; LCMS (FF): tR=2.306 min., (ES+) m/z (M+H)+ = 296.1; ¾-NMR (CD3OD, 400 MHz): 57.84-7.81 (m, IH), 7.28-7.23 (t, J=9.0 Hz, IH), 4.18-4.16 (m, IH), 3.90-3.84 (m, IH), 3.48-3.36 (m, 4H), 3.33-3.30 (m, IH), 2.56-2.54 (m, IH), 2.38-2.32 (m, 1Η),2.16-2.09 (m, 2H), 1.99- 1.95 (m, IH).
[00631] Example 36: (i?)-6-(lH-pyrazol-l-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-36)
Figure imgf000096_0001
[00632] Following general procedure CI, compound (i?)-36 was prepared from compound A-82:
[00633] Compound (i?)-A-82-l (0.15 g, white solid, 27% yield over two steps) was prepared from compound A-82 (0.30 g, 1.3 mmol) and (i?)-quinuclidin-3 -amine (0.16 g, 1.3 mmol). The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μιη; Mobile phase: 22-52% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 330.2, tR= 1.044 min.
[00634] A solution of compound (i?)-A-82-l (0.10 g, 0.30 mmol) and potassium phosphate (0.19 g, 0.91 mmol) in N,N-dimethylformamide (5.0 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 10 μπι; Mobile phase: 16-46% acetonitrile in H20 (add 0.5% HC1, v/v)] to give:
[00635] Compound (R)-36 (50 mg, 48% yield) as a yellow solid: cSFC analytical (D) tR=3.154 min., purity: 95.41%; LCMS (EE): tR=2.174 min., 310.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): 58.40-8.39 (d, J=2.4Hz, 1Η),7.99-7.97 (d, J=8.4 Hz, IH), 7.86 (s, IH), 7.81-7.77 (m, 2H), 6.66 (s, IH), 4.20-4.18 (m, IH), 3.91-3.79 (m, IH), 3.53-3.36 (m, 5H), 2.57-2.56 (m, IH), 2.41-2.31 (m,lH) , 2.18-2.10 (m, 2H), 2.00-1.94 (m,lH).
[00636] Example 37: (i?)-6-(5-methyl-l,3,4-oxadiazol-2-yl)-N-(quinuclidin-3- yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-37)
Figure imgf000097_0001
[00637] Following general procedure CI, compound (i?)-37 was prepared from compound A-89:
[00638] Compound (i?)-A-89-l (0.78 g, yellow solid, crude) was prepared from compound A-89 (0.58 g, 2.3 mmol) and (i?)-quinuclidin-3 -amine (0.28 g, 2.3 mmol). The crude was used for the next step without purification. LCMS (J): (ES+) m/z (M+H)+ = 346.2, tR=0.931 min.
[00639] A solution of compound (i?)-A-89-l (0.78 g, crude) and potassium phosphate (1.4 g, 6.8 mmol) in N N-dimethylformamide (20 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC [Instrument: GX-B; Column: Welch Ultimate AQ-C18 150x30 mm, particle size: 5 μπι; Mobile phase: 10-40% acetonitrile in H20 (add 0.1%TFA, v/v)]. The resulting solid was dissolved in 0.2 Ν hydrochloric acid and again lyophilized to give:
[00640] Compound (i?)-37 (0.13 g, 16% yield over three steps) as a yellow solid: cSFC analytical(D) min., purity: 100%; LCMS (X): tR=1.78 min., 326.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 8.08 (s, 1H), 8.04-8.02 (m, 1H), 7.99-7.97 (m, 1H), 4.23-4.20 (m, 1H), 3.93- 3.86 (m, 1H), 3.51-3.33 (m, 5H), 2.57 (s, 3H), 2.68-2.57 (m, 1H), 2.38-2.37 (m, 1H), 2.17-2.13 (m, 2H), 2.11-1.98 (m, 1H).
[00641] Example 38: (i?)-7-methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-38)
Figure imgf000097_0002
[00642] Following general procedure CI, compound (i?)-38 was prepared from compound A-92:
[00643] Compound (i?)-A-92-l (0.13 g, yellow solid, 13% yield over two steps) was prepared from compound A-92 (0.50 g, 2.3 mmol) and (i?)-quinuclidin-3 -amine (0.4 g, 3.2 mmol) with a reaction time of 4 hours. The product was purified by prep-HPLC [Instrument: GX-C; Column: Phenomenex Gemini C18 250x50mm, particle size: 10 μπι; Mobile phase: 21-51% acetonitrile in H20 (add 0.05% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 308.2, tR=1.092 min.
[00644] A mixture of compound (i?)-A-92-l (0.13 g, 0.41 mmol) and potassium phosphate (0.26 g, 1.2 mmol) in N N-dimethylformamide (20 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC [Instrument: GX- B; Column: Welch Ultimate AQ-C18 150x30 mm, particle size: 5 μπι; Mobile phase: 23-53% acetonitrile in H20 (add 0.1%TFA, v/v)]. The resulting solution was dissolved in 0.2 Ν hydrochloric acid and again lyophilized to give: [00645] Compound (R)-38 (40 mg, 34% yield) as a white solid: cSFC analytical(D) tR=2.64 min., purity: 97.49%; LCMS (X): tR=1.90 min., 288.2 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): δ 7.39-7.38 (d, J=7.2 Hz, IH), 7.10-7.08 (d, J=7.2 Hz, IH), 4.18-4.16 (m, IH), 4.14 (s, 3H), 3.86-3.85 (m, IH), 3.43-3.29 (m, 5H), 2.56 (m, IH), 2. 55 (m, IH), 2. 55 (s, 3H), 2.54-2.51 (m, 2H) , 2.35 (m, IH).
[00646] Example 39: (R)-6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
Figure imgf000098_0001
[00647] Following general procedure CI, compound (i?)-39 was prepared from compound A-96:
[00648] Compound (i?)-A-96-l (0.30 g, white solid, 44% yield over two steps) was prepared from compound A-96 (0.50 g, 2.0 mmol) and (i?)-quinuclidin-3 -amine (0.30 g, 2.4 mmol). The product was purified by prep-HPLC [Instrument: GX-H; Column: Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 30-60% acetonitrile in H20 (add 0.5% ammonia, v/v)]. LCMS (J): (ES+) m/z (M+H)+ = 342.1, tR= 1.223 min.
[00649] A solution of compound (i?)-A-96-l (0.20 g, 0.59 mmol) and potassium phosphate (0.37 g, 1.8 mmol) in N,N-dimethylacetamide (4.0 mL) was stirred at 150 °C for 1 hour. On completion, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC [Instrument: GX-A; Column: Phenomenex Synergi C18 150x30 mm, particle size: 4 μπι; Mobile phase: 25-55% acetonitrile in H20 (add 0.5% HC1, v/v)] to give:
[00650] Compound (i?)-39 (60 mg, 29% yield) as a yellow solid: cSFC analytical (D) tR=2.600 min., purity: 96.70%; LCMS (EE): tR= 2.12 min., 322.1 m/z (M+l); 1H-NMR (CD3OD, 400 MHz): 57.50-7.48 (d, J=8.4 Hz, IH), 7.31-7.29 (d, J=8.0 Hz, IH), 4.51-4.46 (dd, J=14 Hz, J=7.2 Hz, IH), 4.18-4.16 (m, IH), 3.89-3.83 (m, IH), 3.47-3.31 (m, 5H), 2.57-2.54 (m, IH), 2.36-2.32 (m, IH), 2.16- 2.10 (m, 2H), 1.98-1.96 (m, IH), 1.45-1.42 (t, J=7.2 Hz, 3H).
[00651] Example 40: (i?)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine hydrochloride ((i?)-40) and (5)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine
Figure imgf000098_0002
[00652] Following general procedure CI, compound (i?)-40 was prepared from compound A-99:
[00653] Compound (i?)-A-99-l (0.60 g, yellow solid, 48% yield over two steps) was prepared from compound A-99 (1.9 g, 4.0 mmol) and (i?)-quinuclidin-3 -amine (0.50 g, 4.0 mmol) with a reaction of 2 hours. The product was purified by prep-HPLC [Instrument: GX-B; Column:
Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 25-48% acetonitrile in H20 (add 0.05% NH3.H20, v/v)]. LCMS (M): tR=0.529 min., 292.2 m/z (M+l).
[00654] A solution of compound (i?)-A-99-l (0.58 g, 1.8 mmol) and potassium carbonate (0.76 g, 5.5 mmol) in N, N-dimethylformamide (3.0 mL) was stirred at 150 °C for 6 hour. On completion, the reaction mixture was filtered, concentrated in vacuo and purified by prep-HPLC[Instrument: GX-H; Column: Phenomenex Gemini C18 150x25 mm, particle size: 10 μπι; Mobile phase: 36-66% acetonitrile in H20 (add 0.05% NH3.H20-ACN, v/v)]. The resulting solution was lyophilized to give:
[00655] Compound (i?)-40 (210 mg, 42% yield) as a white solid: cSFC analytical (D) tR=2.7 min., chiral purity: 78%;
[00656] A solution of compound (i?)-40 at 78% chiral purity (210 mg, 0.77 mmol) in 4 mL of ethanol was purified by SFC (Instrument: SFC A; Column: AD-10 μπι; Mobile phase: 50% ethanol (0.01% NH3 H20) in C02) at room temperature. In addition to the major product compound (i?)-40, the minor product compound (S)-40 was also collected. Each set of collected fractions was concentrated at room temperature and lyophilized.
[00657] The resulting solids were re-purified by prep-HPLC [Instrument: GX-C; Column:
Phenomenex Gemini C18 250x50 mm, particle size: 10 μπι; Mobile phase: 46-76% acetonitrile in H20 (add 0.05% NH3.H20, v/v)]. The resulting solids was dissolved in 0.2 M hydrochloric acid solution and again lyophilized to give:
[00658] Compound (i?)-40 (100 mg, 48% yield) as a yellow solid : cSFC analytical ( D) tR=2.789 min., purity: 99.85%; LCMS (GG): tR=1.976 min., (ES+) m/z (M+H)+ = 272.2; 1H-NMR (CD3OD, 400 MHz): 57.56-7.54 (d, J=8.4 Hz, 1H), 7.12-7.10 (d, J=8.0 Hz, 1H), 4.17-4.16 (m, 1H), 3.88-3.85 (m, 1H), 3.42-3.36 (m, 5H), 2.56-2.53 (m, 1H), 2.42-2.39 (m, 7H),2.14-1.96 (m,3H); and
[00659] Compound (S)-4 ) (20 mg, 9.5% yield) as a yellow solid : cSFC analytical ( D) tR=3.726 min., purity: 98.48%; LCMS (GG): tR=1.953 min., (ES+) m/z (M+H)+ = 272.2; 1H-NMR (CD30D, 400 MHz): 57.56-7.54 (d, J=8.0 Hz, 1H), 7.11-7.09 (d, J=8.0 Hz, 1H), 4.16-4.15 (m, 1H), 3.86-3.81 (m, 1H), 3.41-3.31 (m, 5H), 2.53-2.52 (m, 1H), 2.40-2.37 (m, 7H), 2.11-1.94 (m,3H).
[00660] Example 41:
[00661] Preparation: (i?)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((i?)-41)
Figure imgf000099_0001
[00662] Following general procedure C2, compound (i?)-41 was prepared from compound A-101:
[00663] Compound (i?)-A-101-l (88 mg, 70% yield) was prepared as a white solid from A-101 (165 mg, 0.7 mmol) and (i?)-quinuclidin-3 -amine (63 mg, 0.5 mmol) using 5 mL of methanol and a reaction time of 1 hour. The product purified by silica gel column chromatography [chloroform: methanol = 1:0 to 17:3]. LCMS (1): tR=3.163 min., (ES+) m/z (M+H)+ = 316.0.
[00664] To a solution of compound (i?)-A-101-l (103 mg, 0.3 mmol) in N,N-dimethylacetamide (5 mL) was added potassium tertbutoxide (37 mg, 0.3 mmol). The mixture was stirred at room temperature for 16 hours. Additional potassium tertbutoxide (9 mg, 0.1 mmol) was added, and the mixture was stirred for an additional 2 hours. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 7 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99: 1 to 9: 1]. The resulting product was triturated with water, collected by filtration and dried in a vacuum oven to afford:
[00665] Compound (R)-4l (32 mg, 32% yield) as a white solid: cHPLC analytical [Chiralcel OD- H, 250x4.6 mm, particle size: 5 μπι; Flow: 1.0 mL/min; Column temp: 25 °C; Mobile phase: 0.1% diethylamine in Heptane/Ethanol = 9/1; detection: DAD (220-320 nm)] tR=6.105 min., purity: 100%; LCMS (1): tR=3.269 min., (ES+) m/z (M+H)+ = 296.0; 1H NMR (300 MHz, CDC13) δ 7.28 - 7.17 (m, 2H), 4.27 (d, J = 5.3 Hz, 1H), 3.90 - 3.79 (m, 1H), 3.54 - 3.42 (m, 1H), 2.96 - 2.74 (m, 4H), 2.67 - 2.56 (m, 1H), 2.27 - 2.19 (m, 1H), 1.86 - 1.62 (m, 3H), 1.56 - 1.42 (m, 1H).
[00666] The hydrochloride salt form of compound (i?)-41 was also prepared by dissolving the freebase form of compound (i?)-41 in 0.2 N hydrochloric acid and subjected to lyophilization to give:
[00667] Compound (i?)-41-hydrochloride as a white solid: cSFC analytical (D) tR=2.31 min., purity: 98.36%; LCMS (FF): tR=1.98 min., 296.1 m/z (M+1); IH-NMR (CD30D, 400 MHz): δ 7.67- 7.72 (d, J=8.4 Hz 1H), 7.38-7.36 (dd, J=5.6 Hz, J=8.4 Hz, 1H), 4.18-4.16 (m, 1H), 3.88-3.82 (m, 1H), 3.41-3.34 (m, 5H), 2.55-2.53 (m, 1H), 2.37-2.30 (m, 1H), 2.18-2.04 (m, 2H), 2.00-1.93 (m, 1H).
[00668] Preparation: (5)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((S)-41)
Figure imgf000100_0001
[00669] Following general procedure C2, compound (S)-41 was prepared from compound A-101:
[00670] Compound ( )-A-101-l (171 mg, 74% yield) was prepared as a white solid from A-101 (165 mg, 0.7 mmol) and (<S)-quinuclidin-3 -amine (92 mg, 0.7 mmol) using 6 mL of methanol and a reaction time of 1 hour. The product purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99: 1 to 9: 1]. LCMS (1): tR=2.847 min., (ES+) m/z (M+H)+ = 316.0.
[00671] To a solution of compound (Λ)-Α-101-1 (171 mg, 0.5 mmol) in N,N-dimethylacetamide (5 mL) was added potassium tertbutoxide (73 mg, 0.7 mmol). The mixture was stirred at room temperature for 2 hours. Additional potassium tertbutoxide (15 mg, 0.1 mmol) was added, and the mixture was stirred for an additional 16 hours. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 7 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99/1 to 9/1]. The resulting product was further purified by preparative HPLC [Instrument: AT;
Column: Phenomenex Gemini-NX C18 100x21.2 mm, particle size: 10 μπι; Mobile phase A: 99% acetonitrile + 1% 10 mM ammonium bicarbonate in water pH=9.0, Mobile phase B: lOmM
ammonium bicarbonate in water pH=9.0] and lyophilized to afford:
[00672] Compound (S)-4l (45 mg, 28% yield) as a white solid: cHPLC analytical [Chiralcel OD-
H, 250x4.6 mm, particle size: 5 μπι; Flow: 1.0 mL/min; Column temp: 25 °C; Mobile phase: 0.1% diethylamine in Heptane/Ethanol = 9/1; detection: DAD (220-320 nm)] tR=17.874 min., purity: 98%; LCMS (1): tR=3.305 min., (ES+) m/z (M+H)+ = 296.0; ¾ NMR (300 MHz, CDC13) δ 7.28 - 7.18 (m, 2H), 4.30 (d, J= 5.2 Hz, 1H), 3.89 - 3.83 (m, 1H), 3.55 - 3.43 (m, 1H), 2.98 - 2.80 (m, 4H), 2.69
- 2.59 (m, 1H), 2.28 - 2.21 (m, 1H), 1.90 - 1.63 (m, 3H), 1.53 - 1.46 (m, 1H).
[00673] Example 42:
[00674] Preparation: (i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((i?)-42)
Figure imgf000101_0001
[00675] Following general procedure C2, compound (i?)-42 was prepared from compound A-103:
[00676] Compound (i?)-A-103-l ((88 mg, 70% yield) was prepared as a white solid from A-103 (90 mg, 0.4 mmol) and (i?)-quinuclidin-3 -amine (50 mg, 0.4 mmol) using 4 mL of methanol and a reaction time of 1 hour. The product was purified by silica gel column chromatography [chloroform: methanol = 1:0 to 17:3]. LCMS (1): tR=2.788 min., (ES+) m/z (M+H)+ = 316.0.
[00677] To a solution of compound (i?)-A-103-l (77 mg, 0.2 mmol) in N,N-dimethylacetamide (3 mL) was added potassium tertbutoxide (33 mg, 0.3 mmol). The mixture was stirred at room temperature for 2 hours. Additional potassium tertbutoxide (7 mg, 0.1 mmol) was added, and the mixture was stirred for an additional hour. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 7 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99: 1 to 9: 1]. The resulting product was lyophilized to afford:
[00678] Compound (R)-42 (30 mg, 41% yield) as a white solid: cHPLC analytical [Column:
Chiralcel OD-H, 250x4.6 mm, particle size: 5 μπι; Flow: 1.0 mL/min; Column temp: 25 °C; Mobile phase: 0.1% diethylamine in Heptane/Ethanol = 9/1; detection: DAD (220-320 nm)] tR=5.949 min., purity: 99%; LCMS (1): tR=3.275 min., (ES+) m/z (M+H)+ = 296.1; ¾NMR (300 MHz, CDC13) δ 7.49 (d, J= 5.5 Hz, 1H), 7.27 (d, J= 7.8 Hz, 1H), 4.19 (d, J= 5.5 Hz, 1H), 3.89 - 3.78 (m, 1H), 3.53
- 3.42 (m, 1H), 2.96 - 2.79 (m, 4H), 2.67 - 2.56 (m, 1H), 2.26 - 2.18 (m, 1H), 1.85 - 1.63 (m, 3H),
I.56 - 1.42 (m, 1H). [00679] e
Figure imgf000102_0001
[00680] Following general procedure C2, compound (S)-42 was prepared from compound A-103:
[00681] Compound (S)-A-103-l (167 mg, 35% yield) was prepared as a white solid from A-103 (185 mg, 0.8 mmol) and (<S)-quinuclidin-3 -amine (103 mg, 0.8 mmol) using 6 mL of methanol and a reaction time of 1 hour. The product was purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99: 1 to 9: 1] to afford (S)-A-103-l (167 mg, 65% yield) as a white solid. LCMS (1): tR=2.806 min., (ES+) m/z (M+H)+ = 316.0.
[00682] To a solution of compound (Λ)-Α-103-1 (167 mg, 0.5 mmol) in NN-dimethylacetamide (5 mL) was added potassium tertbutoxide (71 mg, 0.6 mmol). The mixture was stirred at room temperature for 2 hours. Additional potassium tertbutoxide (15 mg, 0.1 mmol) was added, and the mixture was stirred for an additional 16 hours. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 7 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99/1 to 9/1]. The resulting product was lyophilized to afford:
[00683] Compound (S)-42 (65 mg, 42% yield) as a white solid: cHPLC analytical [Column: Chiralcel OD-H, 250x4.6 mm, particle size: 5 μπι; Flow: 1.0 mL/min; Column temp: 25 °C; Mobile phase: 0.1% diethylamine in Heptane/Ethanol = 9/1; detection: DAD (220-320 nm)] tR=9.752 min., purity: 98%; LCMS (1): tR=3.244 min., (ES+) m/z (M+H)+ = 296.0; ¾NMR (300 MHz, CDC13) δ 7.49 (d, J= 5.5 Hz, 1H), 7.27 (d, J= 7.9 Hz, 1H), 4.21 (d, J = 5.1 Hz, 1H), 3.93 - 3.75 (m, 1H), 3.56 - 3.41 (m, 1H), 3.03 - 2.72 (m, 4H), 2.71 - 2.53 (m, 1H), 2.28 - 2.16 (m, 1H), 1.92 - 1.59 (m, 3H), 1.58 - 1.40 (m, 1H).
[00684] Example 43: (i?)-6-bromo-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine ((i?)-43)
Figure imgf000102_0002
[00685] Following general procedure C2, compound (i?)-43 was prepared from compound A-105:
[00686] Compound (i?)-A-105-l: To a solution of (i?)-quinuclidin-3 -amine (634 mg, 5.0 mmol) and triethylamine (533 mg, 5.3 mmol) in methanol (12 mL) at room temperatue was added a solution of compound A-105 (1.3 g, 5.3 mmol) in methanol (25 mL) over 4 hours using a syringe pump. The mixture was stirred for an additional 12 hours, then filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 99: 1 to 9: 1] to afford (i?)-A-105-l (1.2 g, 70% yield) as a white solid. LCMS (1): tR=2.753 min., (ES+) m/z (M+H)+ = 342.0/344.0.
[00687] To a solution of compound (i?)-A-105-l (320 mg, 0.9 mmol) in dimethylsulfoxide (5 mL) was added potassium tertbutoxide (131 mg, 1.2 mmol). The mixture was stirred at room temperature for 1.5 hours. Additional potassium tertbutoxide (60 mg, 0.5 mmol) was added, and the mixture was stirred for an additional hour. Additional potassium tertbutoxide (40 mg, 0.4 mmol) was added, and the mixture was stirred for 30 min. The solution was put on an SCX column and eluted with methanol. The product was eluted from the column using 3.5 M ammonia in methanol, concentrated and purified by silica gel column chromatography [chloroform: 7M NH3 in methanol = 1/0 to 9/1]. The resulting product was further purified by preparative HPLC [Instrument: AT;
Column: Phenomenex Gemini-NX C18 100x21.2 mm, particle size: 10 μπι; Mobile phase A: 99% acetonitrile + 1% 10 mM ammonium bicarbonate in water pH=9.0, Mobile phase B: lOmM ammonium bicarbonate in water pH=9.0] and lyophilized to afford:
[00688] Compound (i?)-43 (91 mg, 21% yield) as a white solid: LCMS (1): tR=3.222 min., (ES+) m/z (M+H)+ = 322.0/324.0; iNMR ^OO MHz, CDC13) δ 7.61 (dd, J= 1.3, 0.8 Hz, 1H), 7.41 - 7.32 (m, 2H), 4.29 (d, J= 5.0 Hz, 1H), 3.88 - 3.84 (m, 1H), 3.54 - 3.42 (m, 1H), 2.98 - 2.80 (m, 4H), 2.70 - 2.59 (m, 1H), 2.29 - 2.21 (m, 1H), 1.88 - 1.64 (m, 3H), 1.56 - 1.45 (m, 1H).
[00689] Example 44:
[00690] Human a7 nAChR Binding Assay
[00691] The ability of compounds to displace binding of radioactive ligands from human al nAChR was determined, as a measure of the affinity of the compounds for these ligand-gated ion channels. The [125I]-aBungarotoxin competition binding assay was performed under contract by Cerep Poitiers, France following published the methods (Sharpies et al, J Neurosci. 2000;
20(8):2783-91). "SH-SY5Y cells stably expressing human ot7 nicotinic acetylcholine receptors, grown to confluency in 175 cm2 flasks, were washed briefly with warm PBS containing (in mm): (150 NaCl, 8 K2HP04, 2 KH2P04, pH 7.4, 37°C) and scraped into cold phosphate buffer. Cells were washed by centrifugation for 3 min at 500 χ g and resuspended in 10 mL of ice-cold phosphate buffer. The suspension was homogenized for 10 sec using an Ultraturax and centrifuged for 30 min at 45,000 xg. The pellet was resuspended in phosphate buffer (0.5 mL per original flask). SH-SY5Y membranes (30 μg protein) were incubated in a total volume of 2 mL in 50 mM phosphate buffer with 0.05 nM [125I]-aBgt and serial dilutions of test compound. Nonspecific binding was determined in the presence of a-bungarotoxin (1 μΜ). Samples were incubated for 120 min at 37°C. The reaction was terminated by filtration through Whatman GFA/E filter paper (presoaked overnight in 0.3% polyethyleneimine in PBS), using a Brandel Cell Harvester. Each condition was measured in duplicate. Filters were counted for radioactivity using a scintillation counter. The results were expressed as a percent inhibition of control specific binding obtained in the presence of the test compounds where Inhibition (%) = 100 - [(measured specific binding/control specific binding) x 100].
[00692] The IC50 values (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficients (nH) were determined by non-linear regression analysis of the competition curves generated with mean replicate values using Hill equation:
A-D
Y=D+[-
1+(C/C50)nH
where Y = specific binding, A = left asymptote of the curve, D = right asymptote of the curve, C = compound concentration, C50 = IC50, and nH = slope factor.
[00693] This analysis was performed using software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). The inhibition constants (¾ ) were calculated using the Cheng Prusoff equation:
(1 +L Ko)
where L = concentration of radioligand in the assay, and KD = affinity of the radioligand for the receptor.
[00694] A scatchard plot is used to determine the KD. Results are provided in Table 2 (reported as h-ot7 Ki (μΜ)).
[00695] [3H]BRL 43694 competition binding (h-5HT3 Ki (μΜ))
[00696] [ H]BRL 43694competition binding assay was performed under contract by Cerep Poitiers, France following the methods described in Hope, A.G et al., "Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK293 cells " Brit. J. Pharmacol., (1996) 118: 1237-1245.
[00697] In brief, Chinese Hamster Ovary (CHO) cells stably expressing human 5-HT3 serotonin receptors, grown to confluence in 175 cm2 flasks. Following aspiration of the culture medium, cells were harvested by mechanical agitation in ice cold PBS containing (in mM): (150 NaCl, 8 K2HP04, 2 KH2P04, pH 7.4, 37°C), centrifuged at 4,000 g for 10 min and subsequently stored as a cell pellet at - 80 C. When required, the pellet was thawed and resuspended in ice cold homogenization buffer (Tris 50 mM, EGTA 5.0 mM, phenylmethylsulphonylfluoride 0.1 mM, pH 7.6) and homogenized. The homogenate was centrifuged at 48,000 g for 10 minutes at 40°C. The resulting pellet was resuspended in ice cold binding buffer comprising (in mM): NaCl 140, KC1 2.8, CaCl2 1.0; MgCl2, 2.0; HEPES 10 (pH 7.4) and centrifuged as above. The pellet was resuspended in ice cold binding buffer and the protein concentration was determined by the method of Lowry et al., "Protein measurement with the Folin phenol reagent " J. Biol. Chem., (1953) 193, 265-275). The membrane homogenate was adjusted to a protein concentration of approximately 600 mg/mL in binding buffer. Assay tubes were loaded with equal volumes of binding buffer containing [ H]BRL 43694 and test compound and 0.5 mL of membrane homogenate in a total reaction volume of 1 ml. Binding was initiated by the addition of the membrane homogenate and allowed to proceed for 120 min. at room temperature. Bound and free radioligand were separated by the addition of 3 ml of ice-cold binding buffer and immediate vacuum filtration through pre-soaked (0.1% (v/v) polyethyleneimine) Whatman GF/B filters. Filters were washed with a further 2 x 3 mL applications of binding buffer and counted for radioactivity using a scintillation counter.
[00698] The results were expressed as a percent inhibition of control specific binding obtained in the presence of the test compounds where Inhibition (%) = 100 - [(measured specific binding/control specific binding) x 100].
[00699] The IC50 values (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficients (nH) were determined by non-linear regression analysis of the competition curves generated with mean replicate values using Hill equation
A-D
Y=D+f■
1+(C/C5ofH
where Y = specific binding, A = left asymptote of the curve, D = right asymptote of the curve, C = compound concentration, C50 = IC50, and nH = slope factor. This analysis was performed using software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.).
[00700] The inhibition constants (¾ ) were calculated using the Cheng Prusoff equation
' (HL/Ko)
where L = concentration of radioligand in the assay, and KD = affinity of the radioligand for the receptor.
[00701] A scatchard plot is used to determine the KD. Results are provided in Table 2 (reported as h-5HT3 Ki (μΜ)).
[00702] For reference, the literature reported a7 nAChR agonist AQW051 has a Ki of 255 nM in the above described assay provided by Cerep (lit: Kj = 28 nM; radioligand binding assay using recombinantly expressed human l -nAChR and [125I] a-BTX radioligand; Feuerbach etal, Br. J. Pharmacol., 2014, doi: 10.1111/bph.13001).
[00703] Oocyte Electrophysiology Screen (% ACh @ 10μΜ Oocyte)
[00704] The Oocyte Electrophysiology Screen studies were performed under contract by
HiQScreen Geneva, Switzerland. All experiments were carried out at human ot7 nAChRs transiently expressed in Xenopus laevis oocytes using the method of cDNA expression. Currents evoked by acetylcholine or other agonist ligands were recorded using the standard two-electrode voltage-clamp configuration (TEVC). X. laevis oocytes were prepared and injected using standard procedures. Briefly, ovaries were harvested from laevis females that were deeply anesthetized and pithed following the animal rights rule from the Geneva canton. A small piece of ovary was isolated for immediate preparation while the remaining part was placed at 4°C in a sterile Barth solution containing in mM: NaCl 88, KC1 1, NaHC032.4, HEPES 10, MgS04.7H20 0.82, Ca(N03)2.4H20 0.33, CaCl2.6H20 0.41, at pH 7.4, and supplemented with 20 μg/mL of kanamycin, 100 unit/mL penicillin and 100 μg/mL streptomycin. On the second day following dissociation, oocytes were injected with 2 ng of cDNA per oocyte containing the gene encoding human ot7 nicotinic
acetylcholine receptor subunits using an automated injector (Hogg et al, 2008). All recordings were performed at 18°C and cells were superfused with OR2 medium containing in mM: NaCl 82.5, KC1 2.5, HEPES 5, CaCl2.2H202.5, pH 7.4. Cells were held at -80 mV. Data were filtered at 10 Hz, captured at 100 Hz and analyzed using proprietary data acquisition and analysis software running under Matlab (Mathworks Inc.).
[00705] Experimental protocol and analysis
[00706] After establishing a baseline transmembrane current, acetylcholine (ACh) was applied for 5 seconds at a concentration of 0.2 mM to establish a control ACh-evoked current response.
Following a wash period of 90 s in OR2 medium (free of ACh), cells were then exposed for 30 s to the test compound applied at 0.01 mM. The same reference ACh test pulse was immediately given at the end of the compound exposure and again after 90 s of recovery in OR2 Medium (free of ACh or test compound). All data were determined in triplicate. The response evoked by the test compound was expressed as a percentage of that evoked by ACh:
Response (%ACh) = 100 x (Itest / IACh)
where I,es, is the peak inward current measured during exposure to 0.01 mM of test compound and IAch is the peak inward current measured in the presence of ACh.
[00707] Results are provided in Table 2 (reported as % ACh @ 10μΜ Oocyte).
Table 2:
Figure imgf000106_0001
5-P1 1 0.16 548
5-P2 0.159 1.85 645
6-P1 0.96 1.6 157
6-P2 0.41 >10 355
7-P1 0.36 0.74 326
7-P2 0.032 4.2 427
8-P1 6.8 26
8-P2 1.2 221
9-P1 0.0435 0.0595
9-P2 0.29 0.026
(R)-10 >30
(Ryu 0.54 1.9
(R)-12 0.74
(R)-13 >30
(S)-13 >30
(R)-14 >30
(R)-15 0.93
(S)-15 52
(R)-16 2.2
(R)-17 1.7 0.24
(R)-18 2
(S)-18 24
(R)-19 9.7
(R)-20 0.22 0.58
(R)-21 0.82 1.5
(R)-22 0.14 3
(R)-23 0.071 0.19
(R)-24 0.14 0.4
(R)-25 0.245 4.1
(R)-26 11 1.2
(R)-27 0.7
(R)-28 14
(R)-29 0.925 >10
(R)-30 2.5 0.28
(S)-30 7.4
(R)-31 0.18 0.029
(R)-32 4.3
(S)-32 18
(R)-33 0.75 >10
(S)-33 5.8
(R)-35 0.18 0.065
(R)-36 0.7
(R)-37 9 (R)-39 0.12 6.9
(R)-4l 0.046 1.6333
(SMI 0.67
(R)-42 0.26 1.55
(S)-42 0.98
(i?)-43 0.044 0.93
[00708] Example 45:
[00709] Novel Object Recognition Task:
[00710] The Novel Object Recognition (NOR) task is a behavioral assay commonly used to evaluate cognition, particularly recognition memory, in rodent models of CNS disorders. This test is based on the spontaneous tendency of rodents to spend more time exploring a novel object compared to a familiar one. The choice to explore the novel object reflects the use of learning and recognition memory. The assay is commonly used to evaluate potential therapeutic agents for Alzheimer's disease, other neurodegenerative diseases and psychiatric disorders.
[00711] Procedure:
[00712] Male Wistar rats (Harlan Laboratories) weighing 350-400 grams were housed under a reversed light cycle and are tested during the dark cycle. Testing was done under low lux conditions, measured to be~2-7 lux under red light. Animals were habituated and weighed one day prior to testing. During habituation, animals were placed in a cylindrical arena and allowed to explore for 3 minutes. Training (Tl) was conducted approximately 24 hours later, with one set of identical objects placed on opposite sides of the arena. Animals were allowed to explore the objects in 3 -minute sessions. Animals were dosed with a designated treatment 15-60 minutes prior to testing depending on the pharmacokinetic profile of the compound before the start of Tl. Drug or vehicle was dosed subcutaneously based on body weight at 5 mL/kg. Testing (T2) was done at 48 hours after Tl.
During testing, one familiar object is replaced with a novel object. Animals were allowed to explore both objects in 3 -minute sessions.
[00713] Equipment Specification:
[00714] Animals were tracked using Noldus Ethovision XT (EthoVision XT version: 8.5, Noldus Inc. Wageningen, Netherlands) tracking software, using a 2 centimeter (cm) perimeter for each object as a separate zone. The test arena consisted of a cylinder, 80 cm diameter with 40 cm high walls of black acrylic that was opaque and matte. Objects were custom fabricated shapes (cone and bullet) similar in overall size (8cm high x 8cm diameter) and were counterbalanced between treatment groups.
[00715] Data Analysis and Statistics:
[00716] Contact time was defined as the amount of time (seconds) an animal spent within the 2 cm perimeter of an object. All animals that had <5 seconds total contact time were excluded from the study. Statistical significance was determined using a Mann Whitney U-test and the criterion was set at p<0.05.
[00717] Results:
[00718] Natural forgetting in an object recognition task in male Wistar rats (n = 4-20/group). Test compound was administered via sub-cutaneous administration 30 minutes before Tl. Test compounds improved object recognition using a 48-hour retention interval (mean ± SEM). *p < 0.05 = novel (N) vs. familiar (F) object. Results are illustrated in Table 3.
Table 3:
Figure imgf000109_0001
[00719] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[00720] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

What is claimed is:
A Formula (la) or Formula (lb):
Figure imgf000110_0001
wherein:
R1, R2, R3, and R4 independently represent -H, -D, halogen radical, -CN, an unbranched Ci-C - alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OCi-C4-alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6),
-(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C -alkyl radical, the branched C3-C -alkyl radical, the C3-C6- cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C4-alkyl, the -S02Ci-C4-alkyl, the -(CH2)mS02Ci-C4-alkyl, or the -N(R5)S02Ci-C4-alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -SO.d-Q-alkyl,
-S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6),
-N(R5)S02Ci-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched C C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02Ci-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02Ci-C4- alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2- haloalkyl radical, or -OCi-C2-haloalkyl radical;
R5 and R6 independently represent -H; an unbranched Ci-C6-alkyl radical, a branched
C3-C6-alkyl radical; a C3-C6-cycloalkyl radical; or the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di- radical or a (3-6 membered)-heteroalkyl di -radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci-C4-alkyl radical, a branched C3-C - alkyl radical, a C3-C4-cycloalkyl radical, -(CO)-unbranched Ci-C4-alkyl, -(CO)-branched C3-C4-alkyl, -(S02)-unbranched Ci-C4-alkyl, or
-(S02)-branched C3-C4-alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the C2-C6-alkyl di-radical or the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical; and
m independently represents an integer from 1 to 6;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R1 independently represents -H, -D, or halogen radical.
3. The compound of claim 1 or claim 2, wherein R1 independently represents -H, -D, -F, or -CI.
The compound of any one of claims 1-3, wherein R1 independently represents -H, -D, or The compound of any one of claims 1-4, wherein R1 independently represents -H or -D.
6. The compound of any one of claims 1-5, wherein R2 independently represents -H, -D, or halogen radical.
7. The compound of any one of claims 1-6, wherein R2 independently represents -H, -D, -F, or -CI.
8. The compound of any one of claims 1-7, wherein R2 independently represents -H or -D.
9. The compound of any one of claims 1-7, wherein R2 independently represents -F.
10. The compound of any one of claims 1-9, wherein R3 independently represents -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C -alkyl radical, a branched C3-C -alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OCi-C -alkyl, a branched or cyclic -OC3-C -alkyl, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02C1-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02Ci-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C4-alkyl radical, the branched C3-C -alkyl radical, the C3-C6- cycloalkyl radical, the unbranched -OCi-C -alkyl, the branched or cyclic -OC3-C -alkyl, the -S02Ci- C4-alkyl, the -(CH2)mS02Ci-C -alkyl, or the -N(R5)S02Ci-C -alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C C4-alkyl, -S02N(R5)(R6), -(CH^SO.d-d-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched C C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02C C4- alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2- haloalkyl radical.
11. The compound of any one of claims 1-10, wherein R3 independently represents -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C -alkyl radical, a branched C3-C -alkyl radical, a C3-C -cycloalkyl radical, an unbranched -OCi-C -alkyl, a branched or cyclic -OC3-C -alkyl, -OCHF2, -OCH2F, -OCF3, -OCH2CF3, -N(R5)(R6), -(CO)N(R5)(R6), -NR5(CO)(R6), -S02CH3, -S02N(R5)(R6), -CH2CH2S02Ci-C4-alkyl, or -N(R5)S02CH3, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C -alkyl radical, the branched C3-C -alkyl radical, the C3-C -cycloalkyl radical, the unbranched -OCi-C4-alkyl, the branched or cyclic -OC3-C4-alkyl, or the -CH2CH2S02Ci- C4-alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02d-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl,
-(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6-hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2- haloalkyl radical; and wherein the aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -S02d-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4- alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02d-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical.
in
12. The compound of any one of claims 1-11, wherein R3 independently represents -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCF3, -S02CH3, a phenyl radical, or an N-pyrazole radical, or an oxadiazole radical; wherein the phenyl radical, the N-pyrazole radical, or the oxadiazole radical may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -(CO)(CH2)mR5, -(CO)N(R5)(R6), an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical.
13. The compound of any one of claims 1-12, wherein R3 independently represents -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, -OCF3, -S02CH3, a phenyl radical, an N-pyrazole radical, or an oxadiazole radical; wherein the phenyl radical, the N-pyrazole radical, or the oxadiazole radical may be substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, -CN, -OR5, -CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCF3, or -OCH2CF3.
14. The compound of any one of claims 1-13, wherein R3 independently represents -F, -CI, -Br, -CN, -CH3, -CH2CH3, cyclopropyl radical, -CHF2, -CH2F, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, or -OCF3.
15. The compound of any one of claims 1-14, wherein R3 independently represents -F, -CI, -Br, -CH3, or -OCH3.
16. The compound of any one of claims 1-15, wherein R3 independently represents -CI, -CH3, or -OCH3.
17. The compound of any one of claims 1-16, wherein R4 independently represents -H, -D, -F, -CI, -Br, -CN, an unbranched Ci-C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C6-cycloalkyl radical, an unbranched -OCi-C4-alkyl, a branched or cyclic -OC3-C4-alkyl, -N(R5)(R6),
-(CO)N(R5)(R6), -NR5(CO)(R6), -SO.d-C.-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C!-C4-alkyl, an aryl radical, or a heteroaryl radical; wherein the alkyl portion of the unbranched Ci-C4-alkyl radical, the branched C3-C4-alkyl radical, the C3-C6- cycloalkyl radical, the unbranched -OCi-C -alkyl, the branched or cyclic -OC3-C -alkyl, the -S02Ci- C4-alkyl, the -(CH2)mS02Ci-C -alkyl, or the -N(R5)S02Ci-C -alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -SO.d-C.-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl, -(CH2)mS02N(R5)(R6), -N(R5)S02C!-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3, an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical; and wherein aryl radical or the heteroaryl radical may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, -CN, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6),
-(CH2)mN(R5)(R6), -S02d-C4-alkyl, -S02N(R5)(R6), -(CH2)mS02C1-C4-alkyl,
-(CH2)mS02N(R5)(R6), -N(R5)S02C1-C4-alkyl, -(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3, an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical.
18. The compound of any one of claims 1-17, wherein R4 independently represents -H, -D, -F, -CI, -CN, an unbranched Ci-C3-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, an unbranched -OCi-C3-alkyl, a branched or cyclic -OC3-C4-alkyl; wherein the alkyl portion of the unbranched Ci-C3-alkyl radical, the branched C3-C4-alkyl radical, the C3-C4-cycloalkyl radical, the unbranched -OCi-C3-alkyl, or the branched or cyclic -OC3-C4-alkyl, may be independently substituted with up to 5 radical substituents comprising: -D, -F, -CI, -Br, =0, -OR5, -(CH2)mOR5, -N(R5)(R6), -NR5(CO)(R6), -(CH2)mN(R5)(R6), -(CO)(CH2)mR5, -(CO)N(R5)(R6), -OCF3, an unbranched Ci-C6-alkyl radical, a branched C3-C6-alkyl radical, a C3-C6-cycloalkyl radical, a Ci-C6- hydroxyalkyl radical, a Ci-C2-haloalkyl radical, or -OCi-C2-haloalkyl radical.
19. The compound of any one of claims 1-18, wherein R4 independently represents -H, -D, -F, -CI, -CN, -CH3, cyclopropyl radical, cyclobutyl radical, -CH2F, -CHF2, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -O-cyclopropyl, or -OCF3.
20. The compound of any one of claims 1-19, wherein R4 independently represents -H, -D, -F, -CI, -CH3, -OCH3, -OCH2CH3, or -CF3.
21. The compound of any one of claims 1-20, wherein R1 and R2 independently represent -H or -D.
22. The compound of any one of claims 1-20, wherein R2 and R4 independently represent -H or -D.
23. The compound of any one of claims 1-20, wherein R1 and R4 independently represent -H or -D.
24. The compound of any one of claims 1-20, wherein R1, R2, and R4 independently represent -H or -D.
25. The compound of any one of claims 1-24, wherein R3 independently represents -CI.
26. The compound of any one of claims 1-24, wherein R3 independently represents -CH3.
27. The compound of any one of claims 1-24, wherein R3 independently represents -OCH3.
28. The compound of any one of claims 25-27, wherein R4 independently represents -H or -D.
29. The compound of any one of claims 25-27, wherein R4 independently represents -F.
30. The compound of any one of claims 25-27, wherein R4 independently represents -CI.
31. The compound of any one of claims 25-27, wherein R4 independently represents -CH3.
32. The compound of any one of claims 25-27, wherein R4 independently represents -OCH3.
33. The compound of any one of claims 25-27, wherein R4 independently represents -CF3.
34. The compound of any one of claims 1-33, wherein R5 independently represents -H; an unbranched Ci-C6-alkyl radical; a branched C3-C6-alkyl radical; a C3-C6-cycloalkyl radical.
35. The compound of any one of claims 1-34, wherein R6 independently represents -H; an unbranched Ci-C6-alkyl radical; a branched C3-C6-alkyl radical; a C3-C6-cycloalkyl radical.
36. The compound of any one of claims 1-33, wherein the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C6-alkyl di-radical or a (3-6 membered)-heteroalkyl di-radical; wherein the (3-6 membered)-heteroalkyl di-radical comprises at least one ring atom selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when the at least one ring atom is nitrogen, the nitrogen is independently substituted with -H, an unbranched Ci- C4-alkyl radical, a branched C3-C4-alkyl radical, a C3-C4-cycloalkyl radical, -(CO)-unbranched Ci- C4-alkyl, -(CO)-branched C3-C -alkyl, -(S02)-unbranched Ci-C -alkyl, or -(S02)-branched C3-C - alkyl, and with the further proviso that when the at least one ring atom is sulfur, the sulfur may be independently substituted with 0 to 2 =0; wherein the C2-C6-alkyl di-radical or the alky portion of said (3-6 membered)-heteroalkyl di-radical may be independently substituted with up to 5 radical substituents comprising: -D, halogen radical, =0, an unbranched Ci-C6-alkyl radical, or a branched C3-C6-alkyl radical.
37. The compound of any one of claims 1-33, wherein the N(R5)(R6) moiety forms a cycle, wherein R5 and R6 taken together represent a C2-C2-alkyl di-radical.
38. The compound of any one of claims 1-37, wherein m independently represents an integer from 1 to 4.
39. The compound of any one of claims 1-38, wherein m independently represents an integer from 1 to 2.
40. The compound of any one of claims 1-39, wherein the compound is represented by Formula (la).
41. The compound of any one of claims 1-39, wherein the compound is represented by Formula (lb).
42. The compound of any one of claims 1-39, wherein the compound is the pharmaceutically acceptable salt thereof.
43. The compound of any one of claims 1-42, wherein the compound is a single enantiomer or a single diastereomer.
44. The compound of claim 43, wherein the compound is a single enantiomer.
45. The compound of claim 43, wherein the compound is a single diastereomer.
46. The compound of any one of claims 1-45, wherein the compound is selected from the group consisting of:
N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine;
7-chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
5 -chloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine;
6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-cyclopropyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; N-(quinuclidin-3 -yl) -6-(trifluoromethyl)benzo [d] isoxazol -3 -amine ;
6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
4-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
3- (quinuclidin-3-ylamino)benzo[d]isoxazole-6-carbonitrile;
6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6- (tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5.6- dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
N-(quinuclidin-3 -yl) -6 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
7- fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 -fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
4- fluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6.7- difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-chloro-7 -methyl -N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
6- chloro-7-cyclopropyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine; 4-fluoro-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
4.6- dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7- fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-ethoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6- chloro-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-7-carbonitrile;
7- chloro-6-fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-(lH-pyrazol-l-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6- (5-methyl-l,3,4-oxadiazol-2-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-a:
7- methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6.7- dimethyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and 6-bromo-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
igle enantiomers and pharmaceutically acceptable salts thereof.
47. The compound of any one of claims 1-45, wherein the compound is selected from the group consisting of:
6-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-ethyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
6-chloro-N-(quinuclidin-3 -yl)-7-(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 - fluoro-6-methoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6- methoxy-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
6-chloro-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-7-isopropoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6- chloro-7-cyclopropoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
7- ethoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-methoxy-N-(quinuclidin-3 -yl)-7-(trifluoromethyl)benzo [d] isoxazol-3 -amine ;
5 -fluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
5.6- difluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
5.7- difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
6-chloro-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; 6-chloro-5-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
5 ,7-difluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
6,7-dichloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
6-chloro-7-ethoxy-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine.
and single enantiomers and pharmaceutically acceptable salts thereof.
48. The compound of any one of claims 1-46, wherein the compound is selected from the group consisting of:
(i?)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(<S)-7-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (^^-chloro-N-iquinuclidin-S-y^benzofdlisoxazol-S-amine;
(i?)-5-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S)-5 -chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R)-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S) -6 -methoxy-N-(quinuclidin-3 -y l)benzo [d] isoxazol -3 -amine ;
(R) -N-(quinuclidin-3 -yl) -6 -(trifluoromethyl)benzo [d] isoxazol -3 -amine ;
(iS) -N-(quinuclidin-3 -yl) -6 -(trifluoromethyl)benzo [d] isoxazol-3 -amine ;
(i?)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
( ?)-4-chloro-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-4-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-6-carbonitrile;
(<S)-3 -(quinuclidin-3 -ylamino)benzo [d] isoxazole -6 -carbonitrile ;
(i?)-6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-(methylsulfonyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
( ?)-6-(tert-butyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(^^-(tert-buty -N-iquinuclidin-S-y^benzotdlisoxazol-S-amine;
(R)-5,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S)-5 ,6-dichloro-N -(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
(i?)-N-(quinuclidin-3-yl)-6-(trifluoromethoxy)benzo[d]isoxazol-3-amine;
(5)-N-(quinuclidin-3-yl)-6-(trifluoromethoxy)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5 -7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
( ?)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(iS)-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-4-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-4-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; [R)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
^5)-5-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
;i?)-6-chloro-7-cyclopropyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;<S)-6-chloro-7-cyclopropyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
;i?)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-4-fluoro-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-4,6-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;S)-4,6-dichloro-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
^)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;5)-7-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
S) -6 -isopropoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine ;
R) -6 -ethoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
;<S)-6-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
;i?)-6-chloro-3-(quinuclidin-3-ylamino)benzo[d]isoxazole-7-carbonitrile;
;<S)-6-chloro-3 -(quinuclidin-3 -ylamino)benzo [d]isoxazole-7-carbonitrile ;
^)-7-chloro-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-chloro-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
R)-6-( lH-pyrazol- 1 -yl)-N-(quinuclidin-3 -yl)benzo[d]isoxazol-3 -amine;
S)-6-( lH-pyrazol- 1 -yl)-N-(quinuclidin-3 -yl)benzo[d]isoxazol-3 -amine;
;i?)-6-(5-methyl-l,3,4-oxadiazol-2-yl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;S) -6 -(5 -methyl -1,3,4 -oxadiazol-2 -yl) -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
^)-7-methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-7-methoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^5)-6-chloro-7-ethoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
^)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (5)-6,7-dimethyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-bromo-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ; and
(iS) -6 -bromo-N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine ;
and pharmaceutically acceptable salts thereof.
49. The compound of any one of claims 1-47, wherein the compound is selected from the group consisting of:
(i?)-6-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(<S)-6-cyclopropoxy-N-(quinuclidin-3 -yl)benzo [d]isoxazol-3 -amine ;
(R) -6 -ethyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -ethyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethoxy)benzo[d]isoxazol-3-amine;
(iS) -6 -chloro-N-(quinuclidin-3 -yl) -7 -(trifluoromethoxy)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-cyclobutyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5-fluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S)-5 -fluoro-6-methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
(i?)-6-methoxy-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-methoxy-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(5)-6-methyl-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-5,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-5,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(¾-6-chloro-7-(difluoromethyl)-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-isopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-7-cyclopropoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-ethoxy-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S) -7 -ethoxy-6 -methyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-7-ethoxy-6-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (i?)-6-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methoxy-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(5)-6-methoxy-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-5-fluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5,6-difluoro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(iS) -5 , 6-difluoro-7-methyl -N-(quinuclidin-3 -yl)benzo [d] isoxazol -3 -amine ;
(i?)-5,7-difluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(S)-5 ,7-difluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
(i?)-6-chloro-5 -fluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(<S)-6-chloro-5 -fluoro-7-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; (5)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; (i?)-6-chloro-5-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-6-chloro-5-fluoro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5,7-difluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(5)-5,7-difluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6,7-dichloro-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-6,7-dichloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-ethoxy-5 -fluoro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(5)-6-chloro-7-ethoxy-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
(5)-5,7-difluoro-6-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
and pharmaceutically acceptable salts thereof.
50. The compound of any one of claims 1-46 or 48, wherein the compound is selected from the group consisting of:
(i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(iS)-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(i?)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(R)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine;
(i?)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; (i?)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine; and
(i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
and pharmaceutically acceptable salts thereof.
51. The compound of any one of claims 1-46 or 48, wherein the compound is selected from the group consisting of:
(i?)-6-chloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6,7-dichloro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-7-fluoro-6-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methyl-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-7-methoxy-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
(i?)-6-chloro-N-(quinuclidin-3-yl)-7-(trifluoromethyl)benzo[d]isoxazol-3-amine; and (i?)-6-chloro-7-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
and pharmaceutically acceptable salts thereof.
52. The compound of any one of claims 1-46 or 48, wherein the compound is selected from the group consisting of:
(iS)-6-chloro-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(R) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(iS) -6 -methoxy-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine ;
(R)-5 -fluoro-6-methyl-N-(quinuclidin-3 -yl)benzo [d] isoxazol-3 -amine; and
(i?)-6-chloro-5-fluoro-N-(quinuclidin-3-yl)benzo[d]isoxazol-3-amine;
and pharmaceutically acceptable salts thereof.
53. A pharmaceutical composition, comprising:
i) the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52; and ii) at least one pharmaceutically acceptable carrier, excipient or diluent.
54. A method of treating a patient in need thereof, comprising administering to the patient the pharmaceutical composition of claim 53.
55. A method of treating a patient in need thereof, comprising administering to the patient the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52.
56. A method of improving cognition of a patient in need thereof, comprising: administering to the patient the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52.
57. A method of improving cognition of a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising:
i) the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52; and ii) at least one pharmaceutically acceptable carrier, excipient or diluent.
58. A method of treating or improving one or more symptoms associated with a cognitive disease and/or a cognitive impairment in a patient in need thereof, comprising: administering to the patient the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52.
59. A method of treating or improving one or more symptoms associated with a cognitive disease and/or a cognitive impairment in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising:
i) the compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-52; and ii) at least one pharmaceutically acceptable carrier, excipient or diluent.
60. The method of any one of claims 54-59, wherein the patient suffers from a cognitive impairment, suffers from a cognitive loss associated with a cognitive impairment, or suffers from one or more symptoms associated with a cognitive impairment.
61. The method of claim 60, wherein the cognitive impairment comprises Limited Cognitive Impairment (LCI), Mild Cognitive Impairment (MCI), Alzheimer's disease, dementia of an
Alzheimer's-type, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, positive symptoms of schizophrenia, negative symptoms of schizophrenia, or schizophrenia with dementia.
62. The method of claim 60, wherein the cognitive impairment is Limited Cognitive Impairment (LCI).
63. The method of claim 60, wherein the cognitive impairment is Mild Cognitive Impairment (MCI).
64. The method of claim 60, wherein the cognitive impairment is Alzheimer's disease.
65. The method of claim 60. wherein the cognitive impainnent is dementia of an Alzheimer's- type.
66. The method of claim 60, wherein the cognitive impairment is schizophrenia.
67. The method of claim 60, wherein the cognitive impairment is schizophreniform disorder, schizoaffective disorder, or delusional disorder.
68. The method of claim 60. wherein the cognitive impainnent comprises positive symptoms of schizophrenia.
69. The method of claim 60, wherein the cognitive impairment comprises negative symptoms of schizophrenia.
70. The method of claim 60, wherein the cognitive impairment is schizophrenia with dementia.
PCT/US2016/036689 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors Ceased WO2016201096A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2017564556A JP2018516973A (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US15/736,235 US10370370B2 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CA2988968A CA2988968A1 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
CN201680045409.2A CN107847494A (en) 2015-06-10 2016-06-09 Amino benzisoxazole compounds as the nicotinic acetylcholine receptors alpha7s of α 7
EP16808279.0A EP3307269A4 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
MX2017016231A MX2017016231A (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
KR1020187000332A KR20180044256A (en) 2015-06-10 2016-06-09 Aminobenzoisooxazole compounds as agonists of the A7-nicotinic acetylcholine receptor
RU2017145964A RU2017145964A (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as α7-nicotinic acetylcholine receptor agonists
HK18105734.0A HK1246184A1 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
AU2016274694A AU2016274694A1 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
IL256226A IL256226A (en) 2015-06-10 2017-12-10 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
NO20180002A NO20180002A1 (en) 2015-06-10 2018-01-02 Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173717P 2015-06-10 2015-06-10
US62/173,717 2015-06-10

Publications (1)

Publication Number Publication Date
WO2016201096A1 true WO2016201096A1 (en) 2016-12-15

Family

ID=57503923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/036689 Ceased WO2016201096A1 (en) 2015-06-10 2016-06-09 Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors

Country Status (13)

Country Link
US (1) US10370370B2 (en)
EP (1) EP3307269A4 (en)
JP (1) JP2018516973A (en)
KR (1) KR20180044256A (en)
CN (1) CN107847494A (en)
AU (1) AU2016274694A1 (en)
CA (1) CA2988968A1 (en)
HK (1) HK1246184A1 (en)
IL (1) IL256226A (en)
MX (1) MX2017016231A (en)
NO (1) NO20180002A1 (en)
RU (1) RU2017145964A (en)
WO (1) WO2016201096A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105266A (en) * 2018-02-01 2019-08-09 华中科技大学 Synthetic method of one species specificity for the small molecule, anti-tumor drug of CYP2J2
WO2021110891A1 (en) 2019-12-04 2021-06-10 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021151926A1 (en) 2020-01-30 2021-08-05 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
EP3909950A1 (en) 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021228594A1 (en) 2020-05-13 2021-11-18 Basf Se Heterocyclic compounds for the control of invertebrate pests

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523707A (en) * 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー Geminal-substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CN110551147B (en) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 Synthetic method of 3-cyclopropylphenylboronic acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911543B2 (en) * 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7795453B2 (en) * 2002-07-29 2010-09-14 Bayer Schering Pharma Aktiengesellschaft Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
US7902217B2 (en) * 2004-04-22 2011-03-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US8273891B2 (en) * 2006-09-22 2012-09-25 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US20130231365A1 (en) * 2010-11-18 2013-09-05 Gerhard Koenig Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666767A (en) 1970-01-28 1972-05-30 Warner Lambert Co 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
JP3087763B2 (en) 1990-11-30 2000-09-11 三井化学株式会社 Novel heterocyclic compound and pharmaceutical composition containing the same
TW300219B (en) 1991-09-14 1997-03-11 Hoechst Ag
JP2553020B2 (en) 1991-11-07 1996-11-13 吉富製薬株式会社 Quinuclidine compound and its pharmaceutical use
FR2730995B1 (en) 1995-02-23 1997-04-04 Cird Galderma BI-AROMATIC COMPOUNDS DERIVED FROM AMIDE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES THEREOF
US6225310B1 (en) 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6727070B2 (en) 2000-02-14 2004-04-27 The Board Of Regents, The University Of Texas System Protein/solubility folding assessed by structural complementation
AU2001241056A1 (en) 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
AU2001265840A1 (en) 2000-06-26 2002-01-08 Novo-Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
AR036041A1 (en) 2001-06-12 2004-08-04 Upjohn Co HETEROCICLIC AROMATIC COMPOUNDS REPLACED WITH QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE359995T1 (en) 2001-11-19 2007-05-15 Elan Pharm Inc AMINE 1,2 AND 1,3-DIOL COMPOUNDS AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
US20030109519A1 (en) 2001-11-30 2003-06-12 Jeppe Sturis Use of selective potassium channel openers
US20030125323A1 (en) 2001-11-30 2003-07-03 Jeppe Sturis Use of selective potassium channel openers
US20040192594A1 (en) 2002-01-28 2004-09-30 Paul Reid Modified neurotoxins as therapeutic agents for the treatment of diseases and methods of making
JP2003267977A (en) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd Quinuclidine derivative
WO2003082272A1 (en) 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20030235583A1 (en) 2002-06-14 2003-12-25 Jeppe Sturis Combined use of a modulator of CD3 and a beta cell resting compound
AU2003281169A1 (en) 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004016608A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
JP4648703B2 (en) 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム Novel aminoindazole derivatives as pharmaceuticals and pharmaceutical compositions containing them
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
BR0316606A (en) 2002-12-12 2005-10-11 Aventis Pharma Sa Aminoindazole derivatives and their use as kinase inhibitors
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2005016923A1 (en) 2003-08-13 2005-02-24 Neurosearch A/S Novel quinuclidine derivatives and their pharmaceutical use
KR20060118472A (en) 2003-10-16 2006-11-23 카이론 코포레이션 Its use as an inhibitor of substituted benzazoles and RAF kinases
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050239853A1 (en) 2004-02-04 2005-10-27 Tjeerd Barf New compounds
DE602005015682D1 (en) 2004-02-04 2009-09-10 Neurosearch As DIMERE AZACYCLIC COMPOUNDS AND THEIR USE
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CN101044140A (en) * 2004-04-22 2007-09-26 记忆药物公司 Indole, 1H-indazole, 1,2-benzisoxazole and 1,2-benzisothiazole and their preparation and use
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
BRPI0510394A (en) 2004-05-24 2007-11-13 Amgen Inc 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
DE602005025902D1 (en) 2004-10-15 2011-02-24 Neurosearch As NEW AZABIC CYCLIC ARYL DERIVATIVES AND MEDICAL USE THEREOF
CA2591817A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US20070082350A1 (en) 2005-02-09 2007-04-12 Philip Landfield Assay and method for diagnosing and treating alzheimer's disease
DE102005038947A1 (en) 2005-05-18 2006-11-30 Grünenthal GmbH Substituted benzo [d] isoxazol-3-yl-amine compounds and their use in medicaments
US7580791B2 (en) * 2005-08-10 2009-08-25 Rm Acquisition, Llc Route evaluation system
CN101312968A (en) * 2005-09-23 2008-11-26 记忆药物公司 Indazole, benzothiazole, benzisothiazole, benzisoxazole, pyrazolopyridine, isothiazolopyridine, preparation and use thereof
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PE20100743A1 (en) 2005-11-15 2010-11-25 Glaxo Group Ltd NEW PROCEDURES AND FORMULATIONS
JP5204662B2 (en) 2005-11-22 2013-06-05 アムジエン・インコーポレーテツド Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1
TW200734338A (en) 2006-01-16 2007-09-16 Organon Nv 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
PL2018380T3 (en) 2006-05-19 2012-05-31 Abbvie Bahamas Ltd Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
EP2041085A1 (en) 2006-06-27 2009-04-01 Abbott Laboratories Pyrrole derivatives and their methods of use
CA2659762A1 (en) 2006-06-27 2008-01-03 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
ITMI20061279A1 (en) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche SELECTIVE NICOTINIC AGONISTS FOR THE ALFA7 RECEPTOR SUBTIPLE, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
CL2008000596A1 (en) 2007-03-01 2008-09-05 Glaxo Group Ltd DOSAGE FORM INCLUDING 1- (6 - [(3-CYCLLOBUTIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-IL) OXI] -3-PIRIDINIL) -2-PIRROLIDINONA, A STABILIZER , A EXCIPIENT; PREPARATION PROCEDURE; AND ITS USE TO TREAT NEUROLOGICAL DISEASES.
CL2008000597A1 (en) 2007-03-01 2008-09-05 Glaxo Group Ltd DOSAGE FORM INCLUDING 6- (3-CYCLLOBUTIL-2,3,4,5-TETRAHYDRO-1H-BENZO [D] AZEPIN-7-IL OXI) -N-METHYL NICOTINAMIDE, A STABILIZER AND A EXCIPIENT; PREPARATION PROCEDURE; AND ITS USE TO TREAT NEUROLOGICAL DISEASES.
CA2679885A1 (en) 2007-03-23 2008-10-02 Abbott Laboratories Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
EP2129672B1 (en) 2007-03-23 2011-05-18 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
ATE538122T1 (en) 2007-03-23 2012-01-15 Abbott Lab ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTAN AND METHODS OF USE THEREOF
EP2139891B1 (en) 2007-03-23 2012-09-05 Abbott Laboratories 4-substituted azaadamantane derivatives and methods of use thereof
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
US8288389B2 (en) 2007-09-06 2012-10-16 Glaxo Group Limited Piperazine derivative having affinity for the histamine H3 receptor
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
US20090099099A1 (en) 2007-10-16 2009-04-16 Hong Wang Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2009067586A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
WO2009067579A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
JP5498392B2 (en) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1,5-Dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators for the treatment of CNS disorders
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
JP2011511800A (en) 2008-02-07 2011-04-14 アボット・ラボラトリーズ Amide derivatives as positive allosteric modifiers and methods for their use
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
US20110189280A1 (en) 2008-08-29 2011-08-04 Allan James Clarke Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
AU2010262643B2 (en) 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
JO3250B1 (en) 2009-09-22 2018-09-16 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
JP5752691B2 (en) 2009-09-29 2015-07-22 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ New compounds
US8841289B2 (en) 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
WO2011056573A1 (en) 2009-10-28 2011-05-12 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2536717B1 (en) 2010-02-17 2014-06-04 Janssen Pharmaceutica, N.V. Aminothiazolones as estrogen related receptor-alpha modulators
WO2011103091A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
CN103025744A (en) 2010-04-30 2013-04-03 百时美施贵宝公司 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
WO2012028629A1 (en) 2010-09-02 2012-03-08 Glaxo Group Limited 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
PE20131394A1 (en) 2010-09-23 2014-01-11 Abbvie Inc MONOHYDRATE OF AZA-ADAMANTAN DERIVATIVES
FR2966827B1 (en) 2010-10-27 2014-08-22 Kimonella Ventures Ltd PEPTIDE COMPOUND USEFUL FOR INHIBITING AMYLOID PLATE FORMATION
KR20140041442A (en) 2011-02-03 2014-04-04 루핀 리미티드 Pyrrole derivatives used as modulators of alpha7 nachr
JP2014076948A (en) 2011-02-09 2014-05-01 Astellas Pharma Inc Isoquinoline amide derivative
EA024170B1 (en) 2011-02-23 2016-08-31 Люпин Лимитед HETEROARYL DERIVATIVES AS ALPHA7 nAChR MODULATORS
EP2691368A1 (en) 2011-03-31 2014-02-05 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
US9458179B2 (en) 2012-05-24 2016-10-04 Bristol-Myers Squibb Company Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
JOP20130213B1 (en) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co Oppositions to the 5-HT3 Future
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
WO2014083003A1 (en) 2012-11-27 2014-06-05 Shire International Gmbh Pro-cognitive compound
CN104837499B (en) 2012-12-11 2018-02-23 诺华有限公司 Predict the biomarker to alpha 7 nicotinic acetylcholine receptors activators for treating response
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
NZ708593A (en) 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
AU2014229300A1 (en) 2013-03-13 2015-06-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
TW201446243A (en) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
WO2015066371A1 (en) 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018523707A (en) * 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー Geminal-substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911543B2 (en) * 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7795453B2 (en) * 2002-07-29 2010-09-14 Bayer Schering Pharma Aktiengesellschaft Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
US7902217B2 (en) * 2004-04-22 2011-03-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US8273891B2 (en) * 2006-09-22 2012-09-25 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US20130231365A1 (en) * 2010-11-18 2013-09-05 Gerhard Koenig Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3307269A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105266A (en) * 2018-02-01 2019-08-09 华中科技大学 Synthetic method of one species specificity for the small molecule, anti-tumor drug of CYP2J2
WO2021110891A1 (en) 2019-12-04 2021-06-10 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021151926A1 (en) 2020-01-30 2021-08-05 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
EP3909950A1 (en) 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021228594A1 (en) 2020-05-13 2021-11-18 Basf Se Heterocyclic compounds for the control of invertebrate pests

Also Published As

Publication number Publication date
MX2017016231A (en) 2018-11-29
RU2017145964A (en) 2019-07-10
EP3307269A1 (en) 2018-04-18
HK1246184A1 (en) 2018-09-07
JP2018516973A (en) 2018-06-28
NO20180002A1 (en) 2018-01-02
CN107847494A (en) 2018-03-27
EP3307269A4 (en) 2019-02-20
IL256226A (en) 2018-02-28
US20180134696A1 (en) 2018-05-17
CA2988968A1 (en) 2016-12-15
US10370370B2 (en) 2019-08-06
KR20180044256A (en) 2018-05-02
AU2016274694A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
US10370370B2 (en) Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
JP7253640B2 (en) Heterocyclic compounds and uses thereof
JP7095106B2 (en) Oxadiazole Transient Receptor Potential Channel Inhibitor
JP6517239B2 (en) Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive allosteric modulator activity for the treatment of Alzheimer&#39;s disease
JP6531093B2 (en) Nitrogen-containing heterocyclic compound
JP6745824B2 (en) Heterocyclic compound
JP6571077B2 (en) Nitrogen-containing heterocyclic compounds
TWI543974B (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanone and its use as a medicament
RS67682B1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
JP7145875B2 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
CN110072855A (en) Therapeutic compound and its application method
TW201730148A (en) Fused (hetero)cyclic compounds as S1P modulators
JP2023523770A (en) Imidazopyrimidines as modulators of IL-17
JP6483105B2 (en) Piperazine derivatives and their use as medicaments
JP2025032137A (en) Heterocyclic compound
CN114728900A (en) Heterocyclic NMDA antagonists
JP7734152B2 (en) 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists, for example, for treating depression
WO2018235838A1 (en) Heterocyclic compounds
KR20120101551A (en) Bicyclic thiazoles as allosteric modulators of mglur5 receptors
AU2021276623A1 (en) 3-((1H-pyrazol-4-yl)methyl)-6&#39;-(phenyl)-2H-(1,2&#39;-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
WO2017027600A1 (en) GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
HK40057687B (en) Heterocyclic compounds and use thereof
HK40057687A (en) Heterocyclic compounds and use thereof
HK1193100B (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16808279

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2988968

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017564556

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/016231

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187000332

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017145964

Country of ref document: RU

Ref document number: 2016808279

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016274694

Country of ref document: AU

Date of ref document: 20160609

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017026723

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017026723

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171211